foscarnet has been researched along with Cytomegalovirus Infections in 472 studies
Foscarnet: An antiviral agent used in the treatment of cytomegalovirus retinitis. Foscarnet also shows activity against human herpesviruses and HIV.
phosphonoformic acid : Phosphoric acid in which one of the hydroxy groups is replaced by a carboxylic acid group. It is used as the trisodium salt as an antiviral agent in the treatment of cytomegalovirus retinitis (CMV retinitis, an inflamation of the retina that can lead to blindness) and as an alternative to ganciclovir for AIDS patients who require concurrent antiretroviral therapy but are unable to tolerate ganciclovir due to haematological toxicity.
Cytomegalovirus Infections: Infection with CYTOMEGALOVIRUS, characterized by enlarged cells bearing intranuclear inclusions. Infection may be in almost any organ, but the salivary glands are the most common site in children, as are the lungs in adults.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A cohort of 24 patients with acquired immunodeficiency syndrome (AIDS) and CMV retinitis received sodium phosphonoformate (foscarnet) as part of a controlled efficacy trial at the National Institutes of Health." | 10.17 | Increased survival of a cohort of patients with acquired immunodeficiency syndrome and cytomegalovirus retinitis who received sodium phosphonoformate (foscarnet). ( Baird, BF; Davey, RT; deSmet, MD; Falloon, J; Kovacs, JA; Masur, H; Mellow, S; Nussenblatt, RB; Palestine, AG; Polis, MA, 1993) |
| "Forty-eight patients who provided 2 consecutive blood samples that tested positive for cytomegalovirus DNA by polymerase chain reaction (PCR) were randomized to receive either full-dose ganciclovir (5 mg/kg intravenously [iv] twice daily) or half-dose ganciclovir (5 mg/kg iv once daily) plus half-dose foscarnet (90 mg/kg iv once daily) for 14 days." | 9.11 | A randomized, controlled trial comparing ganciclovir to ganciclovir plus foscarnet (each at half dose) for preemptive therapy of cytomegalovirus infection in transplant recipients. ( Amooty, G; Brown, VS; Burroughs, AK; Emery, VC; Geretti, AM; Grace, SC; Griffiths, PD; Hainsworth, EG; Hassan-Walker, AF; Mattes, FM; Nebbia, G; Okwuadi, S; Potter, M; Prentice, G; Sabin, C; Sweny, P, 2004) |
| "A randomized open-label phase 2 trial compared the virological and clinical effects on cytomegalovirus (CMV) infection of a 14-day course of intravenous foscarnet (100 mg/[kg x 12 h]) or no treatment in 42 HIV-infected patients with < 100 CD4 cells/mm3 and persistent asymptomatic CMV viremia." | 9.09 | Effect of a 14-day course of foscarnet on cytomegalovirus (CMV) blood markers in a randomized study of human immunodeficiency virus-infected patients with persistent CMV viremia. Agence National de Recherche du SIDA 023 Study Group. ( Aboulker, JP; Brun-Vézinet, F; Carrière, I; Fillet, AM; Gérard, L; Houhou, N; Leport, C; Ostinelli, J; Salmon-Céron, D; Vildé, JL, 1999) |
| "Patients with symptomatic gastrointestinal disease due to cytomegalovirus (CMV) were randomized to receive open-label ganciclovir (22) or foscarnet (26)." | 9.08 | Treatment of AIDS-associated gastrointestinal cytomegalovirus infection with foscarnet and ganciclovir: a randomized comparison. ( Benhamou, Y; Blanshard, C; Dohin, E; Gazzard, BG; Katlama, C; Lernestedt, JO, 1995) |
| "Eleven clinical centers, a data coordinating center, and a fundus photograph reading center participated in a randomized, controlled, multicenter clinical trial comparing foscarnet and ganciclovir as primary therapy for previously untreated CMV retinitis in 240 patients with AIDS." | 9.08 | Foscarnet-Ganciclovir Cytomegalovirus Retinitis Trial: 5. Clinical features of cytomegalovirus retinitis at diagnosis. Studies of ocular complications of AIDS Research Group in collaboration with the AIDS Clinical Trials Group. ( , 1997) |
| "Although several uncontrolled studies have shown that the response rate to ganciclovir and foscarnet for all forms of cytomegalovirus (CMV) infection in immunocompromised patients is almost similar, to date, no controlled clinical trial has been specifically designed to compare these two agents in the treatment of CMV esophagitis." | 9.08 | Treatment of cytomegalovirus esophagitis in patients with acquired immune deficiency syndrome: a randomized controlled study of foscarnet versus ganciclovir. The Italian Cytomegalovirus Study Group. ( Bianchi Porro, G; Parente, F, 1998) |
| "AIDS patients with newly diagnosed cytomegalovirus (CMV) retinitis who had just completed a 14-day course of ganciclovir induction therapy were randomly assigned to an alternating or concurrent combination regimen of chronic ganciclovir-foscarnet therapy for CMV retinitis." | 9.07 | Randomized phase I trial of two different combination foscarnet and ganciclovir chronic maintenance therapy regimens for AIDS patients with cytomegalovirus retinitis: AIDS clinical Trials Group Protocol 151. ( Bassiakos, Y; Geheb, H; Hooton, T; Jacobson, MA; Korvick, JA; Kramer, F; O'Donnell, JJ; Polsky, B; van der Horst, C; Walker, JD, 1994) |
| "Thirty-two patients with AIDS and previously untreated cytomegalovirus retinitis completed an induction course of foscarnet, 60 mg/kg every 8 h for 14 days, had retinitis stabilize, and were then randomly assigned to receive foscarnet maintenance as either a 90- or 120-mg/kg/day infusion administered over 2 h." | 9.07 | A dose-ranging study of daily maintenance intravenous foscarnet therapy for cytomegalovirus retinitis in AIDS. ( Causey, D; Chown, M; Davis, R; Hardy, D; Heinemann, MH; Holland, GN; Jacobson, MA; Kuppermann, BD; O'Donnell, JJ; Polsky, B, 1993) |
| "In a controlled trial of foscarnet in the treatment of cytomegalovirus (CMV) retinitis in patients with the acquired immunodeficiency syndrome (AIDS), patients with non-immediately sight-threatening lesions were randomized to receive immediate treatment with foscarnet or foscarnet treatment delayed until the first signs of retinitis progression." | 9.07 | Design of a randomized controlled trial of foscarnet in patients with cytomegalovirus retinitis associated with acquired immunodeficiency syndrome. ( Polis, MA, 1992) |
| "Circulating human immunodeficiency virus (HIV) p24 antigen levels were measured in 22 AIDS patients who had detectable serum antigen at baseline after induction and maintenance therapy of foscarnet for cytomegalovirus retinitis in phase I/II multicenter trials." | 9.07 | Effect of foscarnet therapy on human immunodeficiency virus p24 antigen levels in AIDS patients with cytomegalovirus retinitis. ( Causey, DM; Davis, RB; Grieco, MH; Hooton, TM; Jacobson, MA; McKinley, GF; Parenti, DM; Reddy, MM; van der Horst, CM, 1992) |
| "Ganciclovir and Foscarnet were compared in an open randomised trial as treatment and secondary prophylaxis of cytomegalovirus (CMV) retinitis in patients with AIDS." | 9.07 | Foscarnet and Ganciclovir in the treatment of CMV retinitis in AIDS patients: a randomised comparison. ( Gazzard, BG; Harman, C; Mathalone, B; Mitchell, S; Moyle, G, 1992) |
| "We performed a multicenter, randomized, unblinded clinical trial (the Foscarnet-Ganciclovir Cytomegalovirus Retinitis Trial) designed to compare ganciclovir with foscarnet in the treatment of cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome (AIDS)." | 9.07 | Mortality in patients with the acquired immunodeficiency syndrome treated with either foscarnet or ganciclovir for cytomegalovirus retinitis. ( , 1992) |
| "To evaluate foscarnet sodium in treating cytomegalovirus retinitis in patients with AIDS." | 9.07 | A randomized, controlled trial of foscarnet in the treatment of cytomegalovirus retinitis in patients with AIDS. ( Baird, BF; Davey, RT; Davis, M; De Smet, MD; Falloon, J; Kovacs, JA; Palestine, AG; Polis, MA; Zunich, KM; Zurlo, JJ, 1991) |
| "Intravenous foscarnet was given on an emergency basis to 30 immunosuppressed patients with cytomegalovirus (CMV) disease, of whom 28 were organ transplant recipients." | 9.06 | Sensitivity of cytomegalovirus to intravenous foscarnet treatment. ( Akesson-Johansson, A; Lernestedt, JO; Lönnqvist, B; Ringdén, O; Wahren, B, 1986) |
| "The use of ganciclovir in the treatment of cytomegalovirus (CMV) retinitis in patients with acquired immunodeficiency syndrome (AIDS) is limited by marrow toxicity and by the development of resistance to this agent in CMV strains capable of causing progressive disease." | 8.78 | Maintenance therapy for cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome: foscarnet. ( Jacobson, MA, 1992) |
| "Induction regimens of foscarnet and ganciclovir are highly effective in arresting cytomegalovirus (CMV) retinitis in patients with AIDS." | 8.78 | Foscarnet and ganciclovir in the treatment of cytomegalovirus retinitis. ( Polis, MA, 1992) |
| "The pyrophosphate analogue, foscarnet, selectively inhibits the DNA polymerase of human herpes viruses, including cytomegalovirus, and the reverse transcriptase of HIV." | 8.78 | Foscarnet. A review of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with cytomegalovirus retinitis. ( Chrisp, P; Clissold, SP, 1991) |
| "Ganciclovir (GCV) and foscarnet (FOS) are the most commonly used antivirals for preemptive treatment of cytomegalovirus (CMV) viremia in recipients of allogeneic hematopoietic cell transplantation (alloHCT)." | 7.96 | Cost analysis of ganciclovir and foscarnet in recipients of allogeneic hematopoietic cell transplant with cytomegalovirus viremia. ( Abella Ross, J; Al Malki, MM; Chen, J; Dadwal, SS; Dickter, JK; Ito, JI; Kriengkauykiat, J; Mokhtari, S; Nakamura, R; Tegtmeier, B; Yang, D; Zaia, JA, 2020) |
| "Herein, we phenotypically and enzymatically characterize the theoretical mutation Q579I in helix K and the already described clinical mutation K805Q in helix P of cytomegalovirus DNA polymerase for susceptibility to foscarnet." | 7.96 | Hypersusceptibility of Human Cytomegalovirus to Foscarnet Induced by Mutations in Helices K and P of the Viral DNA Polymerase. ( Boivin, G; Pham, VD; Piret, J; Shi, R; Zarrouk, K, 2020) |
| "This single-center, retrospective study included immunosuppressed adults with CMV viremia who received foscarnet between January 2012-July 2017." | 7.91 | Recommended foscarnet dose is not associated with improved outcomes in cytomegalovirus salvage therapy. ( Athans, V; Koval, CE; Lam, SW; Spinner, ML, 2019) |
| " We describe a case of a cytomegalovirus (CMV)-seronegative kidney transplant recipient from a CMV-seropositive donor, whose course was complicated during valganciclovir prophylaxis by CMV disease, ultimately progressing to ganciclovir, foscarnet, and cidofovir resistance." | 7.85 | Ganciclovir Dosing Strategies and Development of Cytomegalovirus Resistance in a Kidney Transplant Recipient: A Case Report. ( Agrawal, N; Beltran, D; Echenique, IA; Najafian, N; Ramirez-Ruiz, L, 2017) |
| "Human cytomegalovirus UL54 DNA polymerase gene mutations that confer foscarnet resistance in clinical practice typically cluster in the amino terminal 2, palm and finger domains." | 7.85 | Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene. ( Chou, S, 2017) |
| "Ganciclovir-resistant cytomegalovirus (GCV-R CMV) is an emerging challenge among solid organ transplant (SOT) recipients." | 7.83 | Ganciclovir-resistant cytomegalovirus infection in solid organ transplant recipients: a single-center retrospective cohort study. ( Angarone, M; Flaherty, J; Ison, MG; Penugonda, S; Rubin, J; Stosor, V; Young, PG, 2016) |
| "(Val)ganciclovir is used to treat cytomegalovirus (CMV) infection following solid organ (SOT) or hematopoietic stem cell (HSCT) transplantation." | 7.79 | The time course of development and impact from viral resistance against ganciclovir in cytomegalovirus infection. ( Cunha-Bang, Cd; Frederiksen, CM; Gustafsson, F; Iversen, M; Kirkby, N; Kjaer, J; Lepri, AC; Lundgren, JD; Rasmussen, A; Sengeløv, H; Sønderholm, M; Sørensen, SS, 2013) |
| "Human cytomegalovirus (CMV) UL54 DNA polymerase (pol) mutants with known patterns of resistance to current antivirals ganciclovir (GCV), foscarnet (FOS), and cidofovir (CDV) were tested for cyclopropavir (CPV) susceptibility by a standardized reporter-based yield reduction assay." | 7.78 | Cyclopropavir susceptibility of cytomegalovirus DNA polymerase mutants selected after antiviral drug exposure. ( Bowlin, TL; Chou, S; Marousek, G, 2012) |
| "Foscarnet (FOS) is a pyrophosphate analogue that inhibits both cytomegalovirus (CMV) and human immunodeficiency virus (HIV) replication." | 7.78 | Emergence of cytomegalovirus resistance to foscarnet in a patient receiving foscarnet salvage therapy for multidrug-resistant HIV infection. ( Agut, H; Boutolleau, D; Burrel, S; Canestri, A; Clavel-Osorio, C; Katlama, C; Marcelin, AG; Seang, S; Wirden, M, 2012) |
| "We present the case of a lung transplant recipient with disseminated crystal precipitation, and granulomatous and fibrinous inflammation after therapy with foscarnet (Foscavir; AstraZeneca, Zug, Switzerland) for recurring ganciclovir-resistant cytomegalovirus (CMV) reactivation." | 7.78 | Crystal precipitation and granulomatous inflammation in multiple organs after foscarnet therapy in a lung transplant recipient. ( Boehler, A; Gaspert, A; Schuurmans, MM; Tischler, V, 2012) |
| "Cytomegalovirus (CMV) infections in kidney transplant recipients are in most cases successfully treated with oral valganciclovir (VGCV)." | 7.77 | Incidence and outcomes of ganciclovir-resistant cytomegalovirus infections in 1244 kidney transplant recipients. ( Asberg, A; Hartmann, A; Haug Dorenberg, D; Kristiansen, KI; Leivestad, T; Myhre, HA; Rollag, H, 2011) |
| "Although foscarnet is a promising alternative for the treatment of cytomegalovirus (CMV) infection, its toxicity can be significant in patients with advanced age." | 7.74 | Reduced dose of foscarnet as preemptive therapy for cytomegalovirus infection following reduced-intensity cord blood transplantation. ( Hori, A; Kami, M; Kato, D; Kusumi, E; Masuoka, K; Matsumura, T; Miyakoshi, S; Morinaga, S; Murashige, N; Narimatsu, H; Shibata, T; Taniguchi, S; Wake, A; Yuji, K, 2007) |
| "Cytomegalovirus (CMV) disease is a major cause of morbidity and mortality after lung transplantation despite ganciclovir prophylaxis." | 7.74 | A single-center experience with ganciclovir-resistant cytomegalovirus in lung transplant recipients: treatment and outcome. ( Hanson, KE; Palmer, SM; Reddy, AJ; Zaas, AK, 2007) |
| "A phenotypic method was developed to test mutations in the human cytomegalovirus (HCMV) DNA polymerase gene (UL54) suspected to confer resistance to foscarnet." | 7.73 | Phenotypic characterisation of cytomegalovirus DNA polymerase: a method to study cytomegalovirus isolates resistant to foscarnet. ( Alain, S; Ducancelle, A; Fillet, AM; Gravisse, J; Mazeron, MC; Petit, F; Pors, MJ, 2005) |
| "Foscarnet is currently licensed for the treatment of human cytomegalovirus (HCMV) infection." | 7.73 | A novel mutation in the UL54 gene of human cytomegalovirus isolates that confers resistance to foscarnet. ( Alain, S; Champier, G; Ducancelle, A; Le Pors, MJ; Mazeron, MC; Petit, F, 2006) |
| "Ganciclovir-resistant (GCV-R) cytomegalovirus (CMV) is now being reported with increasing frequency in solid organ transplant recipients." | 7.71 | Clinical characteristics of 13 solid organ transplant recipients with ganciclovir-resistant cytomegalovirus infection. ( Avery, RK; Braun, W; Flechner, SM; Goldman, M; Gordon, SM; Haug, M; Isada, CM; Kohn, D; Long, J; Longworth, DL; Lurain, NS; Maurer, J; Mawhorter, SD; Mossad, SB; Schilz, R; Schmitt, SK; Taege, AJ; Yen-Lieberman, B, 2002) |
| "The resistance of cytomegalovirus (CMV) to ganciclovir is a factor in therapeutic failure and disease progression." | 7.71 | Combination antiviral therapy for ganciclovir-resistant cytomegalovirus infection in solid-organ transplant recipients. ( Fishman, JA; Kallas, WM; Mylonakis, E, 2002) |
| " Antiviral susceptibility testing of blood cytomegaloviral isolates was done when patients failed to respond to intravenous ganciclovir treatment for symptomatic cytomegalovirus infection." | 7.70 | Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants. ( Boeckh, M; Corey, L; Davis, CL; Koelle, DM; Limaye, AP, 2000) |
| "A rapid screening assay for the detection of resistance to ganciclovir and foscarnet of primary isolates of human cytomegalovirus from culture-positive blood samples was developed by using single doses of both drugs and an immediate-early antigen plaque reduction assay." | 7.69 | Rapid screening for resistance to ganciclovir and foscarnet of primary isolates of human cytomegalovirus from culture-positive blood samples. ( Baldanti, F; Gerna, G; Percivalle, E; Revello, MG; Sarasini, A; Zavattoni, M, 1995) |
| "CMV esophagitis has a favorable response to induction ganciclovir therapy, and a long-term remission may occur after induction therapy alone." | 7.69 | Cytomegalovirus esophagitis in AIDS: a prospective evaluation of clinical response to ganciclovir therapy, relapse rate, and long-term outcome. ( Schwartz, DA; Straub, RF; Wilcox, CM, 1995) |
| "To determine if ganciclovir given three times per week post-transplant is tolerable and effective for prevention of cytomegalovirus (CMV) infection in recipients of T cell-depleted marrow from related or unrelated donors, we have used ganciclovir 2." | 7.69 | Ganciclovir three times per week is not adequate to prevent cytomegalovirus reactivation after T cell-depleted marrow transplantation. ( Andersson, B; Deisseroth, AB; Giralt, S; Goodrich, J; Ippoliti, C; Luna, M; Mehra, R; Panina, A; Przepiorka, D; van Besien, K, 1994) |
| "These results suggest that while ganciclovir therapy may clinically stabilize CMV retinitis in patients with AIDS, it does not appear to prevent the development of, or be effective in the treatment of, CMV encephalitis." | 7.69 | The development of cytomegalovirus encephalitis in AIDS patients receiving ganciclovir. ( Berman, SM; Kim, RC, 1994) |
| "Four human cytomegalovirus (HCMV) isolates from four different AIDS patients treated with both ganciclovir and foscarnet and not responding clinically to antiviral treatment, were studied in order to verify the occurrence of double resistance to both drugs, and to define whether single or multiple HCMV strains could be responsible for the double resistance." | 7.69 | Double resistance to ganciclovir and foscarnet of four human cytomegalovirus strains recovered from AIDS patients. ( Baldanti, F; Barbi, M; Brerra, R; Furione, M; Gerna, G; Percivalle, E; Sarasini, A, 1995) |
| "Three human cytomegalovirus (HCMV) strains (VR4760, VR4955, and VR5120) showing double resistance to ganciclovir (GCV) and foscarnet (PFA) were isolated from three patients with AIDS who underwent multiple sequential courses of therapy with GCV and PFA (A." | 7.69 | Single amino acid changes in the DNA polymerase confer foscarnet resistance and slow-growth phenotype, while mutations in the UL97-encoded phosphotransferase confer ganciclovir resistance in three double-resistant human cytomegalovirus strains recovered f ( Baldanti, F; Biron, KK; Chou, S; Gerna, G; Sarasini, A; Silini, E; Stanat, SC; Underwood, MR, 1996) |
| "Four human cytomegalovirus strains with double resistance to both ganciclovir and foscarnet were recovered from acquired immunodeficiency syndrome (AIDS) patients." | 7.69 | Four dually resistant human cytomegalovirus strains from AIDS patients: single mutations in UL97 and UL54 open reading frames are responsible for ganciclovir- and foscarnet-specific resistance, respectively. ( Baldanti, F; Barbi, M; Biron, KK; Gerna, G; Lazzarin, A; Sarasini, A; Silini, E, 1995) |
| "In a previous study, we showed that patients undergoing allogeneic hemopoietic stem cell transplantation (HSCT) who had cytomegalovirus (CMV) antigenemia with more than 4 CMV antigen-positive cells/200,000 have a high transplant-related mortality (TRM) rate, despite treatment with ganciclovir or foscarnet." | 7.69 | Combined foscarnet-ganciclovir treatment for cytomegalovirus infections after allogeneic hemopoietic stem cell transplantation. ( Bacigalupo, A; Bregante, S; Gualandi, F; Isaza, A; Lamparelli, T; Marmont, AM; Occhini, D; Tedone, E; Trespi, G; Van Lint, MT, 1996) |
| "Cytomegalovirus (CMV) infection is still a problem for organ transplant recipients despite studies that long-term prophylaxis with high dose of acyclovir or ganciclovir given to all organ recipients may limit the consequences of infection and disease." | 7.69 | Early ganciclovir therapy effectively controls viremia and avoids the need for cytomegalovirus (CMV) prophylaxis in renal transplant patients with cytomegalovirus antigenemia. ( Baruzzo, S; Gotti, E; Moioli, F; Perani, V; Remuzzi, G; Suter, F, 1996) |
| "The human cytomegalovirus (HCMV) gene UL97 product was shown to play an important role in phosphorylation of ganciclovir (GCV) in HCMV-infected cells." | 7.68 | Rapid detection of cytomegalovirus strains resistant to ganciclovir through mutations within the gene UL97. ( Alain, S; Mazeron, MC; Morinet, F; Pépin, JM; Raskine, L; Sanson-Le Pors, MJ, 1993) |
| "Foscarnet (phosphonoformate) is a potent virustatic drug against herpes-like viruses and is widely used in the therapy of cytomegalovirus infections in immunosuppressed patients." | 7.68 | Foscarnet penetrates the blood-brain barrier: rationale for therapy of cytomegalovirus encephalitis. ( Brockmeyer, NH; Goos, M; Hengge, UR; Malessa, R; Ravens, U, 1993) |
| "Ganciclovir and foscarnet are both effective for cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome, but the benefits of either agent given alone are limited." | 7.68 | Treatment of aggressive cytomegalovirus retinitis with ganciclovir in combination with foscarnet in a child infected with human immunodeficiency virus. ( Butler, KM; De Smet, MD; Husson, RN; Jarosinski, P; Lovato, G; Manjunath, K; Montrella, K; Mueller, B; Nussenblatt, RB; Pizzo, PA, 1992) |
| "Infections caused by cytomegalovirus (CMV) resistant in vitro to ganciclovir, defined as requiring greater than 6 mumols of ganciclovir for ED50 have developed in some AIDS patients with progressive CMV retinitis despite chronic ganciclovir therapy." | 7.68 | Foscarnet therapy for ganciclovir-resistant cytomegalovirus retinitis in patients with AIDS. ( Drew, WL; Feinberg, J; Jacobson, MA; Miner, RD; O'Donnell, JJ; Parenti, D; Whitmore, PV, 1991) |
| "Foscarnet, administered via a central line, was used for the treatment of 18 episodes of cytomegalovirus (CMV) esophageal ulceration in 15 patients, and in the treatment of 27 episodes of CMV colitis in 22 patients." | 7.68 | Foscarnet in the treatment of cytomegalovirus infection of the esophagus and colon in patients with the acquired immune deficiency syndrome. ( Connolly, GM; Gazzard, BG; Hawkins, DA; Nelson, MR, 1991) |
| "Foscarnet is an investigational antiviral agent that has been used effectively in the treatment of cytomegalovirus (CMV) retinitis in AIDS patients." | 7.68 | Successful foscarnet therapy for cytomegalovirus retinitis in an AIDS patient undergoing hemodialysis: rationale for empiric dosing and plasma level monitoring. ( Gambertoglio, JG; Graziani, AL; Grunwald, JE; MacGregor, RR; Weiss, R, 1991) |
| "Ten patients with acquired immunodeficiency syndrome with newly diagnosed cytomegalovirus (CMV) retinitis were treated with an induction regimen of intravenous foscarnet, 60 mg/kg of body weight, administered as a 2-h infusion and repeated every 8 h for 14 days." | 7.67 | Foscarnet treatment of cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome. ( Jacobson, MA; Mills, J; O'Donnell, JJ, 1989) |
| "Eight patients, 7 renal and 1 combined renal and pancreas allograft recipients with generalized cytomegalovirus (CMV) infection were treated with continuous intravenous foscarnet infusion (0." | 7.67 | Evaluation by immune scanning electron microscopy of foscarnet treatment of cytomegalovirus infection in patients with renal transplants. ( Akesson-Johansson, A; Andersson, J; Brattström, C, 1989) |
| " Following allogeneic bone marrow transplantation, he developed cytomegalovirus retinitis, which was treated successfully with trisodium phosphonoformate (foscarnet)." | 7.67 | Foscarnet as treatment for cytomegalovirus retinitis following bone marrow transplantation. ( Arthur, C; Ganly, PS; Goldman, JM; Schulenburg, WE, 1988) |
| "Foscarnet was started on day +1 after BMT and continued until day +100." | 6.69 | Foscarnet prophylaxis of cytomegalovirus infections in patients undergoing allogeneic bone marrow transplantation (BMT): a dose-finding study. ( Bacigalupo, A; Benvenuto, F; Berisso, G; Bertilson, S; Bregante, S; Figari, O; Gualandi, F; Lamparelli, T; Mordini, N; Raiola, AM; Tedone, E; Trespi, G; Van Lint, MT, 2000) |
| " There was no difference between the 2 groups in either serious adverse events or rise of creatinine to > or = 2." | 6.69 | Safety of oral versus intravenous hydration during induction therapy with intravenous foscarnet in AIDS patients with cytomegalovirus infections. ( Benson, P; Cheung, TW; Jayaweera, DT; Nahass, R; Olson, C; Pearce, D; Wool, GM, 2000) |
| "Treatment with Foscarnet may be initially effective, but does not eliminate cytomegalovirus infection." | 6.66 | Cytomegalovirus colitis and oesophageal ulceration in the context of AIDS: clinical manifestations and preliminary report of treatment with Foscarnet (phosphonoformate). ( Barrison, I; Boylston, A; Forster, S; Jeffries, DJ; Pinching, AJ; Thom, S; Unwin, R; Weber, JN, 1987) |
| "Foscarnet is a suitable option as both pre-emptive therapy or for the treatment of active disease in these patients." | 6.48 | Foscarnet in the management of cytomegalovirus infections in hematopoietic stem cell transplant patients. ( Bacigalupo, A; Boyd, A; Clissold, S; Curtis, J; Slipper, J, 2012) |
| "Foscarnet is a reasonable first line anti CMV agent in this setting." | 6.46 | CMV-related thrombocytopenia treated with foscarnet: a case series and review of the literature. ( Chajek-Shaul, T; Hershcovici, T; Koslowsky, B; Wolf, D; Yaari, S, 2010) |
| "Foscarnet has a low solubility and a high degree of ionization at physiologic pH, requiring it to be administered in higher doses and larger volumes." | 6.38 | Approaches to the treatment of cytomegalovirus retinitis: ganciclovir and foscarnet. ( Jacobson, MA; O'Donnell, JJ, 1991) |
| "A cohort of 24 patients with acquired immunodeficiency syndrome (AIDS) and CMV retinitis received sodium phosphonoformate (foscarnet) as part of a controlled efficacy trial at the National Institutes of Health." | 6.17 | Increased survival of a cohort of patients with acquired immunodeficiency syndrome and cytomegalovirus retinitis who received sodium phosphonoformate (foscarnet). ( Baird, BF; Davey, RT; deSmet, MD; Falloon, J; Kovacs, JA; Masur, H; Mellow, S; Nussenblatt, RB; Palestine, AG; Polis, MA, 1993) |
| "In this phase 3, open-label study, hematopoietic-cell and solid-organ transplant recipients with R/R cytomegalovirus were randomized 2:1 to maribavir 400 mg twice daily or investigator-assigned therapy (IAT; valganciclovir/ganciclovir, foscarnet, or cidofovir) for 8 weeks, with 12 weeks of follow-up." | 5.51 | Maribavir for Refractory Cytomegalovirus Infections With or Without Resistance Post-Transplant: Results From a Phase 3 Randomized Clinical Trial. ( Alain, S; Alexander, BD; Avery, RK; Blumberg, EA; Chemaly, RF; Cordonnier, C; Duarte, RF; Florescu, DF; Fournier, M; Kamar, N; Kumar, D; Maertens, J; Marty, FM; Papanicolaou, GA; Silveira, FP; Sundberg, AK; Witzke, O; Wu, J, 2022) |
| "Although mortality was high in this population, foscarnet use, with proper precautions, was generally safe and significant renal dysfunction was lower than previously reported in other sources, even with extended use." | 5.48 | Safety and efficacy of foscarnet for the management of ganciclovir-resistant or refractory cytomegalovirus infections: A single-center study. ( Allen, A; Ison, MG; Lacloche, L; Pierce, B; Richardson, CL, 2018) |
| "Foscarnet is a main treatment for disseminated cytomegalovirus infection in immunocompromised patients." | 5.46 | Foscarnet-related Hypercalcemia During CMV Treatment in an Infant With SCID: A Case Report and Review of Literature. ( Rabinowicz, S; Somech, R; Yeshayahu, Y, 2017) |
| "Leflunomide has been used to treat resistant CMV infections, however, data on efficacy, safety, and guidance for therapeutic drug level monitoring are lacking." | 5.43 | Adjuvant and salvage therapy with leflunomide for recalcitrant cytomegalovirus infections in hematopoietic cell transplantation recipients: A case series. ( Ariza-Heredia, E; Chemaly, RF; Doan, V; El Chaer, F; Jan, A; Mori, N; Oliver, N; Shah, D; Tayar, J; Tverdek, F; Wang, E, 2016) |
| "Literature search was performed on PubMed with keywords cytomegalovirus, transplantation, ganciclovir, valganciclovir, maribavir, letermovir, cidofovir, and foscarnet." | 5.41 | Oral antiviral drugs for treatment of cytomegalovirus in transplant recipients. ( Razonable, RR, 2023) |
| "Foscarnet was discontinued because of concern about its potential central nervous system toxicity." | 5.31 | Ganciclovir-resistant cytomegalovirus encephalitis in a bone marrow transplant recipient. ( Balfour, HH; Clark, HB; Holman, CJ; Julin, JE; Krivit, W; van Burik, JH; Webb, C, 2002) |
| "Foscarnet was discontinued because of adverse events in 3 (3%) of 97 patients, with treatment being stopped in 2 patients because of renal insufficiency and in 1 patient because of an acute neurologic disorder." | 5.28 | Foscarnet induction therapy for cytomegalovirus retinitis in AIDS: comparison of twice-daily and three-times-daily regimens. ( Brancon, C; Caumes, E; Cochereau-Massin, I; Dahan, R; Dohin, E; Gentilini, M; Katlama, C; Robinet, M; Rogeaux, O, 1992) |
| "Foscarnet was given as a continuous intravenous infusion." | 5.28 | Foscarnet for treatment of cytomegalovirus infections in bone marrow transplant recipients. ( Aschan, J; Ljungman, P; Lönnqvist, B; Ohlman, S; Ringdén, O, 1992) |
| "We treated a patient who had acquired immunodeficiency syndrome and cytomegalovirus retinitis of the left eye." | 5.28 | Intravitreal foscarnet for cytomegalovirus retinitis in a patient with acquired immunodeficiency syndrome. ( Chipont, E; Díaz-Llopis, M; España, E; Menezo, JL; Navea, A; Sanchez, S, 1992) |
| "After withdrawal from maintenance treatment, a relapse of cytomegalovirus retinitis occurred, which was again successfully treated with ganciclovir." | 5.28 | 2.5 years survival with sequential ganciclovir/foscarnet treatment in a patient with acquired immune deficiency syndrome and cytomegalovirus retinitis. ( Geier, SA; Goebel, FD; Klauss, V; Kronawitter, U; Matuschke, A, 1992) |
| "Foscarnet has been shown to be active in vitro against the human immunodeficiency virus and all human herpesviruses including cytomegalovirus (CMV)." | 5.28 | Pharmacokinetics of intermittently administered intravenous foscarnet in the treatment of acquired immunodeficiency syndrome patients with serious cytomegalovirus retinitis. ( Aweeka, F; Gambertoglio, J; Jacobson, MA; Mills, J, 1989) |
| " Adverse effects, such as decreased haemoglobin, decreased renal function and increased serum calcium, were observed in a few patients only." | 5.27 | Pharmacokinetics, safety and preliminary clinical experiences using foscarnet in the treatment of cytomegalovirus infections in bone marrow and renal transplant recipients. ( Ahlmén, J; Klintmalm, G; Lernestedt, JO; Lönnqvist, B; Paulin, T; Ringdén, O; Wahren, B, 1986) |
| "Forty-eight patients who provided 2 consecutive blood samples that tested positive for cytomegalovirus DNA by polymerase chain reaction (PCR) were randomized to receive either full-dose ganciclovir (5 mg/kg intravenously [iv] twice daily) or half-dose ganciclovir (5 mg/kg iv once daily) plus half-dose foscarnet (90 mg/kg iv once daily) for 14 days." | 5.11 | A randomized, controlled trial comparing ganciclovir to ganciclovir plus foscarnet (each at half dose) for preemptive therapy of cytomegalovirus infection in transplant recipients. ( Amooty, G; Brown, VS; Burroughs, AK; Emery, VC; Geretti, AM; Grace, SC; Griffiths, PD; Hainsworth, EG; Hassan-Walker, AF; Mattes, FM; Nebbia, G; Okwuadi, S; Potter, M; Prentice, G; Sabin, C; Sweny, P, 2004) |
| "To evaluate the efficacy and safety of the foscarnet-ganciclovir combination in induction therapy (IT) and maintenance therapy (MT) for cytomegalovirus (CMV) central neurological disorders in HIV-infected patients." | 5.09 | Induction and maintenance therapy of cytomegalovirus central nervous system infection in HIV-infected patients. ( Anduze-Faris, BM; Boukli, N; Caumes, E; Costagliola, D; Fillet, AM; Gasnault, J; Gozlan, J; Katlama, C; Lancar, R; Leport, C; Livartowsky, J; Matheron, S; Salmon, D, 2000) |
| "A randomized open-label phase 2 trial compared the virological and clinical effects on cytomegalovirus (CMV) infection of a 14-day course of intravenous foscarnet (100 mg/[kg x 12 h]) or no treatment in 42 HIV-infected patients with < 100 CD4 cells/mm3 and persistent asymptomatic CMV viremia." | 5.09 | Effect of a 14-day course of foscarnet on cytomegalovirus (CMV) blood markers in a randomized study of human immunodeficiency virus-infected patients with persistent CMV viremia. Agence National de Recherche du SIDA 023 Study Group. ( Aboulker, JP; Brun-Vézinet, F; Carrière, I; Fillet, AM; Gérard, L; Houhou, N; Leport, C; Ostinelli, J; Salmon-Céron, D; Vildé, JL, 1999) |
| "Patients with symptomatic gastrointestinal disease due to cytomegalovirus (CMV) were randomized to receive open-label ganciclovir (22) or foscarnet (26)." | 5.08 | Treatment of AIDS-associated gastrointestinal cytomegalovirus infection with foscarnet and ganciclovir: a randomized comparison. ( Benhamou, Y; Blanshard, C; Dohin, E; Gazzard, BG; Katlama, C; Lernestedt, JO, 1995) |
| "Foscarnet inhibits human immunodeficiency virus (HIV) replication in vitro and decreases p24 antigenemia in patients with cytomegalovirus (CMV) retinitis." | 5.08 | Foscarnet decreases human immunodeficiency virus RNA. ( Furrer, H; Hirschel, B; Kaiser, L; Olmari, M; Perrin, L; Von Overbeck, J; Yerly, S, 1995) |
| "Eleven clinical centers, a data coordinating center, and a fundus photograph reading center participated in a randomized, controlled, multicenter clinical trial comparing foscarnet and ganciclovir as primary therapy for previously untreated CMV retinitis in 240 patients with AIDS." | 5.08 | Foscarnet-Ganciclovir Cytomegalovirus Retinitis Trial: 5. Clinical features of cytomegalovirus retinitis at diagnosis. Studies of ocular complications of AIDS Research Group in collaboration with the AIDS Clinical Trials Group. ( , 1997) |
| "Although several uncontrolled studies have shown that the response rate to ganciclovir and foscarnet for all forms of cytomegalovirus (CMV) infection in immunocompromised patients is almost similar, to date, no controlled clinical trial has been specifically designed to compare these two agents in the treatment of CMV esophagitis." | 5.08 | Treatment of cytomegalovirus esophagitis in patients with acquired immune deficiency syndrome: a randomized controlled study of foscarnet versus ganciclovir. The Italian Cytomegalovirus Study Group. ( Bianchi Porro, G; Parente, F, 1998) |
| "To evaluate the efficacy of ganciclovir, foscarnet, or the combination of both for the treatment of cytomegalovirus polyradiculomyelopathy (CMV-PRAM), we reviewed the records of seven patients with AIDS, diagnosed with CMV-PRAM." | 5.08 | [Cytomegalovirus polyradiculomyelopathy in AIDS]. ( Cassetti, LI; Espinoza, L; Hansman-Whiteman, ML; Jayaweera, DT; Lopardo, GD; Scerpella, EG, 1998) |
| "AIDS patients with newly diagnosed cytomegalovirus (CMV) retinitis who had just completed a 14-day course of ganciclovir induction therapy were randomly assigned to an alternating or concurrent combination regimen of chronic ganciclovir-foscarnet therapy for CMV retinitis." | 5.07 | Randomized phase I trial of two different combination foscarnet and ganciclovir chronic maintenance therapy regimens for AIDS patients with cytomegalovirus retinitis: AIDS clinical Trials Group Protocol 151. ( Bassiakos, Y; Geheb, H; Hooton, T; Jacobson, MA; Korvick, JA; Kramer, F; O'Donnell, JJ; Polsky, B; van der Horst, C; Walker, JD, 1994) |
| "Thirty-two patients with AIDS and previously untreated cytomegalovirus retinitis completed an induction course of foscarnet, 60 mg/kg every 8 h for 14 days, had retinitis stabilize, and were then randomly assigned to receive foscarnet maintenance as either a 90- or 120-mg/kg/day infusion administered over 2 h." | 5.07 | A dose-ranging study of daily maintenance intravenous foscarnet therapy for cytomegalovirus retinitis in AIDS. ( Causey, D; Chown, M; Davis, R; Hardy, D; Heinemann, MH; Holland, GN; Jacobson, MA; Kuppermann, BD; O'Donnell, JJ; Polsky, B, 1993) |
| "In a controlled trial of foscarnet in the treatment of cytomegalovirus (CMV) retinitis in patients with the acquired immunodeficiency syndrome (AIDS), patients with non-immediately sight-threatening lesions were randomized to receive immediate treatment with foscarnet or foscarnet treatment delayed until the first signs of retinitis progression." | 5.07 | Design of a randomized controlled trial of foscarnet in patients with cytomegalovirus retinitis associated with acquired immunodeficiency syndrome. ( Polis, MA, 1992) |
| "Circulating human immunodeficiency virus (HIV) p24 antigen levels were measured in 22 AIDS patients who had detectable serum antigen at baseline after induction and maintenance therapy of foscarnet for cytomegalovirus retinitis in phase I/II multicenter trials." | 5.07 | Effect of foscarnet therapy on human immunodeficiency virus p24 antigen levels in AIDS patients with cytomegalovirus retinitis. ( Causey, DM; Davis, RB; Grieco, MH; Hooton, TM; Jacobson, MA; McKinley, GF; Parenti, DM; Reddy, MM; van der Horst, CM, 1992) |
| "Ganciclovir and Foscarnet were compared in an open randomised trial as treatment and secondary prophylaxis of cytomegalovirus (CMV) retinitis in patients with AIDS." | 5.07 | Foscarnet and Ganciclovir in the treatment of CMV retinitis in AIDS patients: a randomised comparison. ( Gazzard, BG; Harman, C; Mathalone, B; Mitchell, S; Moyle, G, 1992) |
| "We performed a multicenter, randomized, unblinded clinical trial (the Foscarnet-Ganciclovir Cytomegalovirus Retinitis Trial) designed to compare ganciclovir with foscarnet in the treatment of cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome (AIDS)." | 5.07 | Mortality in patients with the acquired immunodeficiency syndrome treated with either foscarnet or ganciclovir for cytomegalovirus retinitis. ( , 1992) |
| "To evaluate foscarnet sodium in treating cytomegalovirus retinitis in patients with AIDS." | 5.07 | A randomized, controlled trial of foscarnet in the treatment of cytomegalovirus retinitis in patients with AIDS. ( Baird, BF; Davey, RT; Davis, M; De Smet, MD; Falloon, J; Kovacs, JA; Palestine, AG; Polis, MA; Zunich, KM; Zurlo, JJ, 1991) |
| "Intravenous foscarnet was given on an emergency basis to 30 immunosuppressed patients with cytomegalovirus (CMV) disease, of whom 28 were organ transplant recipients." | 5.06 | Sensitivity of cytomegalovirus to intravenous foscarnet treatment. ( Akesson-Johansson, A; Lernestedt, JO; Lönnqvist, B; Ringdén, O; Wahren, B, 1986) |
| "Ganciclovir (GCV), the therapy of choice for human cytomegalovirus (CMV) infections and foscarnet, a drug used to treat GCV-resistant CMV infections was approved more than twenty years ago." | 4.87 | The search for new therapies for human cytomegalovirus infections. ( Kern, ER; Prichard, MN, 2011) |
| "Many clinicians are under the impression that the combination of ganciclovir (GCV) and foscarnet is synergistic versus cytomegalovirus (CMV) and/or that combination therapy might prevent the emergence of resistance to one or both antivirals." | 4.83 | Is combination antiviral therapy for CMV superior to monotherapy? ( Drew, WL, 2006) |
| " Herpes virus type 1 and rarely type 2 may lead to painful and resistant oral ulcers, and systemic treatment with acyclovir, valaciclovir or famciclovir is indicated." | 4.79 | Viral lesions of the mouth in HIV-infected patients. ( Itin, PH; Lautenschlager, S, 1997) |
| "The use of ganciclovir in the treatment of cytomegalovirus (CMV) retinitis in patients with acquired immunodeficiency syndrome (AIDS) is limited by marrow toxicity and by the development of resistance to this agent in CMV strains capable of causing progressive disease." | 4.78 | Maintenance therapy for cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome: foscarnet. ( Jacobson, MA, 1992) |
| "Induction regimens of foscarnet and ganciclovir are highly effective in arresting cytomegalovirus (CMV) retinitis in patients with AIDS." | 4.78 | Foscarnet and ganciclovir in the treatment of cytomegalovirus retinitis. ( Polis, MA, 1992) |
| " The antiviral agents ganciclovir and foscarnet are effective against CMV retinitis and gastrointestinal diseases, although dose-limiting adverse effects and the need for long-term maintenance therapy may hinder their use in many patients." | 4.78 | Treatment and prophylaxis of cytomegalovirus disease. ( Jacobson, PA; Levinson, ML, 1992) |
| "The pyrophosphate analogue, foscarnet, selectively inhibits the DNA polymerase of human herpes viruses, including cytomegalovirus, and the reverse transcriptase of HIV." | 4.78 | Foscarnet. A review of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with cytomegalovirus retinitis. ( Chrisp, P; Clissold, SP, 1991) |
| "Letermovir (LTV) might be an alternative treatment to nephrotoxic foscarnet (FOS) in Ganciclovir (GCV) resistant cytomegalovirus (CMV) infection." | 4.02 | Use of letermovir-valganciclovir combination as a step-down treatment after foscarnet for ganciclovir-resistant CMV infection in kidney transplant recipients. ( Müller, TF; Näf, B; Rho, E; Schachter, T; von Moos, S; Wüthrich, RP, 2021) |
| "Ganciclovir (GCV) and foscarnet (FOS) are the most commonly used antivirals for preemptive treatment of cytomegalovirus (CMV) viremia in recipients of allogeneic hematopoietic cell transplantation (alloHCT)." | 3.96 | Cost analysis of ganciclovir and foscarnet in recipients of allogeneic hematopoietic cell transplant with cytomegalovirus viremia. ( Abella Ross, J; Al Malki, MM; Chen, J; Dadwal, SS; Dickter, JK; Ito, JI; Kriengkauykiat, J; Mokhtari, S; Nakamura, R; Tegtmeier, B; Yang, D; Zaia, JA, 2020) |
| "Herein, we phenotypically and enzymatically characterize the theoretical mutation Q579I in helix K and the already described clinical mutation K805Q in helix P of cytomegalovirus DNA polymerase for susceptibility to foscarnet." | 3.96 | Hypersusceptibility of Human Cytomegalovirus to Foscarnet Induced by Mutations in Helices K and P of the Viral DNA Polymerase. ( Boivin, G; Pham, VD; Piret, J; Shi, R; Zarrouk, K, 2020) |
| "This single-center, retrospective study included immunosuppressed adults with CMV viremia who received foscarnet between January 2012-July 2017." | 3.91 | Recommended foscarnet dose is not associated with improved outcomes in cytomegalovirus salvage therapy. ( Athans, V; Koval, CE; Lam, SW; Spinner, ML, 2019) |
| " We describe a case of a cytomegalovirus (CMV)-seronegative kidney transplant recipient from a CMV-seropositive donor, whose course was complicated during valganciclovir prophylaxis by CMV disease, ultimately progressing to ganciclovir, foscarnet, and cidofovir resistance." | 3.85 | Ganciclovir Dosing Strategies and Development of Cytomegalovirus Resistance in a Kidney Transplant Recipient: A Case Report. ( Agrawal, N; Beltran, D; Echenique, IA; Najafian, N; Ramirez-Ruiz, L, 2017) |
| "Human cytomegalovirus UL54 DNA polymerase gene mutations that confer foscarnet resistance in clinical practice typically cluster in the amino terminal 2, palm and finger domains." | 3.85 | Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene. ( Chou, S, 2017) |
| "Ganciclovir-resistant cytomegalovirus (GCV-R CMV) is an emerging challenge among solid organ transplant (SOT) recipients." | 3.83 | Ganciclovir-resistant cytomegalovirus infection in solid organ transplant recipients: a single-center retrospective cohort study. ( Angarone, M; Flaherty, J; Ison, MG; Penugonda, S; Rubin, J; Stosor, V; Young, PG, 2016) |
| "Eight in vitro selection experiments under brincidofovir pressure elicited the known cytomegalovirus DNA polymerase amino acid substitutions N408K and V812L and the novel exonuclease domain substitutions D413Y, E303D, and E303G, which conferred ganciclovir and cidofovir resistance with 6- to 11-fold resistance to brincidofovir or 17-fold when E303G was combined with V812L." | 3.83 | Novel Cytomegalovirus UL54 DNA Polymerase Gene Mutations Selected In Vitro That Confer Brincidofovir Resistance. ( Chou, S; Ercolani, RJ; Lanier, ER, 2016) |
| " Here, we report a case of CMV polyradiculopathy 6 months after renal transplantation that presented as a Guillain-Barre like syndrome and was successfully treated with foscarnet." | 3.79 | Cytomegalovirus polyradiculopathy of late onset in a young renal transplant recipient. ( Goumenos, DS; Kalliakmani, P; Koukoulaki, M; Marangos, M; Papachristou, E; Papasotiriou, M; Savvidaki, E, 2013) |
| "Preemptive therapy with ganciclovir (GCV) based on the results of a cytomegalovirus (CMV) antigenemia assay is a standard strategy for preventing CMV disease after allogeneic hematopoietic cell transplantation (HCT)." | 3.79 | Evaluation of the validity of preemptive therapy against cytomegalovirus disease based on antigenemia assay with a cutoff of 20 positive cells per two slides. ( Ashizawa, M; Ishihara, Y; Kako, S; Kanda, J; Kanda, Y; Kawamura, K; Kikuchi, M; Kimura, S; Machishima, T; Nakasone, H; Nishida, J; Sakamoto, K; Sato, M; Tanihara, A; Terasako-Saito, K; Wada, H; Yamasaki, R; Yamazaki, R, 2013) |
| "(Val)ganciclovir is used to treat cytomegalovirus (CMV) infection following solid organ (SOT) or hematopoietic stem cell (HSCT) transplantation." | 3.79 | The time course of development and impact from viral resistance against ganciclovir in cytomegalovirus infection. ( Cunha-Bang, Cd; Frederiksen, CM; Gustafsson, F; Iversen, M; Kirkby, N; Kjaer, J; Lepri, AC; Lundgren, JD; Rasmussen, A; Sengeløv, H; Sønderholm, M; Sørensen, SS, 2013) |
| "Human cytomegalovirus (CMV) UL54 DNA polymerase (pol) mutants with known patterns of resistance to current antivirals ganciclovir (GCV), foscarnet (FOS), and cidofovir (CDV) were tested for cyclopropavir (CPV) susceptibility by a standardized reporter-based yield reduction assay." | 3.78 | Cyclopropavir susceptibility of cytomegalovirus DNA polymerase mutants selected after antiviral drug exposure. ( Bowlin, TL; Chou, S; Marousek, G, 2012) |
| " Although he was given enough antiviral treatment against CMV and immunosuppression with high-dose methylprednisolone, the patient's vision showed no improvement, and he has almost total bilateral blindness." | 3.78 | Presumed cytomegalovirus-associated retrobulbar optic neuritis in a patient after allogeneic stem cell transplantation. ( Huang, Y; Pan, S; Wang, H; Wang, Z; Yan, H; Zheng, X, 2012) |
| "Foscarnet (FOS) is a pyrophosphate analogue that inhibits both cytomegalovirus (CMV) and human immunodeficiency virus (HIV) replication." | 3.78 | Emergence of cytomegalovirus resistance to foscarnet in a patient receiving foscarnet salvage therapy for multidrug-resistant HIV infection. ( Agut, H; Boutolleau, D; Burrel, S; Canestri, A; Clavel-Osorio, C; Katlama, C; Marcelin, AG; Seang, S; Wirden, M, 2012) |
| "We present the case of a lung transplant recipient with disseminated crystal precipitation, and granulomatous and fibrinous inflammation after therapy with foscarnet (Foscavir; AstraZeneca, Zug, Switzerland) for recurring ganciclovir-resistant cytomegalovirus (CMV) reactivation." | 3.78 | Crystal precipitation and granulomatous inflammation in multiple organs after foscarnet therapy in a lung transplant recipient. ( Boehler, A; Gaspert, A; Schuurmans, MM; Tischler, V, 2012) |
| "Cytomegalovirus (CMV) infections in kidney transplant recipients are in most cases successfully treated with oral valganciclovir (VGCV)." | 3.77 | Incidence and outcomes of ganciclovir-resistant cytomegalovirus infections in 1244 kidney transplant recipients. ( Asberg, A; Hartmann, A; Haug Dorenberg, D; Kristiansen, KI; Leivestad, T; Myhre, HA; Rollag, H, 2011) |
| "Recombinant phenotyping of cytomegalovirus (CMV) pol region III mutations from clinical specimens showed that T813S and G841A each conferred foscarnet resistance and approximately threefold increased ganciclovir resistance; adding the UL97 mutation C592G increased ganciclovir resistance to approximately sixfold." | 3.74 | Growth and drug resistance phenotypes resulting from cytomegalovirus DNA polymerase region III mutations observed in clinical specimens. ( Chou, S; Li, S; Marousek, GI; Van Wechel, LC; Weinberg, A, 2007) |
| "Although foscarnet is a promising alternative for the treatment of cytomegalovirus (CMV) infection, its toxicity can be significant in patients with advanced age." | 3.74 | Reduced dose of foscarnet as preemptive therapy for cytomegalovirus infection following reduced-intensity cord blood transplantation. ( Hori, A; Kami, M; Kato, D; Kusumi, E; Masuoka, K; Matsumura, T; Miyakoshi, S; Morinaga, S; Murashige, N; Narimatsu, H; Shibata, T; Taniguchi, S; Wake, A; Yuji, K, 2007) |
| "A human cytomegalovirus (CMV) UL54 pol exonuclease domain II mutation, D413A, found in a clinical specimen, conferred ganciclovir (GCV) and cidofovir resistance but not foscarnet resistance when incorporated into laboratory strain T2294." | 3.74 | Accelerated evolution of maribavir resistance in a cytomegalovirus exonuclease domain II mutant. ( Chou, S; Marousek, GI, 2008) |
| "Cytomegalovirus (CMV) disease is a major cause of morbidity and mortality after lung transplantation despite ganciclovir prophylaxis." | 3.74 | A single-center experience with ganciclovir-resistant cytomegalovirus in lung transplant recipients: treatment and outcome. ( Hanson, KE; Palmer, SM; Reddy, AJ; Zaas, AK, 2007) |
| "This is the first report of treatment of cytomegalovirus infection with artesunate, for a stem cell transplant recipient with a newly identified foscarnet-resistant and ganciclovir-resistant DNA polymerase L776M mutation." | 3.74 | Artesunate as a potent antiviral agent in a patient with late drug-resistant cytomegalovirus infection after hematopoietic stem cell transplantation. ( Caplan, O; Chou, S; Efferth, T; Lurain, NS; Marschall, M; Neumann, AU; Resnick, IB; Saleh, N; Shapira, MY; Stamminger, T; Wolf, DG, 2008) |
| "Diverse mutations in the cytomegalovirus (CMV) DNA polymerase (pol) gene confer resistance to one or more of the antiviral drugs ganciclovir, foscarnet or cidofovir." | 3.74 | Contrasting drug resistance phenotypes resulting from cytomegalovirus DNA polymerase mutations at the same exonuclease locus. ( Chou, S; Li, S; Marousek, G; Weinberg, A, 2008) |
| "A phenotypic method was developed to test mutations in the human cytomegalovirus (HCMV) DNA polymerase gene (UL54) suspected to confer resistance to foscarnet." | 3.73 | Phenotypic characterisation of cytomegalovirus DNA polymerase: a method to study cytomegalovirus isolates resistant to foscarnet. ( Alain, S; Ducancelle, A; Fillet, AM; Gravisse, J; Mazeron, MC; Petit, F; Pors, MJ, 2005) |
| "Foscarnet is currently licensed for the treatment of human cytomegalovirus (HCMV) infection." | 3.73 | A novel mutation in the UL54 gene of human cytomegalovirus isolates that confers resistance to foscarnet. ( Alain, S; Champier, G; Ducancelle, A; Le Pors, MJ; Mazeron, MC; Petit, F, 2006) |
| "Ganciclovir-resistant (GCV-R) cytomegalovirus (CMV) is now being reported with increasing frequency in solid organ transplant recipients." | 3.71 | Clinical characteristics of 13 solid organ transplant recipients with ganciclovir-resistant cytomegalovirus infection. ( Avery, RK; Braun, W; Flechner, SM; Goldman, M; Gordon, SM; Haug, M; Isada, CM; Kohn, D; Long, J; Longworth, DL; Lurain, NS; Maurer, J; Mawhorter, SD; Mossad, SB; Schilz, R; Schmitt, SK; Taege, AJ; Yen-Lieberman, B, 2002) |
| "To determine the prevalence of the in vitro resistance rate of cytomegalovirus (CMV) to gancyclovir (GCV) and foscarnet (FOS) among patients with AIDS and chorioretinitis." | 3.71 | [Cytomegalovirus sensitivity to anti-retroviral agents in patients infected with the human immunodeficiency virus with chorioretinitis in Spain]. ( Cañizares, MA; Casado, JL; González, J; Guerrero, A; Losada, I; Pérez-Elías, MJ; Rubio, R, 2001) |
| "The resistance of cytomegalovirus (CMV) to ganciclovir is a factor in therapeutic failure and disease progression." | 3.71 | Combination antiviral therapy for ganciclovir-resistant cytomegalovirus infection in solid-organ transplant recipients. ( Fishman, JA; Kallas, WM; Mylonakis, E, 2002) |
| "Seventeen AIDS patients with cytomegalovirus (CMV), herpes simplex virus (HSV), varicella-zoster virus (VZV) infection, Kaposi's sarcoma (KS), or a combination of these were treated with foscarnet." | 3.70 | Foscarnet decreases HIV-1 plasma load. ( Barbeau, P; Breilh, D; Denisi, R; Devianne-Garrigue, I; Dupon, M; Fleury, HJ; Leng, B; Pellegrin, I; Pellegrin, JL; Ragnaud, JM, 1998) |
| " Antiviral susceptibility testing of blood cytomegaloviral isolates was done when patients failed to respond to intravenous ganciclovir treatment for symptomatic cytomegalovirus infection." | 3.70 | Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants. ( Boeckh, M; Corey, L; Davis, CL; Koelle, DM; Limaye, AP, 2000) |
| "A rapid screening assay for the detection of resistance to ganciclovir and foscarnet of primary isolates of human cytomegalovirus from culture-positive blood samples was developed by using single doses of both drugs and an immediate-early antigen plaque reduction assay." | 3.69 | Rapid screening for resistance to ganciclovir and foscarnet of primary isolates of human cytomegalovirus from culture-positive blood samples. ( Baldanti, F; Gerna, G; Percivalle, E; Revello, MG; Sarasini, A; Zavattoni, M, 1995) |
| "CMV esophagitis has a favorable response to induction ganciclovir therapy, and a long-term remission may occur after induction therapy alone." | 3.69 | Cytomegalovirus esophagitis in AIDS: a prospective evaluation of clinical response to ganciclovir therapy, relapse rate, and long-term outcome. ( Schwartz, DA; Straub, RF; Wilcox, CM, 1995) |
| " The first developed three episodes of cytomegaloviremia requiring anti-viral therapy; the third episode accompanied by cytomegalovirus hepatitis which required prolonged therapy with foscarnet." | 3.69 | Unusual infections following allogeneic bone marrow transplantation for chronic lymphocytic leukemia. ( Brincat, S; Catovsky, D; Iveson, T; Jameson, B; Mehta, J; Paul, B; Powles, R; Singhal, S; Treleaven, J; Zomas, A, 1994) |
| "To determine if ganciclovir given three times per week post-transplant is tolerable and effective for prevention of cytomegalovirus (CMV) infection in recipients of T cell-depleted marrow from related or unrelated donors, we have used ganciclovir 2." | 3.69 | Ganciclovir three times per week is not adequate to prevent cytomegalovirus reactivation after T cell-depleted marrow transplantation. ( Andersson, B; Deisseroth, AB; Giralt, S; Goodrich, J; Ippoliti, C; Luna, M; Mehra, R; Panina, A; Przepiorka, D; van Besien, K, 1994) |
| "These results suggest that while ganciclovir therapy may clinically stabilize CMV retinitis in patients with AIDS, it does not appear to prevent the development of, or be effective in the treatment of, CMV encephalitis." | 3.69 | The development of cytomegalovirus encephalitis in AIDS patients receiving ganciclovir. ( Berman, SM; Kim, RC, 1994) |
| "Four human cytomegalovirus (HCMV) isolates from four different AIDS patients treated with both ganciclovir and foscarnet and not responding clinically to antiviral treatment, were studied in order to verify the occurrence of double resistance to both drugs, and to define whether single or multiple HCMV strains could be responsible for the double resistance." | 3.69 | Double resistance to ganciclovir and foscarnet of four human cytomegalovirus strains recovered from AIDS patients. ( Baldanti, F; Barbi, M; Brerra, R; Furione, M; Gerna, G; Percivalle, E; Sarasini, A, 1995) |
| "Three human cytomegalovirus (HCMV) strains (VR4760, VR4955, and VR5120) showing double resistance to ganciclovir (GCV) and foscarnet (PFA) were isolated from three patients with AIDS who underwent multiple sequential courses of therapy with GCV and PFA (A." | 3.69 | Single amino acid changes in the DNA polymerase confer foscarnet resistance and slow-growth phenotype, while mutations in the UL97-encoded phosphotransferase confer ganciclovir resistance in three double-resistant human cytomegalovirus strains recovered f ( Baldanti, F; Biron, KK; Chou, S; Gerna, G; Sarasini, A; Silini, E; Stanat, SC; Underwood, MR, 1996) |
| "Four human cytomegalovirus strains with double resistance to both ganciclovir and foscarnet were recovered from acquired immunodeficiency syndrome (AIDS) patients." | 3.69 | Four dually resistant human cytomegalovirus strains from AIDS patients: single mutations in UL97 and UL54 open reading frames are responsible for ganciclovir- and foscarnet-specific resistance, respectively. ( Baldanti, F; Barbi, M; Biron, KK; Gerna, G; Lazzarin, A; Sarasini, A; Silini, E, 1995) |
| "In a previous study, we showed that patients undergoing allogeneic hemopoietic stem cell transplantation (HSCT) who had cytomegalovirus (CMV) antigenemia with more than 4 CMV antigen-positive cells/200,000 have a high transplant-related mortality (TRM) rate, despite treatment with ganciclovir or foscarnet." | 3.69 | Combined foscarnet-ganciclovir treatment for cytomegalovirus infections after allogeneic hemopoietic stem cell transplantation. ( Bacigalupo, A; Bregante, S; Gualandi, F; Isaza, A; Lamparelli, T; Marmont, AM; Occhini, D; Tedone, E; Trespi, G; Van Lint, MT, 1996) |
| "Drug-resistant human cytomegalovirus (HCMV) strains were selected in human embryonic lung (HEL) fibroblasts under pressure of the (S)-3-hydroxy-2-phosphonylmethoxypropyl (HPMP) derivatives of cytosine (HPMPC) and adenine (HPMPA), the 2-phosphonylmethoxyethyl (PME) derivative of 2,6-diaminopurine (PMEDAP), ganciclovir (GCV), acyclovir (ACV), and foscarnet (PFA)." | 3.69 | Patterns of resistance and sensitivity to antiviral compounds of drug-resistant strains of human cytomegalovirus selected in vitro. ( Andrei, G; De Clercq, E; Snoeck, R, 1996) |
| "Cytomegalovirus (CMV) infection is still a problem for organ transplant recipients despite studies that long-term prophylaxis with high dose of acyclovir or ganciclovir given to all organ recipients may limit the consequences of infection and disease." | 3.69 | Early ganciclovir therapy effectively controls viremia and avoids the need for cytomegalovirus (CMV) prophylaxis in renal transplant patients with cytomegalovirus antigenemia. ( Baruzzo, S; Gotti, E; Moioli, F; Perani, V; Remuzzi, G; Suter, F, 1996) |
| "Antiviral susceptibilities to ganciclovir, foscarnet, and cidofovir and sequencing of UL97 and DNA polymerase were done on 23 cytomegalovirus (CMV) isolates from 10 immunocompromised persons with end-organ CMV disease who were treated with ganciclovir alone or ganciclovir followed by foscarnet." | 3.69 | Antiviral susceptibilities and analysis of UL97 and DNA polymerase sequences of clinical cytomegalovirus isolates from immunocompromised patients. ( Balfour, HH; Boivin, G; Chou, S; Erice, A; Gil-Roda, C; Hanson, MN; Pérez, JL; Sannerud, KJ, 1997) |
| "In a human immunodeficiency virus-infected subject, cytomegalovirus (CMV) isolated 9 months after the patient began oral ganciclovir prophylaxis was resistant to ganciclovir and cidofovir and contained mutations in both UL97 and Pol coding regions." | 3.69 | Evolution of mutations conferring multidrug resistance during prophylaxis and therapy for cytomegalovirus disease. ( Chou, S; Drew, WL; Follansbee, SE; Guentzel, S; Lalezari, JP; Marousek, G; Miner, RC; Poscher, ME, 1997) |
| "In order to assess the value of quantitative measurement of cytomegalovirus (CMV) antigenaemia as a marker for the guidance of antiviral chemotherapy in the AIDS setting, 33 patients with CMV complications and showing at least 20 pp65-positive polymorphonuclear leucocytes per 2 x 10(5) cells, received either ganciclovir or foscarnet as induction and maintenance therapy." | 3.69 | Quantitative cytomegalovirus (CMV) antigenaemia during antiviral treatment of AIDS-related CMV disease. ( Chiodo, F; Coronado, OV; Dal Monte, P; Lazzarotto, T; Manfredi, R; Mastroianni, A; Spezzacatena, P, 1997) |
| " The patient also suffered from recurrent cytomegalovirus (CMV) viremia, treated with foscarnet and ganciclovir." | 3.69 | Successful allogeneic bone marrow transplantation in a 2.5-year-old boy with ongoing cytomegalovirus viremia and severe aplastic anemia after orthotopic liver transplantation for non-A, non-B, non-C hepatitis. ( Ericzon, BG; Hägglund, H; Ringdén, O; Sparrelid, E; Winiarski, J, 1997) |
| " Cytomegalovirus prophylaxis consisted of acyclovir for SIBs and foscarnet for MUDs." | 3.69 | Bone marrow transplantation for chronic myeloid leukemia (CML) from unrelated and sibling donors: single center experience. ( Bacigalupo, A; Barbanti, M; Corvo, R; Delfino, L; Ferrara, GB; Ficai, G; Frassoni, F; Ghinatti, C; Gualandi, F; Lamparelli, T; Morabito, A; Occhini, D; Pozzi, S; Sacchi, N; Van Lint, MT; Vitale, V; Zikos, P, 1997) |
| "While progress has been made in managing cytomegalovirus (CMV) infections, researchers are debating the problem of drug resistance and the significance of ganciclovir resistance research data." | 3.69 | CMV resistance: "more complicated than we thought". ( Mascolini, M, 1996) |
| "The human cytomegalovirus (HCMV) gene UL97 product was shown to play an important role in phosphorylation of ganciclovir (GCV) in HCMV-infected cells." | 3.68 | Rapid detection of cytomegalovirus strains resistant to ganciclovir through mutations within the gene UL97. ( Alain, S; Mazeron, MC; Morinet, F; Pépin, JM; Raskine, L; Sanson-Le Pors, MJ, 1993) |
| "An AIDS patient experienced an exacerbation of cytomegalovirus retinitis and was treated with foscarnet." | 3.68 | Foscarnet-induced severe hypomagnesemia and other electrolyte disorders. ( Gearhart, MO; Sorg, TB, 1993) |
| "Foscarnet (phosphonoformate) is a potent virustatic drug against herpes-like viruses and is widely used in the therapy of cytomegalovirus infections in immunosuppressed patients." | 3.68 | Foscarnet penetrates the blood-brain barrier: rationale for therapy of cytomegalovirus encephalitis. ( Brockmeyer, NH; Goos, M; Hengge, UR; Malessa, R; Ravens, U, 1993) |
| "Ganciclovir and foscarnet are both effective for cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome, but the benefits of either agent given alone are limited." | 3.68 | Treatment of aggressive cytomegalovirus retinitis with ganciclovir in combination with foscarnet in a child infected with human immunodeficiency virus. ( Butler, KM; De Smet, MD; Husson, RN; Jarosinski, P; Lovato, G; Manjunath, K; Montrella, K; Mueller, B; Nussenblatt, RB; Pizzo, PA, 1992) |
| "Foscarnet and ganciclovir appear to be of similar effectiveness in halting active infection when given as induction therapy and in forestalling progression of disease when given as maintenance therapy in persons with AIDS who have cytomegalovirus (CMV) retinitis." | 3.68 | Therapeutic algorithm for treatment of cytomegalovirus retinitis in persons with AIDS. A roundtable summary. ( Balfour, HH; Drew, WL; Hardy, WD; Heinemann, MH; Polsky, B, 1992) |
| "Sequential visual field testing is an extremely helpful adjunct to ophthalmoscopy and fundus photography in the management of cytomegalovirus (CMV) retinitis with the antiviral agents ganciclovir or foscarnet in patients with the acquired immune deficiency syndrome (AIDS)." | 3.68 | Visual field testing in the management of cytomegalovirus retinitis. ( Bachman, DM; Bruni, LM; DiGioia, RA; Harris, PJ; McMackin, CM; Pistole, MC; Thomas, RM; Ward, DJ, 1992) |
| "Infections caused by cytomegalovirus (CMV) resistant in vitro to ganciclovir, defined as requiring greater than 6 mumols of ganciclovir for ED50 have developed in some AIDS patients with progressive CMV retinitis despite chronic ganciclovir therapy." | 3.68 | Foscarnet therapy for ganciclovir-resistant cytomegalovirus retinitis in patients with AIDS. ( Drew, WL; Feinberg, J; Jacobson, MA; Miner, RD; O'Donnell, JJ; Parenti, D; Whitmore, PV, 1991) |
| "Foscarnet, administered via a central line, was used for the treatment of 18 episodes of cytomegalovirus (CMV) esophageal ulceration in 15 patients, and in the treatment of 27 episodes of CMV colitis in 22 patients." | 3.68 | Foscarnet in the treatment of cytomegalovirus infection of the esophagus and colon in patients with the acquired immune deficiency syndrome. ( Connolly, GM; Gazzard, BG; Hawkins, DA; Nelson, MR, 1991) |
| "Foscarnet is an investigational antiviral agent that has been used effectively in the treatment of cytomegalovirus (CMV) retinitis in AIDS patients." | 3.68 | Successful foscarnet therapy for cytomegalovirus retinitis in an AIDS patient undergoing hemodialysis: rationale for empiric dosing and plasma level monitoring. ( Gambertoglio, JG; Graziani, AL; Grunwald, JE; MacGregor, RR; Weiss, R, 1991) |
| "Ten patients with acquired immunodeficiency syndrome with newly diagnosed cytomegalovirus (CMV) retinitis were treated with an induction regimen of intravenous foscarnet, 60 mg/kg of body weight, administered as a 2-h infusion and repeated every 8 h for 14 days." | 3.67 | Foscarnet treatment of cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome. ( Jacobson, MA; Mills, J; O'Donnell, JJ, 1989) |
| "Eight patients, 7 renal and 1 combined renal and pancreas allograft recipients with generalized cytomegalovirus (CMV) infection were treated with continuous intravenous foscarnet infusion (0." | 3.67 | Evaluation by immune scanning electron microscopy of foscarnet treatment of cytomegalovirus infection in patients with renal transplants. ( Akesson-Johansson, A; Andersson, J; Brattström, C, 1989) |
| " Following allogeneic bone marrow transplantation, he developed cytomegalovirus retinitis, which was treated successfully with trisodium phosphonoformate (foscarnet)." | 3.67 | Foscarnet as treatment for cytomegalovirus retinitis following bone marrow transplantation. ( Arthur, C; Ganly, PS; Goldman, JM; Schulenburg, WE, 1988) |
| "During study treatment, severe neutropenia (< 0." | 2.70 | Randomized multicenter trial of foscarnet versus ganciclovir for preemptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation. ( Cordonnier, C; Einsele, H; Engelhard, D; Finke, J; Lee, J; Link, H; Ljungman, P; Reusser, P; Rovira, M; Volin, L, 2002) |
| "Foscarnet was started on day +1 after BMT and continued until day +100." | 2.69 | Foscarnet prophylaxis of cytomegalovirus infections in patients undergoing allogeneic bone marrow transplantation (BMT): a dose-finding study. ( Bacigalupo, A; Benvenuto, F; Berisso, G; Bertilson, S; Bregante, S; Figari, O; Gualandi, F; Lamparelli, T; Mordini, N; Raiola, AM; Tedone, E; Trespi, G; Van Lint, MT, 2000) |
| " There was no difference between the 2 groups in either serious adverse events or rise of creatinine to > or = 2." | 2.69 | Safety of oral versus intravenous hydration during induction therapy with intravenous foscarnet in AIDS patients with cytomegalovirus infections. ( Benson, P; Cheung, TW; Jayaweera, DT; Nahass, R; Olson, C; Pearce, D; Wool, GM, 2000) |
| " However, patients with positive baseline CMV blood cultures had a significantly more shallow dose-response curve." | 2.68 | Relationship between foscarnet exposure, baseline cytomegalovirus (CMV) blood culture and the time to progression of CMV retinitis in HIV-positive patients. ( Aweeka, F; Drusano, GL; Eaton, C; Gambertoglio, J; Jacobson, M; Lane, HC; Martin-Munley, S; Polis, M, 1996) |
| " Two patients developed mild serum-creatinine increases requiring adjustment of the foscarnet dosage according to protocol." | 2.68 | Foscarnet for pre-emptive therapy of CMV infection detected by a leukocyte-based nested PCR in allogeneic bone marrow transplant patients. ( Aschan, J; Ehrnst, A; Ljungman, P; Lönnqvist, B; Oberg, G; Pauksen, K; Sulila, P, 1996) |
| " Adverse events resulted in discontinuance of medication in the case of one patient." | 2.68 | Treatment of gastrointestinal cytomegalovirus infection with twice-daily foscarnet: a pilot study of safety, efficacy, and pharmacokinetics in patients with AIDS. ( Dieterich, DT; Faust, MJ; Johnson, J; Lew, EA; Martin-Munley, S; Nix, D; Poles, MA, 1997) |
| "Foscarnet is a safe and effective agent for prevention of CMV disease in allogeneic transplant recipients unable to receive ganciclovir." | 2.68 | Foscarnet for prevention of cytomegalovirus infection in allogeneic marrow transplant recipients unable to receive ganciclovir. ( Andersson, B; Champlin, R; Gajewski, J; Giralt, S; Ippoliti, C; Khouri, I; Mehra, R; Morgan, A; Przepiorka, D; van Besien, K; Warkentin, D, 1997) |
| "Foscarnet was then given prophylactically in 11 additional TCD patients to test whether we could (1) prevent CMV reactivation, and (2) reduce transplant-related mortality." | 2.67 | CMV prophylaxis with foscarnet in allogeneic bone marrow transplant recipients at high risk of developing CMV infections. ( Bacigalupo, A; Frassoni, F; Gualandi, F; Lonngren, M; Moro, F; Occhini, D; Sanna, MA; Tedone, E; Trespi, G; Van Lint, MT, 1994) |
| "Foscarnet was administered as a continuous infusion of 200 mg/kg (prior to 1988) or as an intermittent infusion of 60 mg/kg t." | 2.67 | Treatment of HIV-related cytomegalovirus disease of the gastrointestinal tract with foscarnet. ( Blanshard, C, 1992) |
| "Treatment with Foscarnet may be initially effective, but does not eliminate cytomegalovirus infection." | 2.66 | Cytomegalovirus colitis and oesophageal ulceration in the context of AIDS: clinical manifestations and preliminary report of treatment with Foscarnet (phosphonoformate). ( Barrison, I; Boylston, A; Forster, S; Jeffries, DJ; Pinching, AJ; Thom, S; Unwin, R; Weber, JN, 1987) |
| "Although cytomegalovirus is one of the most prevalent viral pathogens on the globe, in immunocompetent individuals infected with cytomegalovirus usually no specific antiviral therapy is required." | 2.61 | [Current treatment modalities of immunocompromised patients with cytomegalovirus infection. II. Therapeutic options and management strategies]. ( Sinkó, J, 2019) |
| "Foscarnet is a suitable option as both pre-emptive therapy or for the treatment of active disease in these patients." | 2.48 | Foscarnet in the management of cytomegalovirus infections in hematopoietic stem cell transplant patients. ( Bacigalupo, A; Boyd, A; Clissold, S; Curtis, J; Slipper, J, 2012) |
| "Foscarnet is a reasonable first line anti CMV agent in this setting." | 2.46 | CMV-related thrombocytopenia treated with foscarnet: a case series and review of the literature. ( Chajek-Shaul, T; Hershcovici, T; Koslowsky, B; Wolf, D; Yaari, S, 2010) |
| " New antiviral agents are urgently needed with less adverse effects, good oral bioavailability and possibly novel targets or mechanisms of action to avoid cross-resistance and to improve the ability to suppress the selection of resistant virus strains by combination therapy." | 2.45 | Antiviral treatment of cytomegalovirus infection and resistant strains. ( Bunjes, D; Härter, G; Mertens, T; Michel, D; Schreiber, A; Schubert, A, 2009) |
| " The emergence of drug resistance may be reduced by optimization of host immunity, use of potent antiviral drug regimens, and adherence to dosing regimens that adequately suppress viral replication." | 2.41 | Cytomegalovirus drug resistance and clinical implications. ( Chou, SW, 2001) |
| "Penile ulcers are best managed by stopping the infusion until the ulcers heal; they may be prevented by paying careful attention to personal hygiene." | 2.40 | Minimising the dosage-limiting toxicities of foscarnet induction therapy. ( Jayaweera, DT, 1997) |
| "For the treatment of CMV-associated pneumonitis, it is recommended that ganciclovir and IVIG be used in combination for the bone marrow transplant recipient and that ganciclovir be used with or without IVIG in patients in other transplantation groups." | 2.38 | Prevention and treatment of cytomegalovirus pneumonia in transplant recipients. ( Zaia, JA, 1993) |
| "How to treat cytomegalovirus infections in patients infected with the human immunodeficiency virus constitutes one of the best examples of the quandaries engendered by these advances, and the topic is reviewed in this first AIDS Commentary update." | 2.38 | Cytomegalovirus infection in patients with AIDS. ( Drew, WL, 1992) |
| "Foscarnet has a low solubility and a high degree of ionization at physiologic pH, requiring it to be administered in higher doses and larger volumes." | 2.38 | Approaches to the treatment of cytomegalovirus retinitis: ganciclovir and foscarnet. ( Jacobson, MA; O'Donnell, JJ, 1991) |
| " Myelosuppression may be further exacerbated in AIDS patients by such other agents as zidovudine or trimethoprim/sulfamethoxazole, often necessitating dosage reductions or discontinuation of these agents in patients receiving ganciclovir." | 2.38 | Foscarnet sodium. ( Baltz, JK; Minor, JR, 1991) |
| "CMV disease is a major problem in AIDS, though with a different profile from that seen in other immunosuppressed patients." | 2.38 | Cytomegalovirus infection in the acquired immune deficiency syndrome. ( Pinching, AJ, 1989) |
| "Acyclovir is a prototype of this improved process." | 2.37 | Promising new antiviral drugs. ( Bryson, YJ, 1988) |
| " An important direction for future clinical research is the development of more effective and less toxic therapy, as well as orally bioavailable drugs for maintenance therapy." | 2.37 | Serious cytomegalovirus disease in the acquired immunodeficiency syndrome (AIDS). Clinical findings, diagnosis, and treatment. ( Jacobson, MA; Mills, J, 1988) |
| "Cytomegalovirus retinitis is probably the result of hematogenous spread of the virus to the retina after systemic reactivation of a latent cytomegalovirus infection." | 2.37 | The diagnosis of cytomegalovirus retinitis. ( Bloom, JN; Palestine, AG, 1988) |
| " In the earliest published small case series investigating the optimal infusion modality, patients with acquired immunodeficiency syndrome (AIDS) due to the human immunodeficiency virus (HIV) received either continuous infusion or intermittent dosing of foscarnet." | 1.62 | Continuous-Infusion Foscarnet Facilitates Administration in Hematopoietic Stem Cell Transplantation Patients. ( Brown, JW; Domingo, W; Johnsrud, JJ; Nguyen, IT, 2021) |
| "Although mortality was high in this population, foscarnet use, with proper precautions, was generally safe and significant renal dysfunction was lower than previously reported in other sources, even with extended use." | 1.48 | Safety and efficacy of foscarnet for the management of ganciclovir-resistant or refractory cytomegalovirus infections: A single-center study. ( Allen, A; Ison, MG; Lacloche, L; Pierce, B; Richardson, CL, 2018) |
| "Foscarnet is a main treatment for disseminated cytomegalovirus infection in immunocompromised patients." | 1.46 | Foscarnet-related Hypercalcemia During CMV Treatment in an Infant With SCID: A Case Report and Review of Literature. ( Rabinowicz, S; Somech, R; Yeshayahu, Y, 2017) |
| "Foscarnet was therefore administered and her CMV disease resolved within 2 weeks." | 1.43 | Successful treatment with foscarnet for ganciclovir-resistant cytomegalovirus infection in a kidney transplant recipient: A case report. ( Fujita, H; Hatanaka, K; Higuchi, H; Iwami, D; Morita, K; Ogawa, Y; Oishi, Y; Sasaki, H; Shinohara, N, 2016) |
| "Leflunomide has been used to treat resistant CMV infections, however, data on efficacy, safety, and guidance for therapeutic drug level monitoring are lacking." | 1.43 | Adjuvant and salvage therapy with leflunomide for recalcitrant cytomegalovirus infections in hematopoietic cell transplantation recipients: A case series. ( Ariza-Heredia, E; Chemaly, RF; Doan, V; El Chaer, F; Jan, A; Mori, N; Oliver, N; Shah, D; Tayar, J; Tverdek, F; Wang, E, 2016) |
| "A severely T-cell-depleted patient with chronic lymphocytic leukemia developed CMV pneumonia and high plasma viral loads that were poorly responsive to antiviral therapy." | 1.40 | Improved detection of emerging drug-resistant mutant cytomegalovirus subpopulations by deep sequencing. ( Chou, S; Ercolani, RJ; Lefterova, MI; Pinsky, BA; Sahoo, MK; Strasfeld, LM, 2014) |
| "Foscarnet is an active agent against cytomegalovirus (CMV) infection after hematopoietic stem cell transplantation (HSCT), as well as ganciclovir." | 1.36 | Use of foscarnet for cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation from a related donor. ( Asakura, M; Atsuta, Y; Etoh, T; Fukuda, T; Hatanaka, K; Ikegame, K; Kanamori, H; Mori, T; Ogawa, H; Sakamaki, H; Suzuki, R; Takami, A; Taniguchi, S; Yoshida, T; Yoshihara, S; Yujiri, T, 2010) |
| "Persistent erythema multiforme is a rare disorder with only 23 known cases reported in the literature." | 1.34 | Persistent erythema multiforme and CMV infection. ( Grossman, ME; Hinds, G; Husain, S; Hutt, C; Pol-Rodriguez, M; Wanner, M, 2007) |
| "A 31-year-old man with acute myelogenous leukemia underwent CBT." | 1.33 | Pancreatic hyperamylasemia and hyperlipasemia in association with cytomegalovirus infection following unrelated cord blood transplantation for acute myelogenous leukemia. ( Asano, S; Iseki, T; Konuma, T; Ooi, J; Takahashi, S; Takasugi, K; Tojo, A; Tomonari, A; Tsukada, N, 2006) |
| "Foscarnet was discontinued because of concern about its potential central nervous system toxicity." | 1.31 | Ganciclovir-resistant cytomegalovirus encephalitis in a bone marrow transplant recipient. ( Balfour, HH; Clark, HB; Holman, CJ; Julin, JE; Krivit, W; van Burik, JH; Webb, C, 2002) |
| "Foscarnet is an antiviral agent widely used in the treatment of cytomegalovirus (CMV) infection." | 1.31 | Removal of Foscarnet by hemodialysis using dialysate-side values. ( Gambertoglio, JG; Ing, TS; Leehey, DJ; Patel, SB; Popli, A; Sam, R, 2000) |
| "Foscarnet (90 mg/kg) was given every 12 h, day +11 to day +16." | 1.31 | Foscarnet--an alternative for cytomegalovirus prophylaxis after allogeneic stem cell transplantation? ( Bornhäuser, M; Ehninger, G; Geissler, G; Kroschinsky, F; Naumann, R; Ordemann, R; Schwerdtfeger, R, 2000) |
| "An exacerbation of the myelitis, retinitis, encephalitis and colitis was observed and a cytomegalovirus infection diagnosed." | 1.31 | CMV complications in common variable immunodeficiency. ( Schmidt, RE; Werwitzke, S; Witte, T, 2000) |
| " Continued induction dosing or re-induction may protect against early breakthrough CMV disease and CMV-related death among patients with rising antigenemia on preemptive therapy." | 1.31 | Rising pp65 antigenemia during preemptive anticytomegalovirus therapy after allogeneic hematopoietic stem cell transplantation: risk factors, correlation with DNA load, and outcomes. ( Boeckh, M; Corey, L; Davis, C; Drew, WL; Gooley, T; Huang, M; Miner, R; Nichols, WG, 2001) |
| "Patients with multiple myeloma and lymphoma, possibly owing to a combination of disease-related characteristics and prior immunosuppressive treatment, had high rates of CMV reactivation and may require more frequent diagnostic evaluation and prompt therapeutic intervention." | 1.31 | Cytomegalovirus infection and non-neutropenic fever after autologous stem cell transplantation: high rates of reactivation in patients with multiple myeloma and lymphoma. ( Bolaños-Meade, J; Buddharaju, LN; Chen, T; Cottler-Fox, M; Cross, A; Fassas, AB; Lovchik, JC; Rapoport, A; Tricot, G, 2001) |
| "The initial and maintenance treatment of CMV retinitis must be individualized based on the characteristics of the lesions, including location and extent, specific patient factors, and characteristics of available therapies among others." | 1.30 | Guidelines for the treatment of cytomegalovirus diseases in patients with AIDS in the era of potent antiretroviral therapy: recommendations of an international panel. International AIDS Society-USA. ( Benson, CA; Deutsch, TA; Dieterich, DT; Drew, WL; Feinberg, J; Friedberg, DN; Griffiths, PD; Hardy, WD; Holland, GN; Jabs, DA; Jacobson, MA; Kessler, HA; Polis, MA; Powderly, WG; Spector, SA; Walmsley, S; Whitley, RJ, 1998) |
| "PFA may be an effective therapy for AIDS-related KS; prospective trials are indicated." | 1.30 | Effect of antiviral drugs used to treat cytomegalovirus end-organ disease on subsequent course of previously diagnosed Kaposi's sarcoma in patients with AIDS. ( Gee, L; Jacobson, MA; Lugo, D; Robles, R, 1999) |
| "Foscarnet is an antiviral agent used to treat cytomegalovirus infection in AIDS patients and in transplant recipients." | 1.30 | Irreversible glomerular lesions induced by crystal precipitation in a renal transplant after foscarnet therapy for cytomegalovirus infection. ( Assem, M; Justrabo, E; Martin, L; Maurice-Estepa, L; Mousson, C; Rifle, G; Tanter, Y; Zanetta, G, 1999) |
| "CMV viremia was present in 4 patients." | 1.29 | Cytomegalovirus ventriculoencephalitis in AIDS patients. ( Fernandez-Viladrich, P; Ferrer, I; Gudiol, F; Perez, JL; Podzamczer, D; Reñe, R; Salazar, A; Santin, M, 1995) |
| "Among the 861 patients with AIDS treated in our unit from 1991 to 1993, 7 cases involving cytomegalovirus infection of the conus medullaris and/or the cauda equina were studied retrospectively." | 1.29 | [Lesions of the conus medullaris and the cauda equina caused by cytomegalovirus in HIV infection. 7 cases]. ( el Amrani, M; Girard, PM; Gozlan, J; Jacomet, C; Lebrette, MG; Monfort, L; Rozenbaum, W, 1995) |
| "Furthermore, this patient had sclerosing cholangitis of the intra- and extrahepatic bile ducts as well as papillary stenosis." | 1.29 | Acalculous cholecystitis associated with cytomegalovirus and sclerosing cholangitis in a patient with acquired immunodeficiency syndrome. ( Baron, DL; Brunton, JL; Gallinger, S; Keshavjee, SH; Magee, LA; Mullen, BJ, 1993) |
| "Effective diagnosis and treatment of cytomegalovirus infection of the nervous system in AIDS patients has been limited by a lack of sensitive diagnostic measures." | 1.29 | Prognosis and response to therapy of cytomegalovirus encephalitis and meningomyelitis in AIDS. ( Cohen, BA, 1996) |
| "Since incremental increases in residual clearance of 30% or more generally will result in clinically significant changes in a drug's serum concentration, foscarnet dosage needs to be individualized for patients receiving peritoneal dialysis." | 1.29 | Disposition of foscarnet during peritoneal dialysis. ( Akers, A; Alexander, AC; Aweeka, FT; Fraley, DS; Matzke, GR, 1996) |
| "In persons with AIDS (PWAs), cytomegalovirus (CMV) infection can cause a broad spectrum of clinical manifestations." | 1.29 | Spectrum and treatment of cytomegalovirus disease in persons with AIDS. ( Spector, SA, 1996) |
| "Foscarnet was discontinued because of adverse events in 3 (3%) of 97 patients, with treatment being stopped in 2 patients because of renal insufficiency and in 1 patient because of an acute neurologic disorder." | 1.28 | Foscarnet induction therapy for cytomegalovirus retinitis in AIDS: comparison of twice-daily and three-times-daily regimens. ( Brancon, C; Caumes, E; Cochereau-Massin, I; Dahan, R; Dohin, E; Gentilini, M; Katlama, C; Robinet, M; Rogeaux, O, 1992) |
| "Foscarnet was given as a continuous intravenous infusion." | 1.28 | Foscarnet for treatment of cytomegalovirus infections in bone marrow transplant recipients. ( Aschan, J; Ljungman, P; Lönnqvist, B; Ohlman, S; Ringdén, O, 1992) |
| " Pharmacokinetic parameters remained stable throughout the study." | 1.28 | Pharmacokinetics of foscarnet after twice-daily administrations for treatment of cytomegalovirus disease in AIDS patients. ( Blanshard, C; Dohin, E; Frostegard, C; Gazzard, BG; Gazzard, D; Katlama, C; Singlas, E; Taburet, AM; Zorza, G, 1992) |
| "We treated a patient who had acquired immunodeficiency syndrome and cytomegalovirus retinitis of the left eye." | 1.28 | Intravitreal foscarnet for cytomegalovirus retinitis in a patient with acquired immunodeficiency syndrome. ( Chipont, E; Díaz-Llopis, M; España, E; Menezo, JL; Navea, A; Sanchez, S, 1992) |
| "After withdrawal from maintenance treatment, a relapse of cytomegalovirus retinitis occurred, which was again successfully treated with ganciclovir." | 1.28 | 2.5 years survival with sequential ganciclovir/foscarnet treatment in a patient with acquired immune deficiency syndrome and cytomegalovirus retinitis. ( Geier, SA; Goebel, FD; Klauss, V; Kronawitter, U; Matuschke, A, 1992) |
| "Forty-four percent remained free of recurrences until they died (for up to 15 months); 56% had 1 to 4 recurrences, altogether 35 episodes, of which 14 occurred after withdrawal of therapy." | 1.28 | [Cytomegalovirus retinitis in AIDS. Effectiveness and complications of long-term therapy]. ( Fabricius, EM; Popescu, M; Schmitz, K, 1992) |
| "Neutropenia was the most frequent and serious side-effect of ganciclovir, 76% patients having neutrophil counts less than 1." | 1.28 | Cytomegalovirus infection in AIDS. Patterns of disease, response to therapy and trends in survival. ( Anderson, S; Beck, EJ; Coker, R; Coleman, D; Harris, JR; Main, J; Migdal, C; Peters, BS; Pinching, AJ, 1991) |
| "Fifty AIDS patients were investigated for human cytomegalovirus (HCMV) viraemia when potentially HCMV-related clinical symptoms or syndromes were observed." | 1.28 | Early virus isolation, early structural antigen detection and DNA amplification by the polymerase chain reaction in polymorphonuclear leukocytes from AIDS patients with human cytomegalovirus viraemia. ( Gaballo, A; Gerna, G; Milanesi, G; Parea, M; Percivalle, E; Zavattoni, M; Zipeto, D, 1991) |
| " Therefore we began treatment with trisodium phosphonoformate (Foscavir) at a dosage of 60 mg/kg body weight per day (3 weeks), continuing with maintenance therapy at 90 mg/kg body weight per day (7 days a week)." | 1.28 | [Therapeutic alternative or 2d choice drug. Trisodium phosphonoformate in cytomegalovirus retinitis]. ( Gümbel, H; Helm, EB; Ohrloff, C; Schalnus, R, 1991) |
| "Foscarnet has been shown to be active in vitro against the human immunodeficiency virus and all human herpesviruses including cytomegalovirus (CMV)." | 1.28 | Pharmacokinetics of intermittently administered intravenous foscarnet in the treatment of acquired immunodeficiency syndrome patients with serious cytomegalovirus retinitis. ( Aweeka, F; Gambertoglio, J; Jacobson, MA; Mills, J, 1989) |
| "Foscarnet is a pyrophosphate analogue that has been successfully used in severe cytomegalovirus (CMV) infections." | 1.28 | Foscarnet nephrotoxicity: mechanism, incidence and prevention. ( Baumelou, A; Beaufils, H; Danis, M; Deray, G; Dohin, E; Gentilini, M; Katlama, C; Levaltier, B; Martinez, F; Rozenheim, M, 1989) |
| " Maintenance therapy with DHPG would appear to be necessary to prevent relapse, but the logistics of this are difficult, and the effective dosage of DHPG is as yet uncertain." | 1.27 | Treatment of CMV retinitis in an AIDS patient. ( Acheson, JF; Bradbeer, C; Shah, SM; Spalton, DJ; Thin, RN, 1987) |
| "Foscarnet (FC) is a new antiviral agent which has been recently proposed for the treatment of severe cytomegalovirus (CMV) infections in immunocompromised patients." | 1.27 | Acute renal failure induced by foscarnet: 4 cases. ( Baumelou, A; Cacoub, P; Deray, G; Gentilini, M; Jacobs, C; Le Hoang, P; Rousselie, R; Rozenbaum, W; Soubrie, C, 1988) |
| " The dosage of Foscarnet was increased during the study." | 1.27 | Clinical experiences with phosphonoformate (foscarnet) treatment of viral diseases following renal transplantation. ( Ahlmén, J; Brynger, H; Lycke, E; Wijnween, AC, 1985) |
| " Adverse effects, such as decreased haemoglobin, decreased renal function and increased serum calcium, were observed in a few patients only." | 1.27 | Pharmacokinetics, safety and preliminary clinical experiences using foscarnet in the treatment of cytomegalovirus infections in bone marrow and renal transplant recipients. ( Ahlmén, J; Klintmalm, G; Lernestedt, JO; Lönnqvist, B; Paulin, T; Ringdén, O; Wahren, B, 1986) |
| "Foscarnet was administered to eight AIDS patients for suspected cytomegalovirus (CMV) pneumonitis as a continuous intravenous infusion for a minimum of 8 days." | 1.27 | Treatment of cytomegalovirus pneumonitis with foscarnet (trisodium phosphonoformate) in patients with AIDS. ( Anderson, MG; Chanas, AC; Ellis, ME; Farthing, C; Gazzard, BG, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 42 (8.90) | 18.7374 |
| 1990's | 254 (53.81) | 18.2507 |
| 2000's | 98 (20.76) | 29.6817 |
| 2010's | 62 (13.14) | 24.3611 |
| 2020's | 16 (3.39) | 2.80 |
| Authors | Studies |
|---|---|
| Zou, R | 2 |
| Drach, JC | 3 |
| Townsend, LB | 2 |
| Scott, GM | 2 |
| Weinberg, A | 5 |
| Rawlinson, WD | 2 |
| Chou, S | 17 |
| Marousek, GI | 2 |
| Van Wechel, LC | 1 |
| Li, S | 4 |
| Avery, RK | 4 |
| Alain, S | 6 |
| Alexander, BD | 1 |
| Blumberg, EA | 2 |
| Chemaly, RF | 2 |
| Cordonnier, C | 2 |
| Duarte, RF | 1 |
| Florescu, DF | 1 |
| Kamar, N | 1 |
| Kumar, D | 1 |
| Maertens, J | 1 |
| Marty, FM | 1 |
| Papanicolaou, GA | 1 |
| Silveira, FP | 2 |
| Witzke, O | 1 |
| Wu, J | 1 |
| Sundberg, AK | 1 |
| Fournier, M | 1 |
| Yu, HC | 1 |
| Liu, WD | 1 |
| Kuo, PH | 1 |
| Lin, CC | 1 |
| Wu, UI | 1 |
| Jung, JY | 1 |
| Nho, D | 1 |
| Cho, SY | 1 |
| Lee, DG | 1 |
| Choi, SM | 1 |
| Kim, HJ | 2 |
| Kim, M | 1 |
| Oh, EJ | 1 |
| Qin, A | 1 |
| Chen, S | 1 |
| Li, Q | 1 |
| Huang, X | 1 |
| Xia, L | 1 |
| Lin, Y | 1 |
| Shen, A | 1 |
| Xiang, AP | 1 |
| Zhang, L | 1 |
| Halpern-Cohen, V | 1 |
| Ma, R | 1 |
| He, Y | 1 |
| Xu, LP | 1 |
| Zhang, XH | 1 |
| Wang, Y | 1 |
| Liu, KY | 1 |
| Huang, XJ | 1 |
| Sun, YQ | 1 |
| Razonable, RR | 3 |
| Spinner, ML | 1 |
| Lam, SW | 1 |
| Koval, CE | 1 |
| Athans, V | 1 |
| Chen, J | 1 |
| Abella Ross, J | 1 |
| Tegtmeier, B | 1 |
| Yang, D | 1 |
| Ito, JI | 1 |
| Zaia, JA | 3 |
| Dickter, JK | 1 |
| Nakamura, R | 1 |
| Mokhtari, S | 1 |
| Kriengkauykiat, J | 1 |
| Al Malki, MM | 1 |
| Dadwal, SS | 1 |
| Hakki, M | 2 |
| Zarrouk, K | 1 |
| Pham, VD | 1 |
| Piret, J | 1 |
| Shi, R | 1 |
| Boivin, G | 4 |
| Kang, SH | 1 |
| Yoo, JW | 1 |
| Seo, JK | 1 |
| Kim, H | 1 |
| Koh, KN | 1 |
| Choi, ES | 1 |
| Jang, S | 1 |
| Park, CJ | 1 |
| Seo, JJ | 1 |
| Im, HJ | 1 |
| Kuwatsuka, Y | 1 |
| Atsuta, Y | 2 |
| Hirakawa, A | 1 |
| Uchida, N | 2 |
| Inamoto, Y | 1 |
| Najima, Y | 1 |
| Ikegame, K | 2 |
| Eto, T | 1 |
| Ozawa, Y | 1 |
| Ichinohe, T | 1 |
| Inoue, M | 1 |
| Kimura, T | 1 |
| Okamoto, S | 1 |
| Miyamura, K | 1 |
| Fukuda, T | 2 |
| Baldo, F | 1 |
| Suárez, NM | 1 |
| Davison, AJ | 1 |
| Zanon, D | 1 |
| Barbi, E | 1 |
| Maximova, N | 1 |
| Domingo, W | 1 |
| Nguyen, IT | 1 |
| Johnsrud, JJ | 1 |
| Brown, JW | 1 |
| Ota, R | 1 |
| Hirata, A | 1 |
| Rho, E | 1 |
| Näf, B | 1 |
| Müller, TF | 1 |
| Wüthrich, RP | 1 |
| Schachter, T | 1 |
| von Moos, S | 1 |
| Bruminhent, J | 1 |
| Rotjanapan, P | 1 |
| Watcharananan, SP | 1 |
| Echenique, IA | 1 |
| Beltran, D | 1 |
| Ramirez-Ruiz, L | 1 |
| Najafian, N | 1 |
| Agrawal, N | 1 |
| Wieruszewski, PM | 1 |
| Vijayvargiya, P | 1 |
| Wilhelm, MP | 1 |
| Pierce, B | 1 |
| Richardson, CL | 1 |
| Lacloche, L | 1 |
| Allen, A | 1 |
| Ison, MG | 3 |
| Cintra-Cabrera, M | 1 |
| Suárez-Benjumea, A | 1 |
| Bernal-Blanco, G | 1 |
| González-Roncero, FM | 1 |
| Toapanta-Gaibor, NG | 1 |
| Súñer-Poblet, M | 1 |
| Pérez-Valdivia, MÁ | 1 |
| Fernández-Cuenca, F | 1 |
| Gentil-Govantes, MÁ | 1 |
| Rocha-Castilla, JL | 1 |
| Baghban, A | 1 |
| Malinis, M | 1 |
| Vora, SB | 1 |
| Brothers, AW | 1 |
| Waghmare, A | 1 |
| Englund, JA | 1 |
| Meesing, A | 1 |
| O'Brien, MS | 1 |
| Markovich, KC | 1 |
| Selleseth, D | 1 |
| DeVita, AV | 1 |
| Sethna, P | 1 |
| Gentry, BG | 1 |
| Nawashiro, Y | 1 |
| Shiraki, K | 1 |
| Yamamoto, S | 1 |
| Takizawa, K | 1 |
| Sasada, Y | 1 |
| Suehiro, M | 1 |
| Miura, K | 1 |
| Hattori, M | 1 |
| Daikoku, T | 1 |
| Hisano, M | 1 |
| Czarnecka, P | 1 |
| Czarnecka, K | 1 |
| Tronina, O | 1 |
| Durlik, M | 1 |
| Danziger-Isakov, L | 1 |
| Englund, J | 1 |
| Green, M | 1 |
| Posfay-Barbe, KM | 1 |
| Zerr, DM | 1 |
| Sinkó, J | 1 |
| Or, C | 1 |
| Press, N | 1 |
| Forooghian, F | 1 |
| James, SH | 1 |
| Price, NB | 1 |
| Hartline, CB | 1 |
| Lanier, ER | 2 |
| Prichard, MN | 2 |
| Papasotiriou, M | 1 |
| Papachristou, E | 1 |
| Marangos, M | 1 |
| Koukoulaki, M | 1 |
| Savvidaki, E | 1 |
| Kalliakmani, P | 1 |
| Goumenos, DS | 1 |
| Sakamoto, K | 1 |
| Nakasone, H | 1 |
| Wada, H | 2 |
| Yamasaki, R | 1 |
| Ishihara, Y | 1 |
| Kawamura, K | 1 |
| Ashizawa, M | 1 |
| Sato, M | 1 |
| Terasako-Saito, K | 1 |
| Machishima, T | 1 |
| Kimura, S | 1 |
| Kikuchi, M | 1 |
| Kako, S | 1 |
| Kanda, J | 1 |
| Yamazaki, R | 1 |
| Tanihara, A | 1 |
| Nishida, J | 1 |
| Kanda, Y | 2 |
| Fischer, L | 2 |
| Laib Sampaio, K | 1 |
| Jahn, G | 6 |
| Hamprecht, K | 5 |
| Göhring, K | 2 |
| Minces, LR | 1 |
| Nguyen, MH | 1 |
| Mitsani, D | 1 |
| Shields, RK | 1 |
| Kwak, EJ | 1 |
| Abdel-Massih, R | 1 |
| Pilewski, JM | 1 |
| Crespo, MM | 1 |
| Bermudez, C | 1 |
| Bhama, JK | 1 |
| Toyoda, Y | 1 |
| Clancy, CJ | 1 |
| Verkaik, NJ | 1 |
| Hoek, RA | 1 |
| van Bergeijk, H | 1 |
| van Hal, PT | 1 |
| Schipper, ME | 1 |
| Pas, SD | 1 |
| Beersma, MF | 1 |
| Boucher, CA | 1 |
| Jedema, I | 1 |
| Falkenburg, F | 1 |
| Hoogsteden, HC | 1 |
| van den Blink, B | 1 |
| Murk, JL | 1 |
| Gregg, K | 1 |
| Kaul, DR | 1 |
| Marzal-Alfaro, MB | 1 |
| Manrique-Rodríguez, S | 1 |
| Alcaraz Romero, A | 1 |
| García San Prudencio, M | 1 |
| Fernández-Llamazares, CM | 1 |
| Ercolani, RJ | 2 |
| Sahoo, MK | 1 |
| Lefterova, MI | 1 |
| Strasfeld, LM | 1 |
| Pinsky, BA | 1 |
| Deback, C | 1 |
| Burrel, S | 2 |
| Varnous, S | 1 |
| Carcelain, G | 1 |
| Conan, F | 1 |
| Aït-Arkoub, Z | 1 |
| Autran, B | 1 |
| Gandjbakhch, I | 1 |
| Agut, H | 2 |
| Boutolleau, D | 3 |
| Kneidinger, N | 1 |
| Giessen, C | 1 |
| von Wulffen, W | 1 |
| Milger, K | 1 |
| Schramm, R | 1 |
| Jäger, G | 1 |
| Nitschko, H | 1 |
| Striebinger, H | 1 |
| Behr, J | 1 |
| Neurohr, C | 1 |
| Philipponnet, C | 1 |
| Michel, PA | 1 |
| Daudon, M | 2 |
| Brocheriou, I | 1 |
| Boffa, JJ | 1 |
| Mareri, A | 1 |
| Lasorella, S | 1 |
| Iapadre, G | 1 |
| Maresca, M | 1 |
| Tambucci, R | 1 |
| Nigro, G | 2 |
| Iwami, D | 1 |
| Ogawa, Y | 1 |
| Fujita, H | 1 |
| Morita, K | 1 |
| Sasaki, H | 1 |
| Oishi, Y | 1 |
| Higuchi, H | 1 |
| Hatanaka, K | 2 |
| Shinohara, N | 1 |
| Young, PG | 1 |
| Rubin, J | 1 |
| Angarone, M | 2 |
| Flaherty, J | 1 |
| Penugonda, S | 1 |
| Stosor, V | 1 |
| Imrich, E | 1 |
| Sampaio, KL | 1 |
| Hofmann, J | 1 |
| Ambrose, T | 1 |
| Sharkey, LM | 1 |
| Louis-Auguste, J | 1 |
| Rutter, CS | 1 |
| Duncan, S | 1 |
| English, S | 1 |
| Gkrania-Klotsas, E | 1 |
| Carmichael, A | 2 |
| Woodward, JM | 1 |
| Russell, N | 1 |
| Massey, D | 1 |
| Butler, A | 1 |
| Middleton, S | 1 |
| Garrigue, I | 1 |
| Moulinas, R | 1 |
| Recordon-Pinson, P | 1 |
| Delacour, ML | 1 |
| Essig, M | 1 |
| Kaminski, H | 1 |
| Rerolle, JP | 1 |
| Merville, P | 1 |
| Fleury, H | 1 |
| Kang, GW | 1 |
| Hong, HL | 1 |
| Lee, IH | 1 |
| Ahn, KS | 1 |
| Kim, JD | 1 |
| Choi, DL | 1 |
| Mihm, J | 1 |
| Leyking, S | 1 |
| Dirks, J | 1 |
| Smola, S | 1 |
| Fliser, D | 1 |
| Sester, U | 1 |
| Sester, M | 1 |
| Wilkens, H | 1 |
| Rissland, J | 1 |
| Arav-Boger, R | 1 |
| Marr, KA | 1 |
| Kraus, E | 1 |
| Shoham, S | 1 |
| Lees, L | 1 |
| Trollinger, B | 1 |
| Shah, P | 1 |
| Ambinder, R | 1 |
| Neofytos, D | 1 |
| Ostrander, D | 1 |
| Forman, M | 1 |
| Valsamakis, A | 1 |
| El Chaer, F | 1 |
| Mori, N | 1 |
| Shah, D | 1 |
| Oliver, N | 1 |
| Wang, E | 1 |
| Jan, A | 1 |
| Doan, V | 1 |
| Tverdek, F | 1 |
| Tayar, J | 1 |
| Ariza-Heredia, E | 1 |
| Nomura, JH | 1 |
| Eichhorn, K | 1 |
| Cao, TM | 1 |
| Sahebi, F | 1 |
| Rabinowicz, S | 1 |
| Somech, R | 1 |
| Yeshayahu, Y | 1 |
| Torres-Madriz, G | 1 |
| Boucher, HW | 1 |
| Hubacek, P | 1 |
| Keslova, P | 1 |
| Formankova, R | 1 |
| Pochop, P | 1 |
| Cinek, O | 1 |
| Zajac, M | 1 |
| Lochmanova, J | 1 |
| Stary, J | 1 |
| Sedlacek, P | 1 |
| Péter, A | 1 |
| Telkes, G | 1 |
| Varga, M | 1 |
| Járay, J | 1 |
| Sohal, A | 1 |
| Riordan, A | 1 |
| Mallewa, M | 1 |
| Solomon, T | 1 |
| Kneen, R | 1 |
| Schreiber, A | 1 |
| Härter, G | 1 |
| Schubert, A | 1 |
| Bunjes, D | 1 |
| Mertens, T | 1 |
| Michel, D | 1 |
| Wang, H | 2 |
| Zhu, L | 1 |
| Xue, M | 1 |
| Liu, J | 1 |
| Guo, Z | 2 |
| Sola, E | 1 |
| Vega, E | 1 |
| Gutiérrez, C | 1 |
| López, V | 1 |
| Cabello, M | 1 |
| Burgos, D | 1 |
| González Molina, M | 1 |
| Siles, J | 1 |
| Travi, G | 1 |
| Pergam, SA | 1 |
| Xie, H | 1 |
| Boeckh, MJ | 1 |
| Meghpara, B | 1 |
| Sulkowski, G | 1 |
| Kesen, MR | 1 |
| Tessler, HH | 1 |
| Goldstein, DA | 1 |
| Ridha, E | 1 |
| Cookson, H | 1 |
| Devitt, E | 1 |
| Nelson, M | 1 |
| Tomasik, T | 1 |
| Opozda, A | 1 |
| Pietrzyk, JJ | 1 |
| Yaari, S | 1 |
| Koslowsky, B | 1 |
| Wolf, D | 1 |
| Chajek-Shaul, T | 1 |
| Hershcovici, T | 1 |
| Asakura, M | 1 |
| Yoshihara, S | 1 |
| Taniguchi, S | 3 |
| Mori, T | 1 |
| Etoh, T | 1 |
| Takami, A | 1 |
| Yoshida, T | 1 |
| Kanamori, H | 1 |
| Yujiri, T | 1 |
| Sakamaki, H | 1 |
| Suzuki, R | 1 |
| Ogawa, H | 1 |
| Xia, CS | 1 |
| Zhang, Z | 1 |
| Lurain, NS | 4 |
| De Keyzer, K | 1 |
| Van Laecke, S | 1 |
| Peeters, P | 1 |
| Vanholder, R | 1 |
| Kern, ER | 1 |
| Haouy, S | 1 |
| Rocher, F | 1 |
| Poirée, M | 1 |
| Saint-Paul, MC | 1 |
| De Smet, S | 1 |
| Sirvent, A | 1 |
| Sirvent, N | 1 |
| Myhre, HA | 1 |
| Haug Dorenberg, D | 1 |
| Kristiansen, KI | 1 |
| Rollag, H | 1 |
| Leivestad, T | 1 |
| Asberg, A | 1 |
| Hartmann, A | 1 |
| Marousek, G | 3 |
| Bowlin, TL | 1 |
| Zheng, X | 1 |
| Huang, Y | 1 |
| Wang, Z | 1 |
| Yan, H | 1 |
| Pan, S | 1 |
| Canestri, A | 1 |
| Wirden, M | 1 |
| Seang, S | 1 |
| Clavel-Osorio, C | 1 |
| Marcelin, AG | 1 |
| Katlama, C | 10 |
| Goldsmith, PM | 1 |
| Husain, MM | 1 |
| Zhang, H | 1 |
| Middleton, SJ | 1 |
| Tischler, V | 1 |
| Schuurmans, MM | 1 |
| Boehler, A | 1 |
| Gaspert, A | 1 |
| Chen, HR | 1 |
| Liu, XD | 1 |
| Bian, JM | 1 |
| He, XP | 1 |
| Lou, JX | 1 |
| Chen, P | 1 |
| Yang, K | 1 |
| Liu, D | 1 |
| Zhang, Y | 1 |
| Nakamura, K | 1 |
| Bacigalupo, A | 8 |
| Boyd, A | 1 |
| Slipper, J | 1 |
| Curtis, J | 2 |
| Clissold, S | 1 |
| Cunha-Bang, Cd | 1 |
| Kirkby, N | 1 |
| Sønderholm, M | 1 |
| Sørensen, SS | 1 |
| Sengeløv, H | 1 |
| Iversen, M | 1 |
| Rasmussen, A | 1 |
| Gustafsson, F | 1 |
| Frederiksen, CM | 1 |
| Kjaer, J | 1 |
| Lepri, AC | 1 |
| Lundgren, JD | 1 |
| Kimberlin, DW | 1 |
| Ronghe, MD | 1 |
| Foot, AB | 1 |
| Cornish, JM | 1 |
| Steward, CG | 1 |
| Carrington, D | 1 |
| Goulden, N | 1 |
| Marks, DI | 1 |
| Oakhill, A | 1 |
| Brown, TJ | 1 |
| McCrary, M | 1 |
| Tyring, SK | 1 |
| Baldanti, F | 9 |
| Sarasini, A | 7 |
| Zemlicka, J | 1 |
| Gerna, G | 11 |
| Leśnikowski, ZJ | 1 |
| Paradowska, E | 1 |
| Przepiórkiewicz, M | 1 |
| Olejniczak, A | 1 |
| Emery, VC | 4 |
| Isada, CM | 1 |
| Yen-Lieberman, B | 3 |
| Schilz, R | 1 |
| Kohn, D | 2 |
| Longworth, DL | 2 |
| Taege, AJ | 2 |
| Mossad, SB | 2 |
| Maurer, J | 1 |
| Flechner, SM | 1 |
| Mawhorter, SD | 1 |
| Braun, W | 1 |
| Gordon, SM | 1 |
| Schmitt, SK | 1 |
| Goldman, M | 1 |
| Long, J | 1 |
| Haug, M | 1 |
| Julin, JE | 1 |
| van Burik, JH | 1 |
| Krivit, W | 1 |
| Webb, C | 1 |
| Holman, CJ | 1 |
| Clark, HB | 1 |
| Balfour, HH | 3 |
| Valdez, O | 1 |
| Gaspar, A | 1 |
| Dickson, J | 1 |
| Weigert, A | 1 |
| Machado, D | 1 |
| Boeckh, M | 4 |
| Nichols, WG | 2 |
| Papanicolaou, G | 1 |
| Rubin, R | 1 |
| Wingard, JR | 1 |
| Zaia, J | 1 |
| Halkic, N | 1 |
| Ksontini, R | 1 |
| Scholl, B | 1 |
| Blanc, C | 1 |
| Kovacsovics, T | 1 |
| Meylan, P | 1 |
| Muheim, C | 1 |
| Gillet, M | 1 |
| Mosimann, F | 1 |
| Ducancelle, A | 3 |
| Belloc, S | 1 |
| Scieux, C | 2 |
| Malphettes, M | 1 |
| Petit, F | 3 |
| Brouet, JC | 1 |
| Sanson Le Pors, MJ | 1 |
| Mazeron, MC | 4 |
| Mattes, FM | 1 |
| Hainsworth, EG | 1 |
| Geretti, AM | 1 |
| Nebbia, G | 1 |
| Prentice, G | 1 |
| Potter, M | 1 |
| Burroughs, AK | 1 |
| Sweny, P | 1 |
| Hassan-Walker, AF | 1 |
| Okwuadi, S | 1 |
| Sabin, C | 1 |
| Amooty, G | 1 |
| Brown, VS | 1 |
| Grace, SC | 1 |
| Griffiths, PD | 3 |
| Lurain, N | 3 |
| Sali, E | 1 |
| Anceschi, MM | 1 |
| Mazzocco, M | 1 |
| Maranghi, L | 1 |
| Clerico, A | 1 |
| Castello, MA | 1 |
| Bolwell, BJ | 1 |
| Waldman, WJ | 2 |
| Long, JR | 1 |
| Kalaycio, M | 1 |
| Pohlman, B | 1 |
| Williams, JW | 2 |
| Nakamoto, BK | 1 |
| Dorotheo, EU | 1 |
| Biousse, V | 1 |
| Tang, RA | 1 |
| Schiffman, JS | 1 |
| Newman, NJ | 1 |
| Springer, KL | 1 |
| Giller, RH | 1 |
| Quinones, R | 1 |
| Shira, JE | 1 |
| Gravisse, J | 1 |
| Fillet, AM | 4 |
| Pors, MJ | 1 |
| Tanaka-Taya, K | 2 |
| Cesaro, S | 1 |
| Zhou, X | 1 |
| Manzardo, C | 1 |
| Buonfrate, D | 1 |
| Cusinato, R | 1 |
| Tridello, G | 1 |
| Mengoli, C | 1 |
| Palù, G | 1 |
| Messina, C | 2 |
| Chen, F | 1 |
| Bando, T | 1 |
| Hanaoka, N | 1 |
| Fukuse, T | 1 |
| Hasegawa, S | 1 |
| Drew, WL | 13 |
| Tan, HH | 1 |
| Goh, CL | 1 |
| Ghidini, B | 1 |
| Bellaiche, M | 1 |
| Berrebi, D | 1 |
| Viala, J | 1 |
| Hugot, JP | 1 |
| Mougenot, JF | 1 |
| Munck, A | 1 |
| Peuchmaur, M | 1 |
| Cezard, JP | 1 |
| de Schryver, I | 1 |
| Rozenberg, F | 1 |
| Cassoux, N | 1 |
| Michelson, S | 1 |
| Kestelyn, P | 1 |
| Lehoang, P | 2 |
| Davis, JL | 1 |
| Bodaghi, B | 1 |
| Kitajima, N | 1 |
| Francisci, D | 1 |
| Marroni, M | 1 |
| Morosi, S | 1 |
| Canovari, B | 1 |
| Belfiori, B | 1 |
| Stagni, G | 1 |
| Baldelli, F | 1 |
| Champier, G | 1 |
| Le Pors, MJ | 1 |
| Shereck, EB | 1 |
| Cooney, E | 1 |
| van de Ven, C | 1 |
| Della-Lotta, P | 1 |
| Cairo, MS | 1 |
| Tomonari, A | 1 |
| Takahashi, S | 1 |
| Takasugi, K | 1 |
| Ooi, J | 1 |
| Tsukada, N | 1 |
| Konuma, T | 1 |
| Iseki, T | 1 |
| Tojo, A | 1 |
| Asano, S | 1 |
| Narimatsu, H | 2 |
| Kami, M | 2 |
| Kato, D | 1 |
| Matsumura, T | 2 |
| Murashige, N | 2 |
| Kusumi, E | 2 |
| Yuji, K | 2 |
| Hori, A | 2 |
| Shibata, T | 1 |
| Masuoka, K | 2 |
| Wake, A | 2 |
| Miyakoshi, S | 2 |
| Morinaga, S | 1 |
| Knorr, B | 1 |
| Kessler, U | 1 |
| Pöschl, J | 1 |
| Fickenscher, H | 1 |
| Linderkamp, O | 1 |
| Wanner, M | 1 |
| Pol-Rodriguez, M | 1 |
| Hinds, G | 1 |
| Hutt, C | 1 |
| Husain, S | 1 |
| Grossman, ME | 2 |
| Tanaka, Y | 1 |
| Eizuru, Y | 1 |
| Carbonnel, F | 1 |
| Fica, A | 1 |
| Cervera, C | 1 |
| Pérez, N | 1 |
| Marcos, MA | 1 |
| Ramírez, J | 1 |
| Linares, L | 1 |
| Soto, G | 1 |
| Navasa, M | 1 |
| Cofan, F | 1 |
| Ricart, MJ | 1 |
| Pérez-Villa, F | 1 |
| Pumarola, T | 1 |
| Moreno, A | 1 |
| Michaels, MG | 1 |
| Iwasenko, JM | 1 |
| Ziegler, JB | 1 |
| Rodriguez, J | 1 |
| Casper, K | 1 |
| Smallwood, G | 1 |
| Stieber, A | 1 |
| Fasola, C | 1 |
| Lehneman, J | 1 |
| Heffron, T | 1 |
| Reddy, AJ | 1 |
| Zaas, AK | 1 |
| Hanson, KE | 1 |
| Palmer, SM | 1 |
| Shapira, MY | 1 |
| Resnick, IB | 1 |
| Neumann, AU | 1 |
| Stamminger, T | 1 |
| Caplan, O | 1 |
| Saleh, N | 1 |
| Efferth, T | 1 |
| Marschall, M | 1 |
| Wolf, DG | 2 |
| Bressollette-Bodin, C | 1 |
| Claver, A | 1 |
| Chevallier, P | 1 |
| Guillaume, T | 1 |
| Gastinne, T | 1 |
| Moreau, P | 1 |
| Harousseau, JL | 1 |
| Imbert-Marcille, BM | 1 |
| Le Gouill, S | 1 |
| Lucia, HL | 1 |
| Griffith, BP | 1 |
| Hsiung, GD | 1 |
| Morales, JM | 1 |
| Muñoz, MA | 1 |
| Fernández Zataraín, G | 1 |
| García Cantón, C | 1 |
| García Rubiales, MA | 1 |
| Andrés, A | 1 |
| Aguado, JM | 1 |
| Gonzalez Pinto, I | 1 |
| Holida, MD | 1 |
| Trigg, ME | 1 |
| Rumelhart, SL | 1 |
| Lee, NF | 1 |
| Kook, H | 1 |
| Peters, C | 1 |
| Blanshard, C | 3 |
| Benhamou, Y | 1 |
| Dohin, E | 5 |
| Lernestedt, JO | 7 |
| Gazzard, BG | 9 |
| Salazar, A | 1 |
| Podzamczer, D | 1 |
| Reñe, R | 1 |
| Santin, M | 1 |
| Perez, JL | 3 |
| Ferrer, I | 1 |
| Fernandez-Viladrich, P | 1 |
| Gudiol, F | 1 |
| Roedel, C | 1 |
| Grob, R | 1 |
| Ruef, C | 1 |
| Percivalle, E | 6 |
| Zavattoni, M | 3 |
| Revello, MG | 4 |
| Raffi, F | 1 |
| Jacomet, C | 2 |
| Lebrette, MG | 1 |
| el Amrani, M | 2 |
| Monfort, L | 1 |
| Gozlan, J | 3 |
| Girard, PM | 2 |
| Rozenbaum, W | 3 |
| Le Goff, C | 1 |
| Hurault de Ligny, B | 1 |
| Freymuth, F | 2 |
| Cardineau, E | 1 |
| Lobbedez, T | 1 |
| Ryckelynck, JP | 1 |
| Kaiser, L | 1 |
| Perrin, L | 1 |
| Hirschel, B | 1 |
| Furrer, H | 1 |
| Von Overbeck, J | 1 |
| Olmari, M | 1 |
| Yerly, S | 1 |
| Decker, CF | 1 |
| Tarver, JH | 1 |
| Murray, DF | 1 |
| Martin, GJ | 1 |
| Wilcox, CM | 1 |
| Straub, RF | 1 |
| Schwartz, DA | 1 |
| Zomas, A | 1 |
| Mehta, J | 3 |
| Powles, R | 3 |
| Treleaven, J | 2 |
| Iveson, T | 1 |
| Singhal, S | 3 |
| Jameson, B | 2 |
| Paul, B | 1 |
| Brincat, S | 1 |
| Catovsky, D | 1 |
| van Lint, MT | 7 |
| Tedone, E | 6 |
| Moro, F | 3 |
| Sanna, MA | 2 |
| Longren, M | 1 |
| Trespi, G | 5 |
| Frassoni, F | 3 |
| Occhini, D | 6 |
| Gualandi, F | 7 |
| Lonngren, M | 1 |
| Roullet, E | 1 |
| Assuerus, V | 1 |
| Ropert, A | 1 |
| Saïd, G | 1 |
| Baudrimont, M | 1 |
| Duvivier, C | 1 |
| Gonzales-Canali, G | 1 |
| Liu, YQ | 1 |
| Lor, E | 1 |
| Jacobson, M | 2 |
| Goodrich, JM | 1 |
| Bowden, R | 1 |
| Colebunders, R | 1 |
| Van den Abbeele, K | 1 |
| Fleerackers, Y | 1 |
| Bols, K | 1 |
| Lachenal, M | 1 |
| Van Damme, L | 1 |
| Jacobson, MA | 17 |
| Kramer, F | 1 |
| Bassiakos, Y | 1 |
| Hooton, T | 1 |
| Polsky, B | 3 |
| Geheb, H | 1 |
| O'Donnell, JJ | 7 |
| Walker, JD | 1 |
| Korvick, JA | 1 |
| van der Horst, C | 1 |
| Przepiorka, D | 2 |
| Ippoliti, C | 3 |
| Panina, A | 1 |
| Goodrich, J | 1 |
| Giralt, S | 3 |
| van Besien, K | 2 |
| Mehra, R | 2 |
| Deisseroth, AB | 1 |
| Andersson, B | 2 |
| Luna, M | 2 |
| Karmochkine, M | 1 |
| Molina, JM | 1 |
| Welker, Y | 1 |
| Morinet, F | 2 |
| Decazes, JM | 1 |
| Lagrange, P | 1 |
| Schnell, L | 1 |
| Modai, J | 1 |
| Poles, MA | 5 |
| McMeeking, AA | 1 |
| Scholes, JV | 1 |
| Dieterich, DT | 6 |
| Domingo, P | 1 |
| Puig, M | 1 |
| Iranzo, A | 1 |
| Lopez-Contreras, J | 1 |
| Ris, J | 1 |
| Freeman, WR | 3 |
| Stanley, HD | 1 |
| Charlebois, E | 1 |
| Harb, G | 1 |
| Pépin, JM | 1 |
| Raskine, L | 1 |
| Sanson-Le Pors, MJ | 1 |
| Lew, EA | 3 |
| Razis, E | 1 |
| Cook, P | 1 |
| Mittelman, A | 1 |
| Ahmed, T | 1 |
| Peters, M | 3 |
| Schürmann, D | 3 |
| Bergmann, F | 1 |
| Grünewald, T | 1 |
| Timm, H | 2 |
| Pohle, HD | 3 |
| Ruf, B | 3 |
| Berman, SM | 1 |
| Kim, RC | 1 |
| Ljungman, P | 7 |
| Biron, P | 1 |
| Bosi, A | 1 |
| Cahn, JY | 1 |
| Goldstone, AH | 2 |
| Gorin, NC | 1 |
| Link, H | 2 |
| Michallet, M | 1 |
| Richard, C | 1 |
| Petitjean, J | 1 |
| Eugene-Ruelland, G | 1 |
| Daon, F | 1 |
| Galateau, F | 1 |
| Cello, JP | 1 |
| Smit, WM | 1 |
| Wagemans, MA | 1 |
| Jansen, CL | 1 |
| vd Horn, GJ | 1 |
| Surachno, JS | 1 |
| Heinic, GS | 1 |
| Greenspan, D | 1 |
| Greenspan, JS | 1 |
| Snydman, DR | 1 |
| Rubin, RH | 1 |
| Werner, BG | 1 |
| Polis, MA | 5 |
| deSmet, MD | 1 |
| Baird, BF | 2 |
| Mellow, S | 1 |
| Falloon, J | 2 |
| Davey, RT | 2 |
| Kovacs, JA | 2 |
| Palestine, AG | 3 |
| Nussenblatt, RB | 2 |
| Masur, H | 2 |
| Moyle, G | 2 |
| Barton, S | 1 |
| Gearhart, MO | 1 |
| Sorg, TB | 1 |
| Dicker, M | 1 |
| Tepper, R | 1 |
| Lew, E | 1 |
| Nelson, MR | 3 |
| Hawkins, DA | 3 |
| Brown, DL | 1 |
| Sather, S | 1 |
| Cheitlin, MD | 1 |
| Mendez, PE | 1 |
| Murphy, R | 1 |
| Addessi, A | 1 |
| Holbrook, JT | 1 |
| Naughton, K | 1 |
| Friedberg, DN | 2 |
| Pearson, PA | 1 |
| Jaffe, GJ | 1 |
| Ashton, P | 1 |
| Keijer, WJ | 1 |
| Burger, DM | 1 |
| Neuteboom, GH | 1 |
| Vrooland, JL | 1 |
| Meenhorst, PL | 1 |
| Koks, CH | 1 |
| Beijnen, JH | 1 |
| Miguélez, M | 1 |
| Linares Feria, M | 1 |
| Laynez, P | 1 |
| Méndez, M | 1 |
| Brockmeyer, NH | 2 |
| Hengge, UR | 2 |
| Mertins, L | 1 |
| Malessa, R | 2 |
| Steinmetz, R | 1 |
| Gooss, M | 1 |
| Sarraf, D | 1 |
| Equi, RA | 1 |
| Holland, GN | 3 |
| Yoshizumi, MO | 1 |
| Lee, DA | 1 |
| Wiesner, RH | 1 |
| Marin, E | 1 |
| Porayko, MK | 1 |
| Steers, JL | 1 |
| Krom, RA | 1 |
| Paya, CV | 1 |
| Ravens, U | 1 |
| Goos, M | 1 |
| Flores-Aguilar, M | 1 |
| Kuppermann, BD | 2 |
| Quiceno, JI | 2 |
| Dankner, WM | 1 |
| Capparelli, EV | 1 |
| Connor, JD | 1 |
| Sherwood, CH | 1 |
| Fullerton, S | 1 |
| Gambertoglio, JG | 4 |
| Causey, D | 1 |
| Hardy, D | 1 |
| Chown, M | 1 |
| Davis, R | 1 |
| Heinemann, MH | 3 |
| Keshavjee, SH | 1 |
| Magee, LA | 1 |
| Mullen, BJ | 1 |
| Baron, DL | 1 |
| Brunton, JL | 1 |
| Gallinger, S | 1 |
| Lönnqvist, B | 10 |
| Aschan, J | 6 |
| Ringdén, O | 10 |
| Furione, M | 2 |
| Brerra, R | 1 |
| Barbi, M | 2 |
| Giezendanner, S | 1 |
| Wirth, HP | 1 |
| Zala, G | 1 |
| Weber, R | 1 |
| Flury, R | 1 |
| Meyenberger, C | 1 |
| Len, O | 1 |
| de Otero, J | 1 |
| Ribera, E | 1 |
| Ocaña, I | 1 |
| Walsh, JE | 1 |
| Abinun, M | 1 |
| Peiris, JS | 1 |
| Appleton, AL | 1 |
| Cant, AJ | 1 |
| Huengsberg, M | 1 |
| Stevenson, M | 1 |
| Cohen, BA | 1 |
| Underwood, MR | 1 |
| Stanat, SC | 1 |
| Biron, KK | 2 |
| Silini, E | 2 |
| Lazzarin, A | 1 |
| Jabs, DA | 3 |
| Loré, K | 1 |
| Klaesson, S | 1 |
| Lewensohn-Fuchs, I | 2 |
| Winiarski, J | 3 |
| Ehrnst, A | 2 |
| Flaherty, JF | 1 |
| Danner, SA | 2 |
| Bregante, S | 4 |
| Isaza, A | 2 |
| Lamparelli, T | 5 |
| Marmont, AM | 2 |
| Corral, I | 1 |
| Quereda, C | 1 |
| Cobo, J | 1 |
| Casado, JL | 2 |
| Guerrero, A | 2 |
| Becker, BN | 1 |
| Schulman, G | 1 |
| Patel, SS | 1 |
| Rutzen, AR | 1 |
| Marx, JL | 1 |
| Thach, AB | 1 |
| Chong, LP | 1 |
| Rao, NA | 2 |
| Chang, J | 1 |
| Paton, N | 1 |
| Snoeck, R | 2 |
| Andrei, G | 1 |
| De Clercq, E | 2 |
| Drusano, GL | 1 |
| Aweeka, F | 3 |
| Gambertoglio, J | 3 |
| Polis, M | 1 |
| Lane, HC | 1 |
| Eaton, C | 1 |
| Martin-Munley, S | 3 |
| Oberg, G | 1 |
| Pauksen, K | 1 |
| Sulila, P | 1 |
| Alexander, AC | 1 |
| Akers, A | 1 |
| Matzke, GR | 1 |
| Aweeka, FT | 1 |
| Fraley, DS | 1 |
| Craigen, JL | 1 |
| Grundy, JE | 1 |
| Fishman, JE | 1 |
| Batt, HD | 1 |
| Eddleston, M | 1 |
| Peacock, S | 1 |
| Juniper, M | 1 |
| Warrell, DA | 1 |
| Gotti, E | 1 |
| Suter, F | 1 |
| Baruzzo, S | 1 |
| Perani, V | 1 |
| Moioli, F | 1 |
| Remuzzi, G | 1 |
| Quartier, P | 1 |
| Khouri, J | 1 |
| Maout, F | 1 |
| Courpotin, C | 1 |
| Dollfus, C | 1 |
| Tabone, MD | 1 |
| Leverger, G | 1 |
| Lasfargues, G | 1 |
| Itin, PH | 1 |
| Lautenschlager, S | 1 |
| Breton, G | 1 |
| Crémieux, AC | 1 |
| Rosen, HR | 1 |
| Benner, KG | 1 |
| Flora, KD | 1 |
| Rabkin, JM | 1 |
| Orloff, SL | 1 |
| Olyaei, A | 1 |
| Fujisaki, T | 1 |
| Gondo, H | 1 |
| Matsuo, I | 1 |
| Takenaka, K | 1 |
| Tanimoto, K | 1 |
| Otsuka, T | 1 |
| Minematsu, T | 1 |
| Minamishima, Y | 1 |
| Niho, Y | 1 |
| Zella, D | 1 |
| Cunningham, ET | 1 |
| Jayaweera, DT | 3 |
| Manfredi, R | 2 |
| Mastroianni, A | 2 |
| Coronado, OV | 2 |
| Chiodo, F | 2 |
| Erice, A | 2 |
| Gil-Roda, C | 1 |
| Sannerud, KJ | 1 |
| Hanson, MN | 1 |
| Johnson, J | 1 |
| Nix, D | 1 |
| Faust, MJ | 1 |
| Macartney, M | 1 |
| Gane, EJ | 1 |
| Portmann, B | 1 |
| Williams, R | 1 |
| Gayet, S | 1 |
| Ville, E | 1 |
| Durand, JM | 1 |
| Mars, ME | 1 |
| Morange, S | 1 |
| Kaplanski, G | 1 |
| Gallais, H | 1 |
| Soubeyrand, J | 1 |
| Flood, J | 1 |
| Miner, R | 3 |
| Jekic-McMullen, D | 1 |
| Shen, LP | 1 |
| Kolberg, J | 1 |
| Garvey, J | 1 |
| Follansbee, S | 1 |
| Poscher, M | 1 |
| Zaknun, D | 1 |
| Zangerle, R | 1 |
| Kapelari, K | 1 |
| Fischer, H | 1 |
| Sailer, M | 1 |
| McIntosh, K | 1 |
| Guentzel, S | 1 |
| Follansbee, SE | 1 |
| Poscher, ME | 1 |
| Lalezari, JP | 2 |
| Miner, RC | 2 |
| Cline, JJ | 1 |
| Garrett, AD | 1 |
| Lazzarotto, T | 1 |
| Spezzacatena, P | 1 |
| Dal Monte, P | 1 |
| Morgan, A | 1 |
| Warkentin, D | 1 |
| Khouri, I | 1 |
| Gajewski, J | 1 |
| Champlin, R | 2 |
| Hägglund, H | 1 |
| Sparrelid, E | 2 |
| Ericzon, BG | 1 |
| Terra, L | 1 |
| Pellicanò, S | 1 |
| Calzone, R | 1 |
| Mandica, D | 1 |
| Milano, M | 1 |
| Hebart, H | 3 |
| Kanz, L | 2 |
| Einsele, H | 4 |
| Takahashi, K | 1 |
| Barbanti, M | 1 |
| Sacchi, N | 1 |
| Ficai, G | 1 |
| Ghinatti, C | 1 |
| Ferrara, GB | 1 |
| Delfino, L | 1 |
| Pozzi, S | 1 |
| Morabito, A | 1 |
| Zikos, P | 2 |
| Vitale, V | 1 |
| Corvo, R | 1 |
| Anders, HJ | 1 |
| Weiss, N | 1 |
| Bogner, JR | 1 |
| Goebel, FD | 2 |
| Goodgame, RW | 1 |
| Parente, F | 1 |
| Bianchi Porro, G | 1 |
| Cinque, P | 1 |
| Cleator, GM | 1 |
| Weber, T | 1 |
| Monteyne, P | 1 |
| Sindic, C | 1 |
| van Loon, AM | 1 |
| Klapper, PE | 1 |
| Castagnola, E | 3 |
| Dallorso, S | 2 |
| Rabagliati, M | 1 |
| Sacco, O | 1 |
| Kotitsa, Z | 1 |
| Dini, G | 1 |
| Guery, B | 1 |
| Bochet, M | 1 |
| Deray, G | 5 |
| Monno, L | 1 |
| Di Stefano, M | 1 |
| Zimatore, GB | 1 |
| Andreula, CF | 1 |
| Appice, A | 1 |
| Perulli, LM | 1 |
| Fiore, JR | 1 |
| Pastore, G | 1 |
| Angarano, G | 1 |
| Whitley, RJ | 1 |
| Hardy, WD | 2 |
| Deutsch, TA | 1 |
| Feinberg, J | 3 |
| Spector, SA | 2 |
| Walmsley, S | 1 |
| Powderly, WG | 1 |
| Benson, CA | 1 |
| Kessler, HA | 1 |
| Devianne-Garrigue, I | 1 |
| Pellegrin, I | 1 |
| Denisi, R | 1 |
| Dupon, M | 1 |
| Ragnaud, JM | 1 |
| Barbeau, P | 1 |
| Breilh, D | 1 |
| Leng, B | 1 |
| Fleury, HJ | 1 |
| Pellegrin, JL | 1 |
| Vogel, JU | 2 |
| Scholz, M | 2 |
| Cinatl, J | 2 |
| Torsellini, M | 1 |
| Cassetti, LI | 1 |
| Espinoza, L | 1 |
| Lopardo, GD | 1 |
| Hansman-Whiteman, ML | 1 |
| Scerpella, EG | 1 |
| Moretti, S | 1 |
| Mordini, N | 2 |
| Berisso, G | 2 |
| Bruno, B | 1 |
| Prix, L | 2 |
| Maierl, J | 1 |
| Carlens, S | 1 |
| Larsson, K | 1 |
| Mattsson, J | 1 |
| Verbraak, FD | 1 |
| van den Horn, GJ | 1 |
| van der Meer, JT | 1 |
| Paydafar, D | 1 |
| ten Kate, FJ | 1 |
| Wertheim-van Dillen, PM | 1 |
| Kijlstra, A | 1 |
| Gaudreau, A | 1 |
| Toma, E | 2 |
| Lalonde, R | 2 |
| Routy, JP | 1 |
| Murray, G | 1 |
| Handfield, J | 2 |
| Bergeron, MG | 2 |
| Robles, R | 1 |
| Lugo, D | 1 |
| Gee, L | 1 |
| Wald, A | 1 |
| Mattson, D | 1 |
| Schubert, MA | 1 |
| Stocchi, R | 1 |
| Ward, KN | 1 |
| Fanin, R | 1 |
| Baccarani, M | 1 |
| Apperley, JF | 2 |
| Cheung, TW | 2 |
| Teich, SA | 1 |
| Nguyen, Q | 1 |
| Rolston, K | 1 |
| Raad, I | 1 |
| Jacobson, K | 1 |
| Hecht, D | 1 |
| Tarrand, J | 1 |
| Whimbey, E | 1 |
| Justrabo, E | 2 |
| Zanetta, G | 2 |
| Martin, L | 1 |
| Assem, M | 1 |
| Mousson, C | 2 |
| Maurice-Estepa, L | 2 |
| Rifle, G | 2 |
| Tanter, Y | 2 |
| Alla, P | 1 |
| de Jaureguiberry, JP | 1 |
| Legier, HP | 1 |
| Valance, J | 1 |
| Jaubert, D | 1 |
| Cheng, L | 1 |
| Hostetler, KY | 1 |
| Gardner, MF | 1 |
| Avila, CP | 1 |
| Bergeron-Lynn, G | 1 |
| Keefe, KS | 2 |
| Beadle, JR | 1 |
| Wiley, CA | 2 |
| Parra Ródenas, JV | 1 |
| Riera Ayora, M | 1 |
| Ronda Gasulla, A | 1 |
| Herrera Ballester, A | 1 |
| Knight, DA | 1 |
| Miller, DM | 1 |
| Sedmak, DD | 1 |
| Chong, AS | 1 |
| Manso, JV | 1 |
| Lambert, JL | 1 |
| Oña, M | 1 |
| de la Iglesia, JL | 1 |
| Iglesias, J | 1 |
| Hyun, JJ | 1 |
| Park, HS | 1 |
| Kim, KH | 1 |
| Tiacci, E | 1 |
| Luppi, M | 1 |
| Barozzi, P | 1 |
| Gurdo, G | 1 |
| Tabilio, A | 1 |
| Ballanti, S | 1 |
| Torelli, G | 1 |
| Aversa, F | 1 |
| Kotchetkov, R | 1 |
| Weimer, E | 1 |
| Blaheta, RA | 1 |
| Gümbel, HO | 1 |
| Doerr, HW | 1 |
| Landry, ML | 1 |
| Stanat, S | 1 |
| Biron, K | 1 |
| Brambilla, D | 1 |
| Britt, W | 1 |
| Jokela, J | 1 |
| Gilliam, B | 1 |
| Manischewitz, J | 1 |
| Nokta, M | 1 |
| Reichelderfer, P | 1 |
| Spector, S | 1 |
| Crumpacker, C | 1 |
| Haas, C | 2 |
| Marteau, P | 1 |
| Roudière, L | 2 |
| Gisselbrecht, M | 1 |
| Lowenstein, W | 2 |
| Durand, H | 2 |
| Anduze-Faris, BM | 1 |
| Lancar, R | 1 |
| Boukli, N | 1 |
| Gasnault, J | 1 |
| Caumes, E | 2 |
| Livartowsky, J | 1 |
| Matheron, S | 2 |
| Leport, C | 3 |
| Salmon, D | 2 |
| Costagliola, D | 1 |
| Sam, R | 1 |
| Patel, SB | 1 |
| Popli, A | 1 |
| Leehey, DJ | 1 |
| Ing, TS | 1 |
| Ferguson, CG | 1 |
| Gorin, BI | 1 |
| Thatcher, GR | 1 |
| Salmon-Céron, D | 2 |
| Aboulker, JP | 1 |
| Gérard, L | 1 |
| Houhou, N | 1 |
| Carrière, I | 1 |
| Ostinelli, J | 1 |
| Vildé, JL | 1 |
| Brun-Vézinet, F | 1 |
| Bini, EJ | 1 |
| Gorelick, SM | 1 |
| Weinshel, EH | 1 |
| Rubin, DI | 1 |
| Huycke, MM | 1 |
| Naguib, MT | 1 |
| Stroemmel, MM | 1 |
| Blick, K | 1 |
| Monti, K | 1 |
| Kaufman, C | 1 |
| Bertilson, S | 1 |
| Figari, O | 1 |
| Benvenuto, F | 1 |
| Raiola, AM | 1 |
| Limaye, AP | 1 |
| Corey, L | 2 |
| Koelle, DM | 1 |
| Davis, CL | 1 |
| Ordemann, R | 1 |
| Naumann, R | 1 |
| Geissler, G | 1 |
| Kroschinsky, F | 1 |
| Bornhäuser, M | 1 |
| Schwerdtfeger, R | 1 |
| Ehninger, G | 1 |
| Witte, T | 1 |
| Werwitzke, S | 1 |
| Schmidt, RE | 1 |
| Mousavi-Jazi, M | 3 |
| Sundqvist, VA | 1 |
| Linde, A | 3 |
| Wahren, B | 6 |
| Brytting, M | 3 |
| Eckle, T | 1 |
| Klingebiel, T | 1 |
| Handgretinger, R | 1 |
| Selle, B | 1 |
| Pearce, D | 1 |
| Benson, P | 1 |
| Nahass, R | 1 |
| Olson, C | 1 |
| Wool, GM | 1 |
| Ketteler, M | 1 |
| Preuschof, L | 1 |
| Mertz, A | 1 |
| Stöffler-Meilicke, M | 1 |
| Schäfer, H | 2 |
| Distler, A | 1 |
| Offermann, G | 1 |
| Peggs, KS | 1 |
| Preiser, W | 1 |
| Kottaridis, PD | 1 |
| McKeag, N | 1 |
| Brink, NS | 1 |
| Tedder, RS | 1 |
| Linch, DC | 1 |
| Mackinnon, S | 1 |
| Gooley, T | 1 |
| Huang, M | 1 |
| Davis, C | 1 |
| Fassas, AB | 1 |
| Bolaños-Meade, J | 1 |
| Buddharaju, LN | 1 |
| Rapoport, A | 1 |
| Cottler-Fox, M | 1 |
| Chen, T | 1 |
| Lovchik, JC | 1 |
| Cross, A | 1 |
| Tricot, G | 1 |
| Wilkin, A | 1 |
| Cristina, E | 2 |
| Lanino, E | 2 |
| Giacchino, R | 1 |
| Brugger, W | 1 |
| Grigoleit, U | 1 |
| Gscheidle, B | 1 |
| Loeffler, J | 1 |
| Sinzger, C | 1 |
| Bicart-Sée, A | 1 |
| Obadia, M | 1 |
| Gonzalez, C | 1 |
| Averous, S | 1 |
| Maurette, M | 1 |
| Auvergnat, JC | 1 |
| Cheng, B | 1 |
| Mascolini, M | 1 |
| Smart, T | 1 |
| Greijer, AE | 1 |
| Verschuuren, EA | 1 |
| Dekkers, CA | 1 |
| Adriaanse, HM | 1 |
| van der Bij, W | 1 |
| The, TH | 1 |
| Middeldorp, JM | 1 |
| Kiehl, MG | 1 |
| Basara, N | 1 |
| Miano, M | 1 |
| Morreale, G | 1 |
| Chierici, M | 1 |
| Schloss, L | 2 |
| Harmenberg, J | 1 |
| Hambach, L | 1 |
| Eder, M | 1 |
| Dammann, E | 1 |
| Battmer, K | 1 |
| Stucki, A | 1 |
| Heil, G | 1 |
| Ganser, A | 1 |
| Hertenstein, B | 1 |
| Arnulf, B | 1 |
| Chebbi, F | 1 |
| Lefrere, F | 1 |
| Ait Arkoub, Z | 1 |
| Varet, B | 1 |
| Chakrabarti, S | 1 |
| Collingham, KE | 1 |
| Osman, H | 1 |
| Fegan, CD | 1 |
| Milligan, DW | 1 |
| Numazaki, K | 1 |
| Reusser, P | 3 |
| Lee, J | 1 |
| Volin, L | 1 |
| Rovira, M | 1 |
| Engelhard, D | 1 |
| Finke, J | 1 |
| Hökeberg, I | 1 |
| Zweygberg-Wirgart, B | 1 |
| Grillner, L | 1 |
| Cañizares, MA | 1 |
| Losada, I | 1 |
| Pérez-Elías, MJ | 1 |
| González, J | 1 |
| Rubio, R | 1 |
| Chou, SW | 1 |
| Mylonakis, E | 1 |
| Kallas, WM | 1 |
| Fishman, JA | 1 |
| Williams, IG | 1 |
| Healy, B | 1 |
| Hirsch, MS | 1 |
| Butler, KM | 1 |
| De Smet, MD | 2 |
| Husson, RN | 1 |
| Mueller, B | 1 |
| Manjunath, K | 1 |
| Montrella, K | 1 |
| Lovato, G | 1 |
| Jarosinski, P | 1 |
| Pizzo, PA | 1 |
| Salit, IE | 1 |
| Evans, JK | 1 |
| Scoular, A | 1 |
| Miller, RF | 2 |
| Nicoli, F | 1 |
| Dhiver, C | 1 |
| Chave, B | 1 |
| Poizot-Martin, I | 1 |
| Gastaut, JA | 1 |
| Gastaut, JL | 1 |
| Cerrina, J | 1 |
| Le Roy Ladurie, F | 1 |
| Wilson, RJ | 1 |
| Skolnik, PR | 1 |
| Jacobs, C | 2 |
| Bachman, DM | 2 |
| Timm, U | 1 |
| Cochereau-Massin, I | 1 |
| Brancon, C | 1 |
| Robinet, M | 2 |
| Rogeaux, O | 2 |
| Dahan, R | 1 |
| Gentilini, M | 3 |
| Manji, H | 1 |
| Malin, A | 2 |
| Connolly, S | 1 |
| Evans, LM | 1 |
| Cotte, L | 1 |
| Langlois, M | 1 |
| Trepo, C | 1 |
| Ohlman, S | 1 |
| Lilleby, K | 1 |
| Meyers, JD | 3 |
| Reddy, MM | 1 |
| Grieco, MH | 1 |
| McKinley, GF | 1 |
| Causey, DM | 1 |
| van der Horst, CM | 1 |
| Parenti, DM | 1 |
| Hooton, TM | 1 |
| Davis, RB | 1 |
| Levinson, ML | 1 |
| Jacobson, PA | 1 |
| Harman, C | 1 |
| Mitchell, S | 1 |
| Mathalone, B | 1 |
| Bedos, JP | 1 |
| Wolf, M | 1 |
| Vachon, F | 1 |
| Spratt, PM | 1 |
| Peterson, TJ | 1 |
| Crapotta, J | 1 |
| Listhaus, AD | 1 |
| Bruni, LM | 1 |
| DiGioia, RA | 1 |
| Harris, PJ | 1 |
| McMackin, CM | 1 |
| Pistole, MC | 1 |
| Thomas, RM | 1 |
| Ward, DJ | 1 |
| Taburet, AM | 1 |
| Zorza, G | 1 |
| Gazzard, D | 1 |
| Frostegard, C | 1 |
| Singlas, E | 1 |
| Blair, SD | 1 |
| Forbes, A | 1 |
| Parkins, RA | 1 |
| Lauchart, W | 1 |
| Díaz-Llopis, M | 1 |
| Chipont, E | 1 |
| Sanchez, S | 1 |
| España, E | 1 |
| Navea, A | 1 |
| Menezo, JL | 1 |
| Silvia, PA | 1 |
| Geier, SA | 1 |
| Klauss, V | 1 |
| Matuschke, A | 1 |
| Kronawitter, U | 1 |
| Morinelli, EN | 1 |
| Dugel, PU | 1 |
| Lee, M | 1 |
| Klatt, EC | 1 |
| Schmitz, K | 1 |
| Fabricius, EM | 1 |
| Popescu, M | 1 |
| Morris, DJ | 1 |
| Wood, CA | 1 |
| Enting, R | 1 |
| de Gans, J | 1 |
| Reiss, P | 2 |
| Jansen, C | 1 |
| Portegies, P | 1 |
| Saint-Marc, T | 1 |
| Fournier, F | 1 |
| Touraine, JL | 1 |
| Marneff, E | 1 |
| Whitmore, PV | 1 |
| Miner, RD | 1 |
| Parenti, D | 1 |
| Petersen, EA | 1 |
| Reed, EC | 2 |
| Connolly, GM | 2 |
| Charpentier, B | 1 |
| Drobyski, WR | 2 |
| Knox, KK | 2 |
| Carrigan, DR | 2 |
| Ash, RC | 1 |
| MacGregor, RR | 1 |
| Graziani, AL | 1 |
| Weiss, R | 1 |
| Grunwald, JE | 1 |
| Zurlo, JJ | 1 |
| Zunich, KM | 1 |
| Davis, M | 1 |
| Marwick, C | 1 |
| Moeland, A | 1 |
| Bruun, JN | 1 |
| Smyth, RL | 1 |
| Scott, JP | 1 |
| Borysiewicz, LK | 1 |
| Sharples, LD | 1 |
| Stewart, S | 1 |
| Wreghitt, TG | 1 |
| Gray, JJ | 1 |
| Higenbottam, TW | 1 |
| Wallwork, J | 1 |
| Nightingale, SL | 1 |
| Minor, JR | 2 |
| Peters, BS | 2 |
| Beck, EJ | 1 |
| Anderson, S | 1 |
| Coleman, D | 1 |
| Coker, R | 1 |
| Main, J | 1 |
| Migdal, C | 2 |
| Harris, JR | 2 |
| Pinching, AJ | 4 |
| Fadlallah, JP | 1 |
| Deneux, C | 1 |
| Harb, GE | 1 |
| Bacchetti, P | 1 |
| Zipeto, D | 1 |
| Parea, M | 1 |
| Gaballo, A | 1 |
| Milanesi, G | 1 |
| Gümbel, H | 1 |
| Ohrloff, C | 1 |
| Schalnus, R | 1 |
| Helm, EB | 1 |
| Neyts, J | 1 |
| Schols, D | 1 |
| Himpens, B | 1 |
| Jenkins, RE | 1 |
| Barter, G | 1 |
| Hawkins, D | 1 |
| Coker, RJ | 1 |
| Tomlinson, D | 1 |
| Horner, P | 1 |
| Chrisp, P | 1 |
| Clissold, SP | 1 |
| Paul, AA | 1 |
| Leeper, HF | 1 |
| Friberg, TR | 1 |
| Söderlund, C | 1 |
| Bratt, G | 1 |
| Grützmeier, S | 1 |
| Rieger, A | 1 |
| Sandström, E | 1 |
| Sjunnesson, M | 1 |
| Henderly, DE | 1 |
| Jampol, LM | 1 |
| Baltz, JK | 1 |
| Van Der Pijl, JW | 1 |
| Frissen, PH | 1 |
| Hulsebosch, HJ | 1 |
| Van Den Tweel, JG | 1 |
| Lange, JM | 1 |
| Youle, M | 1 |
| Chanas, A | 2 |
| Gazzard, B | 1 |
| Fanning, MM | 2 |
| Read, SE | 2 |
| Benson, M | 1 |
| Vas, S | 1 |
| Rachlis, A | 2 |
| Kozousek, V | 1 |
| Mortimer, C | 1 |
| Harvey, P | 1 |
| Schwartz, C | 1 |
| Chew, E | 2 |
| Farese, RV | 1 |
| Schambelan, M | 1 |
| Hollander, H | 1 |
| Stringari, S | 1 |
| Cotton, P | 1 |
| Bryson, YJ | 1 |
| Sakuma, T | 1 |
| Azuma, M | 1 |
| Chiba, S | 1 |
| Girard, B | 1 |
| Marcel, P | 1 |
| Zazoun, L | 1 |
| Morer, I | 1 |
| Mills, J | 5 |
| Martinez, F | 1 |
| Levaltier, B | 1 |
| Beaufils, H | 1 |
| Danis, M | 1 |
| Rozenheim, M | 1 |
| Baumelou, A | 2 |
| Sundberg, B | 1 |
| Andersson, J | 1 |
| Akesson-Johansson, A | 3 |
| Brattström, C | 1 |
| Nyberg, G | 1 |
| Svalander, C | 1 |
| Blohmé, I | 1 |
| Persson, H | 1 |
| Wood, G | 1 |
| Whitby, M | 1 |
| Hogan, P | 1 |
| Frazer, I | 1 |
| Acheson, JF | 1 |
| Shah, SM | 1 |
| Spalton, DJ | 1 |
| Bradbeer, C | 1 |
| Thin, RN | 1 |
| Debs, RJ | 1 |
| Montgomery, AB | 1 |
| Brunette, EN | 1 |
| DeBruin, M | 1 |
| Shanley, JD | 1 |
| Walmsley, SL | 1 |
| Vellend, H | 1 |
| Salit, I | 1 |
| Cacoub, P | 1 |
| Le Hoang, P | 2 |
| Soubrie, C | 1 |
| Rousselie, R | 1 |
| Crowe, S | 1 |
| Levy, J | 1 |
| McManus, N | 1 |
| Rush, J | 1 |
| Miller, RG | 1 |
| Greco, C | 1 |
| Gonzales, MF | 1 |
| Bloom, JN | 1 |
| Ganly, PS | 1 |
| Arthur, C | 1 |
| Goldman, JM | 2 |
| Schulenburg, WE | 2 |
| Wyngaarden, JB | 1 |
| Michon, C | 1 |
| Ngovan, P | 1 |
| Simonpoli, AM | 1 |
| Marcus, RE | 1 |
| Wardle, DG | 1 |
| Gravett, PJ | 1 |
| Wilczek, H | 1 |
| Gahrton, G | 2 |
| Heley, A | 1 |
| Klintmalm, G | 2 |
| Oberg, B | 1 |
| Lundgren, G | 1 |
| Robert, KH | 1 |
| Groth, CG | 1 |
| Singer, DR | 1 |
| Fallon, TJ | 1 |
| Williams, G | 1 |
| Cohen, J | 1 |
| Ahlmén, J | 2 |
| Wijnween, AC | 1 |
| Brynger, H | 1 |
| Lycke, E | 1 |
| Paulin, T | 1 |
| Larson, A | 1 |
| Frödin, L | 2 |
| Tufveson, G | 2 |
| Larsson, E | 1 |
| Källander, CF | 2 |
| Gronowitz, JS | 2 |
| Larsson, A | 1 |
| Claesson, K | 1 |
| Sjöberg, O | 1 |
| Brochard, L | 1 |
| Salmeron, S | 1 |
| Herve, P | 1 |
| Petitpretz, P | 1 |
| Boissonnas, A | 1 |
| Simonneau, G | 1 |
| Duroux, P | 1 |
| Weber, JN | 1 |
| Thom, S | 1 |
| Barrison, I | 1 |
| Unwin, R | 1 |
| Forster, S | 1 |
| Jeffries, DJ | 1 |
| Boylston, A | 1 |
| Gluckman, E | 1 |
| Keable, H | 1 |
| Meletis, J | 1 |
| Bombail, D | 1 |
| Jolivet, I | 1 |
| Huart, JJ | 1 |
| Nebout, T | 1 |
| Cavazzana, M | 1 |
| De Castro, H | 1 |
| Farthing, C | 1 |
| Anderson, MG | 1 |
| Ellis, ME | 1 |
| Chanas, AC | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 3, Multicenter, Randomized, Open-label, Active-controlled Study to Assess the Efficacy and Safety of Maribavir Treatment Compared to Investigator-assigned Treatment in Transplant Recipients With Cytomegalovirus (CMV) Infections That Are Refractory[NCT02931539] | Phase 3 | 352 participants (Actual) | Interventional | 2016-12-22 | Completed | ||
| A Phase I Open-Labeled Study of Long Term Combined or Alternating Foscarnet/Ganciclovir Maintenance Therapy for AIDS Patients With CMV Retinitis After Ganciclovir Induction Therapy[NCT00000970] | Phase 1 | 30 participants | Interventional | Completed | |||
| [NCT00005228] | 0 participants | Observational | 1988-07-31 | Completed | |||
| Foscarnet Treatment of Serious CMV Retinitis Infection in Patients With Acquired Immunodeficiency Syndrome[NCT00000726] | Phase 1 | 53 participants | Interventional | Completed | |||
| Phase III Multicenter, Open-Label, Randomized Trial of Induction Versus Induction Plus Maintenance Foscarnet ( Foscavir ) Therapy for Gastrointestinal CMV Disease[NCT00002145] | Phase 3 | 145 participants | Interventional | Completed | |||
| Foscarnet-Ganciclovir CMV Retinitis Trial[NCT00000136] | Phase 3 | 234 participants (Actual) | Interventional | 1990-03-31 | Completed | ||
| Phase II, Multicentric, Prospective and Opened Clinical Trial of Advance Valganciclovir Treatment of CMV in Allogenic Hematopoietic Progenitors Transplant[NCT00386412] | Phase 2 | 132 participants (Anticipated) | Interventional | 2005-11-30 | Completed | ||
| A Randomized, Controlled Study of the Safety and Preventive Efficacy of Oral Ganciclovir When Used in Conjunction With An Intravitreal Ganciclovir Implant in the Treatment of Cytomegalovirus Retinitis[NCT00002134] | 450 participants | Interventional | Completed | ||||
| A Phase I/II Pilot Treatment Study Of CSF Penetration And Response To Ganciclovir And Foscarnet In CMV Neurologic Disease.[NCT00000856] | Phase 1 | 0 participants (Actual) | Interventional | Withdrawn | |||
| Studies of the Ocular Complications of AIDS (SOCA) CMV Retinitis Trial: Foscarnet-Ganciclovir Component[NCT00000665] | 240 participants | Interventional | Completed | ||||
| A Phase II Randomized Controlled Trial of Immediate Versus Delayed Foscarnet Therapy in AIDS Patients With Non-Immediately Sight-Threatening CMV Retinitis Who Cannot Be Treated With Ganciclovir Due to Myelosuppression[NCT00000697] | Phase 2 | 0 participants (Actual) | Interventional | Withdrawn | |||
| A Phase II Dose-Ranging, Open-Labelled Trial of Foscarnet Salvage Therapy for AIDS Patients With Sight-Threatening CMV Retinitis Who Cannot Be Treated With Ganciclovir Due To Myelosuppression or Treatment Failure[NCT00000691] | Phase 2 | 156 participants | Interventional | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
All-cause mortality was analyzed by the end of study regardless of the use of rescue treatment or alternative anti-CMV treatment. Number of participants who died during the entire study period were reported. (NCT02931539)
Timeframe: From enrollment up to end of study (approximately 44 months)
| Intervention | Participants (Count of Participants) |
|---|---|
| Investigator-assigned Anti-CMV Treatment (IAT) | 13 |
| Maribavir 400 mg | 27 |
Confirmed CMV viremia clearance was defined as plasma CMV DNA concentration
Timeframe: Up to Week 16
| Intervention | percentage of participants (Number) |
|---|---|
| Maribavir Rescue Arm | 27.3 |
Confirmed CMV viremia clearance was defined as plasma CMV DNA concentration
Timeframe: From start of maribavir rescue treatment through 8 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| Maribavir Rescue Arm | 50.0 |
Confirmed CMV viremia clearance was defined as plasma CMV DNA concentration less than (<) lower limit of quantification (LLOQ) that is, <137 International Units per milliliter (IU/mL) when assessed by COBAS® AmpliPrep/COBAS® TaqMan® CMV Test in 2 consecutive postbaseline samples, separated by at least 5 days. Percentage of participants with confirmed CMV viremia clearance at end of study Week 8 regardless of whether either study-assigned treatment was discontinued before the end of the stipulated 8 weeks of therapy, and could not have received alternative anti-CMV treatment were reported. (NCT02931539)
Timeframe: Week 8
| Intervention | percentage of participants (Number) |
|---|---|
| Investigator-assigned Anti-CMV Treatment (IAT) | 23.9 |
| Maribavir 400 mg | 55.7 |
Confirmed CMV viremia clearance was defined as plasma CMV DNA concentration
Timeframe: Up to Week 16
| Intervention | percentage of participants (Number) |
|---|---|
| Investigator-assigned Anti-CMV Treatment (IAT) | 10.3 |
| Maribavir 400 mg | 18.7 |
Recurrence of CMV viremia was defined as plasma CMV DNA concentration >=LLOQ when assessed by COBAS® AmpliPrep/COBAS® TaqMan® CMV test in 2 consecutive plasma samples at least 5 days apart, after achieving confirmed viremia clearance. Percentage of participants who completed 8 weeks of study-assigned treatment with recurrence of CMV viremia during the 12 weeks of follow-up period were reported. (NCT02931539)
Timeframe: End of Week 8 up to Week 20 (12 weeks follow-up period)
| Intervention | percentage of participants (Number) |
|---|---|
| Investigator-assigned Anti-CMV Treatment (IAT) | 35.5 |
| Maribavir 400 mg | 40.9 |
Recurrence of CMV viremia was defined as plasma CMV DNA concentration >=LLOQ when assessed by COBAS® AmpliPrep/COBAS® TaqMan® CMV test in 2 consecutive plasma samples at least 5 days apart, after achieving confirmed viremia clearance. Percentage of participants with Recurrence of CMV viremia was defined as plasma CMV DNA concentration >=LLOQ when assessed by COBAS® AmpliPrep/COBAS® TaqMan® CMV test in 2 consecutive plasma samples at least 5 days apart, after achieving confirmed viremia clearance. Percentage of participants who completed 8 weeks of study-assigned treatment with recurrence of CMV viremia during the 20 weeks of study were reported. (NCT02931539)
Timeframe: Baseline up to Week 20
| Intervention | percentage of participants (Number) |
|---|---|
| Investigator-assigned Anti-CMV Treatment (IAT) | 45.2 |
| Maribavir 400 mg | 56.1 |
Recurrence of CMV viremia was defined as plasma CMV DNA concentration >=LLOQ when assessed by COBAS® AmpliPrep/COBAS® TaqMan® CMV test in 2 consecutive plasma samples at least 5 days apart, after achieving confirmed viremia clearance. Percentage of participants with recurrence of CMV viremia during the first 8 Weeks of the treatment who completed 8 weeks of study-assigned treatment were reported. (NCT02931539)
Timeframe: Baseline up to Week 8
| Intervention | percentage of participants (Number) |
|---|---|
| Investigator-assigned Anti-CMV Treatment (IAT) | 9.7 |
| Maribavir 400 mg | 15.2 |
Recurrence of CMV viremia was defined as plasma CMV DNA concentration >=LLOQ when assessed by COBAS® AmpliPrep/COBAS® TaqMan® CMV test in 2 consecutive plasma samples at least 5 days apart, after achieving confirmed viremia clearance, regardless of whether either study-assigned treatment was discontinued before the end of the stipulated 8 weeks of therapy. Percentage of participants with recurrence of CMV viremia during at any time on study regardless of whether study-assigned treatment was discontinued before 8 weeks of therapy were reported. (NCT02931539)
Timeframe: Baseline up to Week 20
| Intervention | percentage of participants (Number) |
|---|---|
| Investigator-assigned Anti-CMV Treatment (IAT) | 33.8 |
| Maribavir 400 mg | 56.5 |
Recurrence of CMV viremia was defined as plasma CMV DNA concentration >=LLOQ when assessed by COBAS® AmpliPrep/COBAS® TaqMan® CMV test in 2 consecutive plasma samples at least 5 days apart, after achieving confirmed viremia clearance, regardless of whether either study-assigned treatment was discontinued before the end of the stipulated 8 weeks of therapy. Percentage of participants with recurrence of CMV viremia during the 12 weeks follow-up period regardless of whether study-assigned treatment was discontinued before 8 weeks of therapy were reported. (NCT02931539)
Timeframe: End of Week 8 up to Week 20 (12 weeks follow-up period)
| Intervention | percentage of participants (Number) |
|---|---|
| Investigator-assigned Anti-CMV Treatment (IAT) | 21.5 |
| Maribavir 400 mg | 38.6 |
Recurrence of CMV viremia was defined as plasma CMV DNA concentration greater than or equal to (>=) LLOQ when assessed by COBAS® AmpliPrep/COBAS® TaqMan® CMV test in 2 consecutive plasma samples at least 5 days apart, after achieving confirmed viremia clearance, regardless of whether either study-assigned treatment was discontinued before the end of the stipulated 8 weeks of therapy. Percentage of participants with recurrence of CMV viremia during the first 8 weeks of study regardless of whether study-assigned treatment was discontinued before 8 weeks of therapy were reported. (NCT02931539)
Timeframe: At Week 8
| Intervention | percentage of participants (Number) |
|---|---|
| Investigator-assigned Anti-CMV Treatment (IAT) | 12.3 |
| Maribavir 400 mg | 17.9 |
Recurrence of CMV viremia was defined as plasma CMV DNA concentration >=LLOQ when assessed by COBAS® AmpliPrep/COBAS® TaqMan® CMV test in 2 consecutive plasma samples at least 5 days apart, after achieving confirmed viremia clearance. Percentage of participants with recurrence of CMV viremia while off study-assigned treatment during follow-up period were reported. (NCT02931539)
Timeframe: Termination of study treatment (Week 8) up to the End of the Study (Week 20)
| Intervention | percentage of participants (Number) |
|---|---|
| Investigator-assigned Anti-CMV Treatment (IAT) | 29.2 |
| Maribavir 400 mg | 40.8 |
Recurrence of CMV viremia was defined as plasma CMV DNA concentration >=LLOQ when assessed by COBAS® AmpliPrep/COBAS® TaqMan® CMV test in 2 consecutive plasma samples at least 5 days apart, after achieving confirmed viremia clearance. Percentage of participants with recurrence of CMV viremia while on study-assigned treatment period were reported. (NCT02931539)
Timeframe: Baseline up to termination of study treatment (up to Week 8)
| Intervention | percentage of participants (Number) |
|---|---|
| Investigator-assigned Anti-CMV Treatment (IAT) | 4.6 |
| Maribavir 400 mg | 15.8 |
The time to all-cause mortality by the end of the study participation in days was calculated. Participants who were alive at the last study follow-up (regardless of use of rescue or alternative anti-CMV treatment), withdrew from study or were lost to follow-up were censored at the date of last contact. (NCT02931539)
Timeframe: From enrollment to last serious adverse event (SAE) follow-up (approximately Week 28)
| Intervention | days (Median) |
|---|---|
| Investigator-assigned Anti-CMV Treatment (IAT) | 73.0 |
| Maribavir 400 mg | 55.0 |
Resistance-associated amino acid substitutions (RASs) to maribavir are known to generally map to the pUL97 and pUL27 genes. Genotyping was performed to identify RASs mapping to the pUL97 and pUL27 genes. Number of participants who had maribavir CMV resistance at baseline were reported. (NCT02931539)
Timeframe: At Baseline
| Intervention | Participants (Count of Participants) | ||
|---|---|---|---|
| RASs associated with pUL97 only | RASs associated with pUL27 only | RASs associated with pUL97 and pUL27 | |
| Investigator-assigned Anti-CMV Treatment (IAT) | 3 | 0 | 0 |
| Maribavir 400 mg | 0 | 1 | 0 |
| Maribavir Rescue Arm | 1 | 0 | 0 |
Resistance-associated amino acid substitutions (RASs) to maribavir are known to generally map to the pUL97 and pUL27 genes. Genotyping was performed to identify RASs mapping to the pUL97 and pUL27 genes. Number of participants who had post-baseline resistance to maribavir were reported. (NCT02931539)
Timeframe: After first dose of study drug up to Week 20
| Intervention | Participants (Count of Participants) | ||
|---|---|---|---|
| RASs associated with pUL97 only | RASs associated with pUL27 only | RASs associated with pUL97 and pUL27 | |
| Investigator-assigned Anti-CMV Treatment (IAT) | 0 | 0 | 0 |
| Maribavir 400 mg | 45 | 0 | 0 |
| Maribavir Rescue Arm | 4 | 0 | 0 |
An adverse event (AE) is any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. Serious AE was any untoward medical occurrence (whether considered to be related to study-assigned treatment or not) that at any dose resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, resulted in a congenital abnormality/birth defect, or was an important medical event. TEAEs was defined as any adverse events (classified by preferred term) that had a start date on or after the first dose of study treatment or that had a start date before the date of first dose of study treatment, but increased in severity after the first dose of study treatment. (NCT02931539)
Timeframe: Baseline up to 7 days or 21 days (if cidofovir used) after the last dose of study treatment (up to Week 8)
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| TEAEs | Serious TEAEs | |
| Investigator-assigned Anti-CMV Treatment (IAT) | 106 | 43 |
| Maribavir 400 mg | 228 | 90 |
| Maribavir Rescue Arm | 22 | 11 |
Confirmed CMV viremia clearance was defined as plasma CMV DNA concentration
Timeframe: At Week 8 through Weeks 12, 16 and 20
| Intervention | percentage of participants (Number) | |||
|---|---|---|---|---|
| At Week 8 | At Week 12 | At Week 16 | At Week 20 | |
| Investigator-assigned Anti-CMV Treatment (IAT) | 18.8 | 5.1 | 5.1 | 4.3 |
| Maribavir 400 mg | 54.9 | 22.6 | 18.7 | 18.3 |
Confirmed CMV viremia clearance was defined as plasma CMV DNA concentration
Timeframe: At Week 8 through Weeks 12, 16 and 20
| Intervention | percentage of participants (Number) | |||
|---|---|---|---|---|
| At Week 8 | At Week 12 | At Week 16 | At Week 20 | |
| Investigator-assigned Anti-CMV Treatment (IAT) | 18.8 | 5.1 | 5.1 | 4.3 |
| Maribavir 400 mg | 54.9 | 22.6 | 18.7 | 18.3 |
Confirmed CMV viremia clearance was defined as plasma CMV DNA concentration
Timeframe: At Week 8 through Weeks 12 and 20
| Intervention | percentage of participants (Number) | ||
|---|---|---|---|
| At Week 8 | At Week 12 | At Week 20 | |
| Investigator-assigned Anti-CMV Treatment (IAT) | 23.9 | 10.3 | 9.4 |
| Maribavir 400 mg | 55.7 | 22.6 | 18.3 |
Cmin of maribavir was reported. (NCT02931539)
Timeframe: Predose at Week 1, 4 and 8
| Intervention | micrograms per milliliter (mcg/mL) (Mean) | ||
|---|---|---|---|
| Cmin at Week 1 | Cmin at Week 4 | Cmin at Week 8 | |
| Maribavir 400 mg | 8.77 | 7.59 | 7.19 |
| Maribavir Rescue Arm | 8.57 | 5.75 | 5.65 |
(NCT00000136)
Timeframe: All patients enrolled will be followed until a common study closing date, which was chosen to provide a minimum of 1 year of follow-up for all patients enrolled in the trial.
| Intervention | participants (Number) |
|---|---|
| Foscarnet | 107 |
| Ganciclovir | 127 |
99 reviews available for foscarnet and Cytomegalovirus Infections
| Article | Year |
|---|---|
New Perspectives on Antimicrobial Agents: Maribavir.
Topics: Adult; Anti-Infective Agents; Antiviral Agents; Benzimidazoles; Child; Cidofovir; Cytomegalovirus In | 2022 |
Oral antiviral drugs for treatment of cytomegalovirus in transplant recipients.
Topics: Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; Foscarnet; Ganciclovir; Humans; Trans | 2023 |
Moving Past Ganciclovir and Foscarnet: Advances in CMV Therapy.
Topics: Animals; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; Cytomegalovirus Vaccines; Dr | 2020 |
Resistant Cytomegalovirus Infection After Renal Transplantation: Literature Review.
Topics: Adult; Antibodies, Monoclonal; Antilymphocyte Serum; Antiviral Agents; Basiliximab; Cytomegalovirus; | 2018 |
Ganciclovir and foscarnet dual-therapy for cytomegalovirus encephalitis: A case report and review of the literature.
Topics: Antiviral Agents; Cytomegalovirus Infections; Drug Therapy, Combination; Encephalitis, Viral; Female | 2018 |
New Developments in the Management of Cytomegalovirus Infection After Transplantation.
Topics: Acetates; Antiviral Agents; Cidofovir; Cytomegalovirus; Cytomegalovirus Infections; Drug Resistance, | 2018 |
Cytomegalovirus Disease After Liver Transplant-A Description of a Treatment-Resistant Case: A Case Report and Literature Review.
Topics: Adult; Antilymphocyte Serum; Antiviral Agents; Cytomegalovirus Infections; Drug Resistance, Viral; F | 2018 |
[Current treatment modalities of immunocompromised patients with cytomegalovirus infection. II. Therapeutic options and management strategies].
Topics: Acetates; Acyclovir; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; Foscarnet; Ganci | 2019 |
Leflunomide as part of the treatment for multidrug-resistant cytomegalovirus disease after lung transplantation: case report and review of the literature.
Topics: Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; Drug Resistance, Viral; Drug Therapy, | 2013 |
Management of multidrug-resistant CMV infection in immunocompromised patients: case report of a heart-transplant recipient and review of the literature.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antiviral Agents; Cyclosporine; Cytomegalovirus; Cytomegalovir | 2015 |
Anti-viral therapy for congenital cytomegalovirus infection: pharmacokinetics, efficacy and side effects.
Topics: Antiviral Agents; Cidofovir; Cytomegalovirus Infections; Cytosine; Foscarnet; Ganciclovir; Humans; I | 2016 |
Immunocompromised hosts: perspectives in the treatment and prophylaxis of cytomegalovirus disease in solid-organ transplant recipients.
Topics: Antiviral Agents; Chemoprevention; Cidofovir; Cytomegalovirus Infections; Cytosine; Drug Resistance, | 2008 |
[Gastrointestinal cytomegalovirus infections in organ transplant patients].
Topics: Acyclovir; Antiviral Agents; Biopsy; Cidofovir; Cytomegalovirus; Cytomegalovirus Infections; Cytosin | 2008 |
Antiviral treatment of cytomegalovirus infection and resistant strains.
Topics: Antiviral Agents; Cidofovir; Cytomegalovirus Infections; Cytosine; Drug Resistance, Viral; Drug Ther | 2009 |
CMV-related thrombocytopenia treated with foscarnet: a case series and review of the literature.
Topics: Adult; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; Drug Therapy, Combination; Fem | 2010 |
Antiviral drug resistance of human cytomegalovirus.
Topics: Antiviral Agents; Cidofovir; Cytomegalovirus; Cytomegalovirus Infections; Cytosine; DNA-Directed DNA | 2010 |
The search for new therapies for human cytomegalovirus infections.
Topics: Antiviral Agents; Cidofovir; Cyclopropanes; Cytomegalovirus; Cytomegalovirus Infections; Cytosine; F | 2011 |
Foscarnet in the management of cytomegalovirus infections in hematopoietic stem cell transplant patients.
Topics: Antiviral Agents; Cytomegalovirus Infections; Foscarnet; Ganciclovir; Hematopoietic Stem Cell Transp | 2012 |
Prevention and management of CMV-related problems after hematopoietic stem cell transplantation.
Topics: Acyclovir; Antiviral Agents; Cidofovir; Cytomegalovirus; Cytomegalovirus Infections; Cytosine; Fosca | 2002 |
Antiviral agents: Non-antiretroviral [correction of Nonantiviral] drugs.
Topics: 2-Aminopurine; Acyclovir; Antiviral Agents; Chickenpox; Cytomegalovirus Infections; Famciclovir; Fos | 2002 |
[Drugs against human cytomegalovirus].
Topics: Acyclovir; AIDS-Related Opportunistic Infections; Antiviral Agents; Cidofovir; Cytomegalovirus Infec | 2002 |
Cytomegalovirus in hematopoietic stem cell transplant recipients: Current status, known challenges, and future strategies.
Topics: Acyclovir; Antigens, CD34; Antiviral Agents; Cidofovir; Cytomegalovirus Infections; Cytosine; Foscar | 2003 |
Clinical and biologic aspects of human cytomegalovirus resistance to antiviral drugs.
Topics: Acquired Immunodeficiency Syndrome; Antiretroviral Therapy, Highly Active; Cidofovir; Cytomegaloviru | 2004 |
Progressive outer retinal necrosis presenting with isolated optic neuropathy.
Topics: Acyclovir; Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; Cytomegalovirus Infection | 2004 |
[Human cytomegalovirus infection].
Topics: Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; Foscarnet; gamma-Globulins; Ganciclov | 2005 |
Is combination antiviral therapy for CMV superior to monotherapy?
Topics: Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; Drug Synergism; Drug Therapy, Combina | 2006 |
Viral infections affecting the skin in organ transplant recipients: epidemiology and current management strategies.
Topics: 2-Aminopurine; Acyclovir; Antiviral Agents; Cidofovir; Cytomegalovirus Infections; Cytosine; Drug Ad | 2006 |
[Therapy for cytomegalovirus infection].
Topics: AIDS-Related Opportunistic Infections; Antiviral Agents; Cytomegalovirus Infections; Foscarnet; Ganc | 2006 |
[Human cytomegalovirus infection].
Topics: Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; Foscarnet; Ganciclovir; Globins; Huma | 2007 |
[Mechanism of drug-resistance in human cytomegalovirus].
Topics: Antiviral Agents; Cidofovir; Cytomegalovirus; Cytomegalovirus Infections; Cytosine; DNA-Directed DNA | 2007 |
[Management of severe or corticosteroid resistant ulcerative colitis].
Topics: Anti-Inflammatory Agents; Antibodies, Monoclonal; Antiviral Agents; Colectomy; Colitis, Ulcerative; | 2007 |
Treatment of congenital cytomegalovirus: where are we now?
Topics: Antiviral Agents; Cidofovir; Cytomegalovirus Infections; Cytosine; Female; Foscarnet; Ganciclovir; H | 2007 |
Prevention and early treatment of opportunistic viral infections in patients with leukemia and allogeneic stem cell transplantation recipients.
Topics: Antiviral Agents; Benzimidazoles; Cytomegalovirus Infections; Foscarnet; Ganciclovir; Herpes Zoster; | 2008 |
[Cytomegalovirus infections in AIDS].
Topics: Acquired Immunodeficiency Syndrome; AIDS-Related Opportunistic Infections; Cytomegalovirus Infection | 1995 |
Strategies for the prevention of cytomegalovirus disease after marrow transplantation.
Topics: Bone Marrow Transplantation; Clinical Trials as Topic; Cytomegalovirus Infections; Foscarnet; Gancic | 1994 |
Retinal disease associated with AIDS.
Topics: AIDS-Related Opportunistic Infections; CD4-Positive T-Lymphocytes; Cytomegalovirus Infections; Eye I | 1993 |
Prevention and treatment of cytomegalovirus pneumonia in transplant recipients.
Topics: Acyclovir; Cytomegalovirus Infections; Foscarnet; Ganciclovir; Humans; Immunoglobulins, Intravenous; | 1993 |
[Cytomegalovirus infection after transplantation. Virological diagnosis, antiviral treatment].
Topics: Antibodies, Viral; Antigens, Viral; Cytomegalovirus; Cytomegalovirus Infections; DNA, Viral; Enzyme- | 1993 |
Oral CMV lesions and the HIV infected. Early recognition can help prevent morbidity.
Topics: AIDS-Related Opportunistic Infections; Cytomegalovirus Infections; Foscarnet; Ganciclovir; HIV Infec | 1993 |
New developments in cytomegalovirus prevention and management.
Topics: Antibodies, Viral; Cytomegalovirus; Cytomegalovirus Infections; Foscarnet; Ganciclovir; Humans; Immu | 1993 |
Increased survival of a cohort of patients with acquired immunodeficiency syndrome and cytomegalovirus retinitis who received sodium phosphonoformate (foscarnet).
Topics: Acquired Immunodeficiency Syndrome; Cohort Studies; Cytomegalovirus Infections; Didanosine; Drug Tol | 1993 |
Ocular complications of the acquired immunodeficiency syndrome. Focus on the treatment of cytomegalovirus retinitis with ganciclovir and foscarnet.
Topics: Acquired Immunodeficiency Syndrome; Cytomegalovirus Infections; Eye Diseases; Foscarnet; Ganciclovir | 1993 |
Advances in the diagnosis, treatment, and prevention of cytomegalovirus infections after liver transplantation.
Topics: Cytomegalovirus Infections; Foscarnet; Ganciclovir; Humans; Immunization, Passive; Incidence; Liver | 1993 |
Cytomegalovirus pneumonia: presentation, diagnosis, and treatment.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Bone Marrow Transplantation; Cytomegalovirus I | 1995 |
Management of cytomegalovirus disease.
Topics: Antiviral Agents; Cidofovir; Cytomegalovirus Infections; Cytosine; Drug Therapy, Combination; Foscar | 1995 |
Cytomegalovirus polyradiculopathy treated successfully with foscarnet.
Topics: Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; Cytomegalovirus Infections; Foscarne | 1996 |
Nephrotoxicity of antiviral therapies.
Topics: Acquired Immunodeficiency Syndrome; Acyclovir; Antiviral Agents; Cytomegalovirus Infections; Foscarn | 1996 |
Severe cytomegalovirus infection in immunocompetent patients.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Child; Cytomegalovirus Infections; Diagnosis, Differentia | 1997 |
Viral lesions of the mouth in HIV-infected patients.
Topics: 2-Aminopurine; Acyclovir; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Cytomegalovirus In | 1997 |
[Treatment of cytomegalovirus infections in HIV infection].
Topics: AIDS-Related Opportunistic Infections; Antiviral Agents; Cytomegalovirus Infections; Cytomegalovirus | 1996 |
Minimising the dosage-limiting toxicities of foscarnet induction therapy.
Topics: Animals; Antiviral Agents; Cytomegalovirus Infections; Dose-Response Relationship, Drug; Female; Fos | 1997 |
Combination antiviral therapy for cytomegalovirus disease in patients with AIDS.
Topics: AIDS-Related Opportunistic Infections; Antiviral Agents; Cytomegalovirus Infections; Drug Therapy, C | 1997 |
Resistance to antivirals in human cytomegalovirus: mechanisms and clinical significance.
Topics: Antiviral Agents; Cidofovir; Codon; Cytomegalovirus; Cytomegalovirus Infections; Cytosine; Drug Resi | 1997 |
Management of cytomegalovirus infection after solid-organ or stem-cell transplantation. Current guidelines and future prospects.
Topics: Acyclovir; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; Foscarnet; Ganciclovir; Gu | 1998 |
[Recent advances in antiviral drugs--antiviral agents to HCMV, HHV-6, and HHV-7].
Topics: Antiviral Agents; Cidofovir; Cytomegalovirus; Cytomegalovirus Infections; Cytosine; Drug Resistance, | 1998 |
Ganciclovir and foscarnet efficacy in AIDS-related CMV polyradiculopathy.
Topics: Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Inf | 1998 |
Diagnosis and clinical management of neurological disorders caused by cytomegalovirus in AIDS patients. European Union Concerted Action on Virus Meningitis and Encephalitis.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus Infections; Diagnostic Techniq | 1998 |
Treatment of cytomegalovirus diseases.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cidofovir; Cytomegalovirus Infections; Cytosin | 1997 |
Use of the human cytomegalovirus (HCMV) antigenemia assay for diagnosis and monitoring of HCMV infections and detection of antiviral drug resistance in the immunocompromised.
Topics: Antigens, Viral; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; DNA, Viral; Drug Res | 1998 |
Management of human cytomegalovirus infection and disease after allogeneic bone marrow transplantation.
Topics: Acyclovir; Adolescent; Adult; Antigens, Viral; Antiviral Agents; Bone Marrow Transplantation; Child; | 1999 |
Cytomegalovirus infection in patients with HIV infection.
Topics: AIDS-Related Opportunistic Infections; Antiviral Agents; Cidofovir; Cytomegalovirus Infections; Cyto | 1999 |
Cytomegalovirus: disease syndromes and treatment.
Topics: AIDS-Related Opportunistic Infections; Antiviral Agents; Central Nervous System Diseases; Chorioreti | 1999 |
Cytomegalovirus drug resistance.
Topics: Antiviral Agents; Cidofovir; Cytomegalovirus Infections; Cytosine; Drug Resistance; Foscarnet; Ganci | 1998 |
Cytomegalovirus infection following stem cell transplantation.
Topics: Acyclovir; Antibodies, Viral; Antiviral Agents; Blood Donors; Cidofovir; Cytomegalovirus; Cytomegalo | 1999 |
Prophylaxis against fungal infections and cytomegalovirus disease after bone marrow transplantation.
Topics: Antifungal Agents; Antiviral Agents; Bone Marrow Transplantation; Cytomegalovirus Infections; Foscar | 2000 |
Progress in understanding cytomegalovirus drug resistance.
Topics: Antiviral Agents; Cidofovir; Cytomegalovirus; Cytomegalovirus Infections; Cytosine; Drug Resistance, | 2001 |
Donor cell-derived acute myeloid leukemia developing 14 months after matched unrelated bone marrow transplantation for chronic myeloid leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Bone Marrow Transplantation | 2001 |
Cytomegalovirus infection: the point in 2001.
Topics: AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antiv | 2001 |
[Cytomegalovirus infection].
Topics: Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; Disease Transmission, Infectious; Fem | 2001 |
Cytomegalovirus drug resistance and clinical implications.
Topics: Antiviral Agents; Cidofovir; Cytomegalovirus; Cytomegalovirus Infections; Cytosine; Drug Resistance, | 2001 |
Management of CMV disease in HIV infection.
Topics: AIDS-Related Opportunistic Infections; Antiviral Agents; Cidofovir; Cytomegalovirus Infections; Cyto | 1999 |
Characteristics of cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus Infections; Eye Infections, Vi | 1992 |
Maintenance therapy for cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome: foscarnet.
Topics: Antiviral Agents; Cytomegalovirus Infections; Drug Therapy, Combination; Eye Infections, Viral; Fosc | 1992 |
Cytomegalovirus infection in patients with AIDS.
Topics: Acquired Immunodeficiency Syndrome; Chorioretinitis; Cytomegalovirus Infections; Encephalitis; Fosca | 1992 |
[Cytomegalovirus infection in patients after lung transplantation].
Topics: Acyclovir; Antiviral Agents; Blood Transfusion; Cytomegalovirus; Cytomegalovirus Infections; Foscarn | 1992 |
Cytomegalovirus retinitis in AIDS.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus Infections; Diagnosis, Differe | 1992 |
Combined and alternating ganciclovir and foscarnet in acute and maintenance therapy of human immunodeficiency virus-related cytomegalovirus encephalitis refractory to ganciclovir alone. A case report and review of the literature.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infect | 1992 |
Foscarnet and ganciclovir in the treatment of cytomegalovirus retinitis.
Topics: Cytomegalovirus Infections; Drug Therapy, Combination; Foscarnet; Ganciclovir; Humans; Phosphonoacet | 1992 |
Foscarnet-induced penile ulcer.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Cytomegalovirus Infections; Foscarnet; | 1992 |
Treatment and prophylaxis of cytomegalovirus disease.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus Infections; Foscarnet; Gancicl | 1992 |
[Clinical aspects and therapy of infection with cytomegalovirus].
Topics: AIDS-Related Opportunistic Infections; Antiviral Agents; Cytomegalovirus Infections; Foscarnet; Ganc | 1992 |
[Incidence, prevention and therapy of cytomegalovirus and pneumocystis carinii pneumonia after liver transplantation].
Topics: Acyclovir; Combined Modality Therapy; Cytomegalovirus Infections; Foscarnet; Ganciclovir; Humans; Im | 1992 |
Extrapulmonary cytomegalovirus disease in transplant patients.
Topics: Antiviral Agents; Bone Marrow Transplantation; Cytomegalovirus Infections; Foscarnet; Ganciclovir; H | 1991 |
Treatment of cytomegalovirus pneumonia in transplant patients.
Topics: Cytomegalovirus Infections; Drug Therapy, Combination; Foscarnet; Ganciclovir; Humans; Immunization, | 1991 |
[Cytomegalovirus infections in transplant patients].
Topics: Antiviral Agents; Cytomegalovirus Infections; Foscarnet; Ganciclovir; Humans; Immune Tolerance; Inci | 1991 |
[Treatment of herpesvirus infections].
Topics: Acyclovir; Antiviral Agents; Cytomegalovirus Infections; Drug Resistance, Microbial; Foscarnet; Ganc | 1991 |
Advances in the prevention and treatment of cytomegalovirus infection in hospital patients.
Topics: Antibodies, Monoclonal; Antiviral Agents; Bronchoalveolar Lavage Fluid; Cross Infection; Cytomegalov | 1991 |
Foscarnet. A review of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with cytomegalovirus retinitis.
Topics: Acquired Immunodeficiency Syndrome; Anemia; Animals; Antiviral Agents; Cytomegalovirus; Cytomegalovi | 1991 |
Approaches to the treatment of cytomegalovirus retinitis: ganciclovir and foscarnet.
Topics: Antiviral Agents; Cytomegalovirus Infections; Drug Therapy, Combination; Eye Infections, Viral; Fosc | 1991 |
Diagnosis and treatment of cytomegalovirus retinitis.
Topics: Antiviral Agents; Cytomegalovirus Infections; Diagnosis, Differential; Eye Infections, Viral; Foscar | 1991 |
Foscarnet sodium.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus Infections; Eye Infections, Vi | 1991 |
Treatment of cytomegalovirus infection.
Topics: Acyclovir; Clinical Trials as Topic; Cytomegalovirus Infections; Foscarnet; Ganciclovir; Humans; Imm | 1987 |
Promising new antiviral drugs.
Topics: Acyclovir; Animals; Antiviral Agents; Bromodeoxyuridine; Cytomegalovirus Infections; Foscarnet; Ganc | 1988 |
Cotton-wool spots and cytomegalovirus retinitis in AIDS.
Topics: Acquired Immunodeficiency Syndrome; Acyclovir; Cytomegalovirus Infections; Diabetic Retinopathy; Dia | 1989 |
Cytomegalovirus infection in the acquired immune deficiency syndrome.
Topics: Acquired Immunodeficiency Syndrome; Acyclovir; Addison Disease; Antiviral Agents; Colitis; Cytomegal | 1989 |
Serious cytomegalovirus disease in the acquired immunodeficiency syndrome (AIDS). Clinical findings, diagnosis, and treatment.
Topics: Acquired Immunodeficiency Syndrome; Acyclovir; Antiviral Agents; Cytomegalovirus Infections; Foscarn | 1988 |
Management of cytomegalovirus infection.
Topics: Acyclovir; Antiviral Agents; Cytomegalovirus Infections; Foscarnet; Ganciclovir; Humans; Immunizatio | 1988 |
The diagnosis of cytomegalovirus retinitis.
Topics: Acquired Immunodeficiency Syndrome; Acyclovir; Antiviral Agents; Cytomegalovirus Infections; Diagnos | 1988 |
[Treatment of cytomegalovirus infections in immunosuppressed patients].
Topics: Acquired Immunodeficiency Syndrome; Acyclovir; Antiviral Agents; Cytomegalovirus Infections; Foscarn | 1988 |
49 trials available for foscarnet and Cytomegalovirus Infections
| Article | Year |
|---|---|
Maribavir for Refractory Cytomegalovirus Infections With or Without Resistance Post-Transplant: Results From a Phase 3 Randomized Clinical Trial.
Topics: Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; Dichlororibofuranosylbenzimidazole; D | 2022 |
[Clinical analysis of the efficacies of ganciclovir plus foscarnet and a single antiviral drug for the treatment of cytomegalovirus infection after haploidentical stem cell transplantation].
Topics: Antiviral Agents; Cytomegalovirus Infections; Foscarnet; Ganciclovir; Hematopoietic Stem Cell Transp | 2023 |
A randomized, controlled trial comparing ganciclovir to ganciclovir plus foscarnet (each at half dose) for preemptive therapy of cytomegalovirus infection in transplant recipients.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Bone Marrow Transplantation; Child; Child, Preschool; Cyt | 2004 |
A pilot phase II study of alternate day ganciclovir and foscarnet in preventing cytomegalovirus (CMV) infections in at-risk pediatric and adolescent allogeneic stem cell transplant recipients.
Topics: Adolescent; Adult; Antiviral Agents; Child; Child, Preschool; Cytomegalovirus Infections; Drug Admin | 2007 |
Treatment of AIDS-associated gastrointestinal cytomegalovirus infection with foscarnet and ganciclovir: a randomized comparison.
Topics: Adult; AIDS-Related Opportunistic Infections; Antigens, Viral; Cytomegalovirus; Cytomegalovirus Infe | 1995 |
Foscarnet decreases human immunodeficiency virus RNA.
Topics: Acquired Immunodeficiency Syndrome; AIDS-Related Opportunistic Infections; CD4 Lymphocyte Count; Cyt | 1995 |
Early treatment of CMV infections in allogeneic bone marrow transplant recipients with foscarnet or ganciclovir.
Topics: Adult; Anemia, Aplastic; Antigens, Viral; Bone Marrow Transplantation; Cytomegalovirus; Cytomegalovi | 1994 |
CMV prophylaxis with foscarnet in allogeneic bone marrow transplant recipients at high risk of developing CMV infections.
Topics: Acyclovir; Adult; Bone Marrow Transplantation; Cytomegalovirus Infections; Dose-Response Relationshi | 1994 |
Randomized phase I trial of two different combination foscarnet and ganciclovir chronic maintenance therapy regimens for AIDS patients with cytomegalovirus retinitis: AIDS clinical Trials Group Protocol 151.
Topics: Adolescent; Adult; AIDS-Related Opportunistic Infections; Cells, Cultured; Clinical Protocols; Cytom | 1994 |
Safety of alternating ganciclovir and foscarnet maintenance therapy in human immunodeficiency virus (HIV)-related cytomegalovirus infections. An open-labeled pilot study.
Topics: Adult; AIDS-Related Opportunistic Infections; Cytomegalovirus Infections; Drug Administration Schedu | 1994 |
Increased survival of a cohort of patients with acquired immunodeficiency syndrome and cytomegalovirus retinitis who received sodium phosphonoformate (foscarnet).
Topics: Acquired Immunodeficiency Syndrome; Cohort Studies; Cytomegalovirus Infections; Didanosine; Drug Tol | 1993 |
Foscarnet treatment of cytomegalovirus gastrointestinal infections in acquired immunodeficiency syndrome patients who have failed ganciclovir induction.
Topics: Adult; AIDS-Related Opportunistic Infections; Cytomegalovirus Infections; Drug Resistance; Foscarnet | 1993 |
Foscarnet in the treatment of cytomegalovirus esophagitis.
Topics: Cytomegalovirus Infections; Esophagitis; Foscarnet; HIV Seropositivity; HIV-1; Humans | 1993 |
A dose-ranging study of daily maintenance intravenous foscarnet therapy for cytomegalovirus retinitis in AIDS.
Topics: Adolescent; Adult; Aged; AIDS-Related Opportunistic Infections; Cytomegalovirus Infections; Foscarne | 1993 |
Use of a semi-quantitative PCR for cytomegalovirus DNA as a basis for pre-emptive antiviral therapy in allogeneic bone marrow transplant patients.
Topics: Antiviral Agents; Bone Marrow Transplantation; Cytomegalovirus; Cytomegalovirus Infections; DNA, Vir | 1996 |
Relationship between foscarnet exposure, baseline cytomegalovirus (CMV) blood culture and the time to progression of CMV retinitis in HIV-positive patients.
Topics: Analysis of Variance; Antiviral Agents; Cytomegalovirus Infections; Cytomegalovirus Retinitis; Disea | 1996 |
Foscarnet for pre-emptive therapy of CMV infection detected by a leukocyte-based nested PCR in allogeneic bone marrow transplant patients.
Topics: Adolescent; Adult; Antiviral Agents; Bone Marrow Transplantation; Child; Cytomegalovirus Infections; | 1996 |
Treatment of gastrointestinal cytomegalovirus infection with twice-daily foscarnet: a pilot study of safety, efficacy, and pharmacokinetics in patients with AIDS.
Topics: Acquired Immunodeficiency Syndrome; Adult; AIDS-Related Opportunistic Infections; Animals; Antiviral | 1997 |
Cytomegalovirus (CMV) culture results, drug resistance, and clinical outcome in patients with AIDS and CMV retinitis treated with foscarnet or ganciclovir. Studies of Ocular Complications of AIDS (SOCA) in collaboration with the AIDS Clinical Trial Group.
Topics: AIDS-Related Opportunistic Infections; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections | 1997 |
Foscarnet-Ganciclovir Cytomegalovirus Retinitis Trial: 5. Clinical features of cytomegalovirus retinitis at diagnosis. Studies of ocular complications of AIDS Research Group in collaboration with the AIDS Clinical Trials Group.
Topics: Acquired Immunodeficiency Syndrome; Adolescent; Adult; Antiviral Agents; Cytomegalovirus Infections; | 1997 |
Foscarnet for prevention of cytomegalovirus infection in allogeneic marrow transplant recipients unable to receive ganciclovir.
Topics: Actuarial Analysis; Adolescent; Adult; Bone Marrow Transplantation; Cytomegalovirus Infections; Fema | 1997 |
Treatment of cytomegalovirus esophagitis in patients with acquired immune deficiency syndrome: a randomized controlled study of foscarnet versus ganciclovir. The Italian Cytomegalovirus Study Group.
Topics: AIDS-Related Opportunistic Infections; Biopsy; Cytomegalovirus Infections; Esophagitis; Foscarnet; G | 1998 |
Renal tolerance of combined treatment with foscarnet and indinavir.
Topics: Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; Cytomegalovirus Infections; Drug The | 1998 |
[Cytomegalovirus polyradiculomyelopathy in AIDS].
Topics: Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; Cytomegalovirus Infections; Drug The | 1998 |
Forscarnet vs ganciclovir for cytomegalovirus (CMV) antigenemia after allogeneic hemopoietic stem cell transplantation (HSCT): a randomised study.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Child; Cytomegalovirus; Cytomegalovirus Infections; Femal | 1998 |
Induction and maintenance therapy of cytomegalovirus central nervous system infection in HIV-infected patients.
Topics: Adult; Aged; AIDS-Related Opportunistic Infections; Antiviral Agents; Cytomegalovirus; Cytomegalovir | 2000 |
Effect of a 14-day course of foscarnet on cytomegalovirus (CMV) blood markers in a randomized study of human immunodeficiency virus-infected patients with persistent CMV viremia. Agence National de Recherche du SIDA 023 Study Group.
Topics: AIDS-Related Opportunistic Infections; Antigens, Viral; Antiviral Agents; Biomarkers; Cytomegaloviru | 1999 |
A double-blind placebo-controlled crossover trial of intravenous magnesium sulfate for foscarnet-induced ionized hypocalcemia and hypomagnesemia in patients with AIDS and cytomegalovirus infection.
Topics: Acquired Immunodeficiency Syndrome; Adult; AIDS-Related Opportunistic Infections; Calcium; Cross-Ove | 2000 |
Foscarnet prophylaxis of cytomegalovirus infections in patients undergoing allogeneic bone marrow transplantation (BMT): a dose-finding study.
Topics: Adult; Antiviral Agents; Blood Pressure; Body Weight; Bone Marrow Transplantation; Cytomegalovirus I | 2000 |
Safety of oral versus intravenous hydration during induction therapy with intravenous foscarnet in AIDS patients with cytomegalovirus infections.
Topics: Acquired Immunodeficiency Syndrome; Administration, Oral; Adult; AIDS-Related Opportunistic Infectio | 2000 |
Foscarnet administered by portable infusion device in AIDS patients with CMV infection.
Topics: Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; Cytomegalovirus Infections; Dose-Res | 1997 |
Cidofovir for cytomegalovirus-preemptive therapy in stem cell transplant recipients.
Topics: Antiviral Agents; Cidofovir; Cytomegalovirus; Cytomegalovirus Infections; Cytosine; Drug Resistance, | 2001 |
Randomized multicenter trial of foscarnet versus ganciclovir for preemptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation.
Topics: Adolescent; Adult; Antiviral Agents; Child; Cytomegalovirus Infections; Disease-Free Survival; Drug | 2002 |
The treatment of cytomegalovirus in AIDS--more than meets the eye.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus Infections; Drug Therapy, Comb | 1992 |
Design of a randomized controlled trial of foscarnet in patients with cytomegalovirus retinitis associated with acquired immunodeficiency syndrome.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Cytomegalovirus Infections; Eye Infecti | 1992 |
Studies of ocular complications of AIDS Foscarnet-Ganciclovir Cytomegalovirus Retinitis Trial: 1. Rationale, design, and methods. AIDS Clinical Trials Group (ACTG).
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Clinical Trials as Topic; Cytomegalovirus Infe | 1992 |
Studies of ocular complications of AIDS Foscarnet-Ganciclovir Cytomegalovirus Retinitis Trial: 1. Rationale, design, and methods. AIDS Clinical Trials Group (ACTG).
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Clinical Trials as Topic; Cytomegalovirus Infe | 1992 |
Studies of ocular complications of AIDS Foscarnet-Ganciclovir Cytomegalovirus Retinitis Trial: 1. Rationale, design, and methods. AIDS Clinical Trials Group (ACTG).
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Clinical Trials as Topic; Cytomegalovirus Infe | 1992 |
Studies of ocular complications of AIDS Foscarnet-Ganciclovir Cytomegalovirus Retinitis Trial: 1. Rationale, design, and methods. AIDS Clinical Trials Group (ACTG).
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Clinical Trials as Topic; Cytomegalovirus Infe | 1992 |
Treatment of HIV-related cytomegalovirus disease of the gastrointestinal tract with foscarnet.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus Infections; Female; Foscarnet; | 1992 |
Phase I-II trial of foscarnet for prevention of cytomegalovirus infection in autologous and allogeneic marrow transplant recipients.
Topics: Adolescent; Adult; Antiviral Agents; Bone Marrow Transplantation; Cytomegalovirus Infections; Drug E | 1992 |
Effect of foscarnet therapy on human immunodeficiency virus p24 antigen levels in AIDS patients with cytomegalovirus retinitis.
Topics: Acquired Immunodeficiency Syndrome; Adult; Cytomegalovirus Infections; Dose-Response Relationship, D | 1992 |
Foscarnet and Ganciclovir in the treatment of CMV retinitis in AIDS patients: a randomised comparison.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus Infections; Foscarnet; Gancicl | 1992 |
Mortality in patients with the acquired immunodeficiency syndrome treated with either foscarnet or ganciclovir for cytomegalovirus retinitis.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; CD4-Positive T-Lymphocytes; Cytomegalov | 1992 |
Mortality in patients with the acquired immunodeficiency syndrome treated with either foscarnet or ganciclovir for cytomegalovirus retinitis.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; CD4-Positive T-Lymphocytes; Cytomegalov | 1992 |
Mortality in patients with the acquired immunodeficiency syndrome treated with either foscarnet or ganciclovir for cytomegalovirus retinitis.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; CD4-Positive T-Lymphocytes; Cytomegalov | 1992 |
Mortality in patients with the acquired immunodeficiency syndrome treated with either foscarnet or ganciclovir for cytomegalovirus retinitis.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; CD4-Positive T-Lymphocytes; Cytomegalov | 1992 |
AIDS file.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus Infections; Foscarnet; Gancicl | 1991 |
A randomized, controlled trial of foscarnet in the treatment of cytomegalovirus retinitis in patients with AIDS.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Cytomegalovirus Infections; Eye Infecti | 1991 |
Foscarnet versus ganciclovir in the management of cytomegalovirus disease in patients with AIDS.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus Infections; Foscarnet; Gancicl | 1991 |
Treatment of acquired immune deficiency syndrome (AIDS)-related pneumonitis with foscarnet: a double-blind placebo controlled study.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; D | 1990 |
Treatment of cytomegalovirus infection.
Topics: Acyclovir; Clinical Trials as Topic; Cytomegalovirus Infections; Foscarnet; Ganciclovir; Humans; Imm | 1987 |
Sensitivity of cytomegalovirus to intravenous foscarnet treatment.
Topics: Antiviral Agents; Bone Marrow Transplantation; Cytomegalovirus; Cytomegalovirus Infections; Female; | 1986 |
From the National Institutes of Health. Progress in AIDS research.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Clinical Trials as Topic; Cytomegalovirus Infe | 1988 |
Cytomegalovirus colitis and oesophageal ulceration in the context of AIDS: clinical manifestations and preliminary report of treatment with Foscarnet (phosphonoformate).
Topics: Acquired Immunodeficiency Syndrome; Adult; Clinical Trials as Topic; Colitis; Cytomegalovirus Infect | 1987 |
326 other studies available for foscarnet and Cytomegalovirus Infections
| Article | Year |
|---|---|
Design, synthesis, and antiviral evaluation of 2-substituted 4,5-dichloro- and 4,6-dichloro-1-beta-D-ribofuranosylbenzimidazoles as potential agents for human cytomegalovirus infections.
Topics: Antiviral Agents; Benzimidazoles; Cell Division; Cell Line; Cytomegalovirus; Cytomegalovirus Infecti | 1997 |
Design, synthesis, and antiviral evaluation of 2-chloro-5,6-dihalo-1-beta-D-ribofuranosylbenzimidazoles as potential agents for human cytomegalovirus infections.
Topics: Antiviral Agents; Benzimidazoles; Cell Division; Cell Line; Cytomegalovirus; Cytomegalovirus Infecti | 1997 |
Multidrug resistance conferred by novel DNA polymerase mutations in human cytomegalovirus isolates.
Topics: Antiviral Agents; Cidofovir; Cytomegalovirus; Cytomegalovirus Infections; Cytosine; DNA Replication; | 2007 |
Growth and drug resistance phenotypes resulting from cytomegalovirus DNA polymerase region III mutations observed in clinical specimens.
Topics: Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; DNA-Directed DNA Polymerase; Drug Res | 2007 |
Cutaneous presentation of disseminated cytomegalovirus infection in a non-transplant patient with hematological malignancy: A case report.
Topics: Antiviral Agents; Cytomegalovirus Infections; Fatal Outcome; Foscarnet; Ganciclovir; Hematologic Neo | 2022 |
Intra-host diversity of drug-resistant cytomegalovirus: A case report of cytomegalovirus infection after allogeneic hematopoietic cell transplantation.
Topics: Antiviral Agents; Cidofovir; Cytomegalovirus; Cytomegalovirus Infections; Drug Resistance, Viral; Fo | 2022 |
Artificial stem cells mediated inflammation-tropic delivery of antiviral drugs for pneumonia treatment.
Topics: Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; Fatty Acids, Monounsaturated; Foscarn | 2022 |
Recommended foscarnet dose is not associated with improved outcomes in cytomegalovirus salvage therapy.
Topics: Adult; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; Drug Dosage Calculations; Fema | 2019 |
Cost analysis of ganciclovir and foscarnet in recipients of allogeneic hematopoietic cell transplant with cytomegalovirus viremia.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Chemoprevention; Child; Costs and Cost Analysis; Cytomega | 2020 |
Hypersusceptibility of Human Cytomegalovirus to Foscarnet Induced by Mutations in Helices K and P of the Viral DNA Polymerase.
Topics: Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; DNA-Directed DNA Polymerase; DNA, Vir | 2020 |
The role of interim-foscarnet prophylaxis in preventing cytomegalovirus infection after ex vivo αβ T cell-depleted haploidentical hematopoietic cell transplant in children.
Topics: Antiviral Agents; Child; Cytomegalovirus Infections; Foscarnet; Hematopoietic Stem Cell Transplantat | 2021 |
Use of unapproved or off-label drugs in Japan for the treatment of graft-versus-host disease and post-transplant viral infection.
Topics: Acute Disease; Adult; Beclomethasone; Chronic Disease; Cidofovir; Cytomegalovirus Infections; Etaner | 2020 |
Post-HSCT graft failure due to refractory human cytomegalovirus successfully treated with haploidentical donor-derived immunoglobulins and stem cell graft infusion: A case report.
Topics: beta-Thalassemia; Child; Cytomegalovirus; Cytomegalovirus Infections; Female; Foscarnet; Hematopoiet | 2021 |
Continuous-Infusion Foscarnet Facilitates Administration in Hematopoietic Stem Cell Transplantation Patients.
Topics: Cytomegalovirus Infections; Foscarnet; Ganciclovir; Hematopoietic Stem Cell Transplantation; Humans; | 2021 |
Relationship between renal dysfunction and electrolyte abnormalities in hematopoietic stem cell transplant patients treated with foscarnet.
Topics: Adult; Aged; Antiviral Agents; Creatinine; Cytomegalovirus Infections; Electrolytes; Female; Foscarn | 2021 |
Use of letermovir-valganciclovir combination as a step-down treatment after foscarnet for ganciclovir-resistant CMV infection in kidney transplant recipients.
Topics: Acetates; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; Foscarnet; Ganciclovir; Hum | 2021 |
Epidemiology and Outcome of Ganciclovir-Resistant Cytomegalovirus Infection After Solid Organ Transplantation: A Single Transplant Center Experience in Thailand.
Topics: Adult; Antiviral Agents; Cidofovir; Cytomegalovirus; Cytomegalovirus Infections; Cytosine; Drug Resi | 2017 |
Ganciclovir Dosing Strategies and Development of Cytomegalovirus Resistance in a Kidney Transplant Recipient: A Case Report.
Topics: Aged; Antiviral Agents; Cidofovir; Cytomegalovirus; Cytomegalovirus Infections; Cytosine; Dose-Respo | 2017 |
Cytomegaloviraemia clearance with foscarnet during renal replacement therapy.
Topics: Aged; Antiviral Agents; Cytomegalovirus Infections; Foscarnet; Hemofiltration; Humans; Male; Renal D | 2018 |
Safety and efficacy of foscarnet for the management of ganciclovir-resistant or refractory cytomegalovirus infections: A single-center study.
Topics: Adult; Aged; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; Drug Resistance, Viral; | 2018 |
Antiviral combination therapy for cytomegalovirus infection in high-risk infants.
Topics: Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; Drug Therapy, Combination; Female; Fo | 2018 |
In vitro evaluation of current and novel antivirals in combination against human cytomegalovirus.
Topics: Antiviral Agents; Benzimidazoles; Cell Line; Cidofovir; Cyclopropanes; Cytomegalovirus; Cytomegalovi | 2018 |
Persistent Primary Cytomegalovirus Infection After Deceased Donor Kidney Transplant: Ganciclovir Susceptibility of Human Cytomegalovirus With UL97 D605E Mutation: A Case Report.
Topics: Adolescent; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; Drug Resistance, Microbia | 2018 |
Cytomegalovirus in Pediatric Hematopoietic Stem Cell Transplantation: A Case-Based Panel Discussion of Current Challenges.
Topics: Antiviral Agents; Child; Cytomegalovirus; Cytomegalovirus Infections; Drug Resistance, Viral; Fatal | 2018 |
Acute retinal necrosis secondary to cytomegalovirus following successful treatment of cytomegalovirus anterior uveitis in an immunocompetent adult.
Topics: Antiviral Agents; Aqueous Humor; Cytomegalovirus; Cytomegalovirus Infections; DNA, Viral; Drug Thera | 2013 |
Selection and recombinant phenotyping of a novel CMX001 and cidofovir resistance mutation in human cytomegalovirus.
Topics: Amino Acid Sequence; Antiviral Agents; Base Sequence; Cells, Cultured; Chromosomes, Artificial, Bact | 2013 |
Cytomegalovirus polyradiculopathy of late onset in a young renal transplant recipient.
Topics: Adult; Antiviral Agents; Cytomegalovirus Infections; Foscarnet; Ganciclovir; Humans; Kidney Transpla | 2013 |
Evaluation of the validity of preemptive therapy against cytomegalovirus disease based on antigenemia assay with a cutoff of 20 positive cells per two slides.
Topics: Adolescent; Adult; Antigens, Viral; Antiviral Agents; Blood Donors; Combined Modality Therapy; Cytom | 2013 |
Generation and characterization of a GCV resistant HCMV UL97-mutation and a drug sensitive UL54-mutation.
Topics: Antiviral Agents; Chromosomes, Artificial, Bacterial; Cidofovir; Cytomegalovirus; Cytomegalovirus In | 2013 |
Ganciclovir-resistant cytomegalovirus infections among lung transplant recipients are associated with poor outcomes despite treatment with foscarnet-containing regimens.
Topics: Adult; Aged; Antiviral Agents; Cytomegalovirus Infections; Drug Resistance, Viral; Female; Foscarnet | 2014 |
UL54 foscarnet mutation in an hematopoietic stem cell transplant recipient with cytomegalovirus disease.
Topics: Antiviral Agents; Cidofovir; Cytomegalovirus; Cytomegalovirus Infections; Cytosine; DNA-Directed DNA | 2014 |
[Systemic cytomegalovirus infection: changes in serum calcium and magnesium levels with foscarnet treatment].
Topics: Antiviral Agents; Calcium; Child, Preschool; Cytomegalovirus Infections; Foscarnet; Humans; Magnesiu | 2015 |
Improved detection of emerging drug-resistant mutant cytomegalovirus subpopulations by deep sequencing.
Topics: Antiviral Agents; Cidofovir; Cytomegalovirus; Cytomegalovirus Infections; Cytosine; DNA-Directed DNA | 2014 |
Trip to immunity: resistant cytomegalovirus infection in a lung transplant recipient.
Topics: Adult; Antiviral Agents; Cytomegalovirus Infections; Drug Resistance, Viral; Female; Foscarnet; Ganc | 2014 |
Intravascular foscarnet crystal precipitation causing multiorgan failure.
Topics: Antiviral Agents; Biopsy; Chemical Precipitation; Crystallization; Cytomegalovirus Infections; Femal | 2015 |
Successful treatment with foscarnet for ganciclovir-resistant cytomegalovirus infection in a kidney transplant recipient: A case report.
Topics: Adult; Allografts; Antiviral Agents; Biopsy; Cytomegalovirus Infections; Drug Resistance, Viral; Fem | 2016 |
Ganciclovir-resistant cytomegalovirus infection in solid organ transplant recipients: a single-center retrospective cohort study.
Topics: Adult; Aged; Alemtuzumab; Antibodies, Monoclonal, Humanized; Antiviral Agents; Cohort Studies; Commu | 2016 |
Novel Cytomegalovirus UL54 DNA Polymerase Gene Mutations Selected In Vitro That Confer Brincidofovir Resistance.
Topics: Antiviral Agents; Cidofovir; Cytomegalovirus; Cytomegalovirus Infections; Cytosine; DNA-Directed DNA | 2016 |
Identification of resistance-associated HCMV UL97- and UL54-mutations and a UL97-polymporphism with impact on phenotypic drug-resistance.
Topics: Adolescent; Adult; Antiviral Agents; Child; Chromosomes, Artificial, Bacterial; Cidofovir; Cytomegal | 2016 |
Cytomegalovirus Infection and Rates of Antiviral Resistance Following Intestinal and Multivisceral Transplantation.
Topics: Adult; Aged; Antiviral Agents; Cytomegalovirus Infections; Drug Resistance, Viral; Female; Foscarnet | 2016 |
Contribution of next generation sequencing to early detection of cytomegalovirus UL97 emerging mutants and viral subpopulations analysis in kidney transplant recipients.
Topics: Aged; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; Drug Resistance, Viral; Female; | 2016 |
Ganciclovir and Foscarnet Therapy of Cytomegalovirus-Associated Meningoencephalitis in a Hemodialysis Patient With Liver Transplantation: Case Report.
Topics: Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; Drug Therapy, Combination; Female; Fo | 2016 |
Immune-based guidance of foscarnet treatment duration in a transplant recipient with ganciclovir-resistant cytomegalovirus infection.
Topics: Adult; Antiviral Agents; CD4-Positive T-Lymphocytes; Cytomegalovirus; Cytomegalovirus Infections; Dr | 2016 |
Outcomes in Transplant Recipients Treated With Foscarnet for Ganciclovir-Resistant or Refractory Cytomegalovirus Infection.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Child; Cytomegalovirus Infections; Drug Resistance, Viral | 2016 |
Adjuvant and salvage therapy with leflunomide for recalcitrant cytomegalovirus infections in hematopoietic cell transplantation recipients: A case series.
Topics: Aged; Antiviral Agents; Chemotherapy, Adjuvant; Cytomegalovirus; Cytomegalovirus Infections; Drug Mo | 2016 |
Cytomegalovirus sinusitis complicated by orbital apex syndrome in an immunocompromised host.
Topics: Aged; Antiviral Agents; Biopsy; Blindness; Cytomegalovirus; Cytomegalovirus Infections; Diplopia; Ex | 2016 |
Foscarnet-related Hypercalcemia During CMV Treatment in an Infant With SCID: A Case Report and Review of Literature.
Topics: Bone Matrix; Cytomegalovirus Infections; Foscarnet; Humans; Hypercalcemia; Infant; Interleukin-7 Rec | 2017 |
Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene.
Topics: Amino Acid Substitution; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; DNA-Directed | 2017 |
Cytomegalovirus encephalitis/retinitis in allogeneic haematopoietic stem cell transplant recipient treated successfully with combination of cidofovir and foscarnet.
Topics: Adolescent; Antiviral Agents; Cidofovir; Cytomegalovirus Infections; Cytosine; Encephalitis, Viral; | 2009 |
Successful treatment of cytomegalovirus polyradiculopathy in a 9-year-old child with congenital human immunodeficiency virus infection.
Topics: AIDS-Related Opportunistic Infections; Antiviral Agents; Brain; Child; Cytomegalovirus Infections; D | 2009 |
Low-dose foscarnet preemptive therapy for cytomegalovirus viremia after haploidentical bone marrow transplantation.
Topics: Antiviral Agents; Bone Marrow Transplantation; Cytomegalovirus; Cytomegalovirus Infections; Female; | 2009 |
[Disease by CMV resistant to Ganciclovir. Should plasma valganciclovir levels be monitored in high risk patients?].
Topics: Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; Drug Monitoring; Drug Resistance, Mul | 2009 |
Donor CMV serostatus not predictive of relapse in D-/R- pediatric HCT.
Topics: Acyclovir; Adolescent; Adult; Antibodies, Viral; Antigens, Viral; Antiviral Agents; Child; Child, Pr | 2009 |
Long-term follow-up of acute retinal necrosis.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Child; Cytomegalovirus; Cytomegalovirus Infections; Drug | 2010 |
Febrile neutropenia in a HIV positive individual post-chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Cyclophosphamide; Cytomegalovirus | 2010 |
[Cytomegalovirus infection--diagnostic and therapeutic difficulties in neonatal intensive care unit].
Topics: Antiviral Agents; Cross-Sectional Studies; Cytomegalovirus Infections; Foscarnet; Ganciclovir; Human | 2010 |
Use of foscarnet for cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation from a related donor.
Topics: Adolescent; Adult; Aged; Cytomegalovirus Infections; Drug Evaluation; Family; Female; Foscarnet; Gan | 2010 |
Analysis of human cytomegalovirus glycoprotein N genotypes in Chinese hematopoietic stem cell transplant recipients.
Topics: Antiviral Agents; China; Cytomegalovirus; Cytomegalovirus Infections; DNA, Viral; Female; Foscarnet; | 2011 |
De novo thrombotic microangiopathy induced by cytomegalovirus infection leading to renal allograft loss.
Topics: Cytomegalovirus Infections; Foscarnet; Ganciclovir; Humans; Immunoglobulins, Intravenous; Kidney Fai | 2010 |
Phenotypic diversity of cytomegalovirus DNA polymerase gene variants observed after antiviral therapy.
Topics: Antiviral Agents; Chromosomes, Artificial, Bacterial; Cytomegalovirus; Cytomegalovirus Infections; D | 2011 |
Isolated esophageal ulcerations in immunocompromised patients: mycophenolate mofetil or foscarnet, who is guilty?
Topics: Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Antiviral Agents; Cytomegalovirus Infections; E | 2011 |
Incidence and outcomes of ganciclovir-resistant cytomegalovirus infections in 1244 kidney transplant recipients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Child; Child, Preschool; Cytomegalovir | 2011 |
Cyclopropavir susceptibility of cytomegalovirus DNA polymerase mutants selected after antiviral drug exposure.
Topics: Alkaline Phosphatase; Antiviral Agents; Cidofovir; Cyclopropanes; Cytomegalovirus; Cytomegalovirus I | 2012 |
Presumed cytomegalovirus-associated retrobulbar optic neuritis in a patient after allogeneic stem cell transplantation.
Topics: Adult; Antiviral Agents; Blindness; Cytomegalovirus Infections; Foscarnet; Humans; Immunosuppressive | 2012 |
Emergence of cytomegalovirus resistance to foscarnet in a patient receiving foscarnet salvage therapy for multidrug-resistant HIV infection.
Topics: Antiretroviral Therapy, Highly Active; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections | 2012 |
Case report: Multidrug-resistant cytomegalovirus in a modified multivisceral transplant recipient.
Topics: Adult; Antiviral Agents; Cidofovir; Cytomegalovirus; Cytomegalovirus Infections; Cytosine; Drug Resi | 2012 |
Crystal precipitation and granulomatous inflammation in multiple organs after foscarnet therapy in a lung transplant recipient.
Topics: Adult; Antiviral Agents; Crystallization; Cytomegalovirus Infections; Foscarnet; Granuloma; Heart Di | 2012 |
[Clinical analysis of cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation].
Topics: Adolescent; Adult; Child; Child, Preschool; Cytomegalovirus Infections; Female; Foscarnet; Ganciclov | 2012 |
[Q & A. Enteritis found in a young man].
Topics: Adult; Antiviral Agents; Cytomegalovirus Infections; Enteritis; Foscarnet; Ganciclovir; Humans; Male | 2011 |
The time course of development and impact from viral resistance against ganciclovir in cytomegalovirus infection.
Topics: Adult; Cytomegalovirus; Cytomegalovirus Infections; Drug Resistance, Viral; Female; Foscarnet; Ganci | 2013 |
Antiviral therapy for cytomegalovirus infections in pediatric patients.
Topics: Acquired Immunodeficiency Syndrome; Administration, Oral; Adolescent; Adult; AIDS-Related Opportunis | 2002 |
The impact of transfusion of leucodepleted platelet concentrates on cytomegalovirus disease after allogeneic stem cell transplantation.
Topics: Acyclovir; Adolescent; Adult; Antiviral Agents; Child; Child, Preschool; Cytomegalovirus Infections; | 2002 |
Z-isomers of 2-hydroxymethylcyclopropylidenemethyl adenine (synadenol) and guanine (synguanol) are active against ganciclovir- and foscarnet-resistant human cytomegalovirus UL97 mutants.
Topics: Adenine; Antiviral Agents; Cyclopropanes; Cytomegalovirus; Cytomegalovirus Infections; Drug Resistan | 2002 |
Clinical characteristics of 13 solid organ transplant recipients with ganciclovir-resistant cytomegalovirus infection.
Topics: Cytomegalovirus; Cytomegalovirus Infections; Drug Resistance, Viral; Drug Therapy, Combination; Fema | 2002 |
Ganciclovir-resistant cytomegalovirus encephalitis in a bone marrow transplant recipient.
Topics: Adult; Antiviral Agents; Bone Marrow Transplantation; Cytomegalovirus; Cytomegalovirus Infections; D | 2002 |
Cytomegalovirus infection resistant to ganciclovir in a renal transplant patient.
Topics: Adult; Anti-Bacterial Agents; Antifungal Agents; Antiviral Agents; Cadaver; Candidiasis; Cytomegalov | 2003 |
Recurrent cytomegalovirus disease, visceral leishmaniosis, and Legionella pneumonia after liver transplantation: a case report.
Topics: Anti-Bacterial Agents; Antimony Sodium Gluconate; Antiviral Agents; Bone and Bones; Clarithromycin; | 2004 |
Comparison of sequential cytomegalovirus isolates in a patient with lymphoma and failing antiviral therapy.
Topics: Aged; Antiviral Agents; Cidofovir; Cytomegalovirus; Cytomegalovirus Infections; Cytosine; DNA, Viral | 2004 |
Foscarnet therapy for congenital cytomegalovirus liver fibrosis following prenatal ascites.
Topics: Adult; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; Diagnosis, Differential; DNA, | 2004 |
Use of leflunomide in an allogeneic bone marrow transplant recipient with refractory cytomegalovirus infection.
Topics: Bone Marrow Transplantation; Cytomegalovirus Infections; Drug Resistance, Viral; Drug Therapy, Combi | 2004 |
How evolution of mutations conferring drug resistance affects viral dynamics and clinical outcomes of cytomegalovirus-infected hematopoietic cell transplant recipients.
Topics: Adolescent; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; Drug Resistance, Viral; E | 2005 |
Phenotypic characterisation of cytomegalovirus DNA polymerase: a method to study cytomegalovirus isolates resistant to foscarnet.
Topics: Cytomegalovirus; Cytomegalovirus Infections; DNA-Directed DNA Polymerase; Drug Resistance, Viral; Fo | 2005 |
Cidofovir for cytomegalovirus reactivation in pediatric patients after hematopoietic stem cell transplantation.
Topics: Adolescent; Antigens, Viral; Antiviral Agents; Child; Cidofovir; Creatinine; Cytomegalovirus Infecti | 2005 |
Early onset of ganciclovir-resistant cytomegalovirus infection in a lung-transplant recipient.
Topics: Adult; Antiviral Agents; Cytomegalovirus Infections; Drug Resistance, Viral; Female; Foscarnet; Ganc | 2005 |
Cytomegalovirus colitis in children with inflammatory bowel disease.
Topics: Antiviral Agents; Child; Colitis; Cytomegalovirus Infections; Foscarnet; Ganciclovir; Humans; Inflam | 2006 |
Diagnosis and treatment of cytomegalovirus iridocyclitis without retinal necrosis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Chronic Disease; Cytomegalovirus; Cyto | 2006 |
Fatal haemolytic uraemic syndrome in an AIDS patient with disseminated adenovirus and cytomegalovirus co-infection.
Topics: Acquired Immunodeficiency Syndrome; Acute Kidney Injury; Adenovirus Infections, Human; Colitis; Cyto | 2006 |
A novel mutation in the UL54 gene of human cytomegalovirus isolates that confers resistance to foscarnet.
Topics: Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; DNA-Directed DNA Polymerase; Drug Res | 2006 |
Pancreatic hyperamylasemia and hyperlipasemia in association with cytomegalovirus infection following unrelated cord blood transplantation for acute myelogenous leukemia.
Topics: Adult; Amylases; Antiviral Agents; Cord Blood Stem Cell Transplantation; Cytomegalovirus Infections; | 2006 |
Reduced dose of foscarnet as preemptive therapy for cytomegalovirus infection following reduced-intensity cord blood transplantation.
Topics: Adolescent; Adult; Aged; Antigens, Viral; Antiviral Agents; Cord Blood Stem Cell Transplantation; Cy | 2007 |
A haemophagocytic lymphohistiocytosis (HLH)-like picture following breastmilk transmitted cytomegalovirus infection in a preterm infant.
Topics: Anti-Inflammatory Agents; Antiviral Agents; Cytomegalovirus Infections; Foscarnet; Humans; Infant, N | 2007 |
Persistent erythema multiforme and CMV infection.
Topics: Antiviral Agents; Bone Marrow Diseases; Cytomegalovirus Infections; Erythema Multiforme; Fatal Outco | 2007 |
Cytomegalovirus infections following umbilical cord blood transplantation using reduced intensity conditioning regimens for adult patients.
Topics: Adolescent; Adult; Aged; Cord Blood Stem Cell Transplantation; Cytomegalovirus; Cytomegalovirus Infe | 2007 |
Immunohistochemically proven cytomegalovirus end-organ disease in solid organ transplant patients: clinical features and usefulness of conventional diagnostic tests.
Topics: Adult; Aged; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; Disease Progression; DNA | 2007 |
Emergence and persistence of multiple antiviral-resistant CMV strains in a highly immunocompromised child.
Topics: Antiviral Agents; Child; Cytomegalovirus; Cytomegalovirus Infections; Drug Monitoring; Drug Resistan | 2007 |
Resistance to combined ganciclovir and foscarnet therapy in a liver transplant recipient with possible dual-strain cytomegalovirus coinfection.
Topics: Antibodies, Viral; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; DNA, Viral; Drug R | 2007 |
Accelerated evolution of maribavir resistance in a cytomegalovirus exonuclease domain II mutant.
Topics: Amino Acid Sequence; Amino Acid Substitution; Antiviral Agents; Benzimidazoles; Cells, Cultured; Cid | 2008 |
A single-center experience with ganciclovir-resistant cytomegalovirus in lung transplant recipients: treatment and outcome.
Topics: Adult; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; Drug Resistance, Viral; Drug T | 2007 |
Artesunate as a potent antiviral agent in a patient with late drug-resistant cytomegalovirus infection after hematopoietic stem cell transplantation.
Topics: Antiviral Agents; Artemisinins; Artesunate; Child; Cytomegalovirus; Cytomegalovirus Infections; Drug | 2008 |
Surgical treatment of a foscavir-resistant atypical Cytomegalovirus pneumonia in an allogeneic stem cell transplant recipient.
Topics: Antiviral Agents; Cytomegalovirus Infections; DNA-Directed DNA Polymerase; Drug Resistance, Viral; F | 2008 |
Contrasting drug resistance phenotypes resulting from cytomegalovirus DNA polymerase mutations at the same exonuclease locus.
Topics: Antiviral Agents; Cidofovir; Cytomegalovirus; Cytomegalovirus Infections; Cytosine; DNA-Directed DNA | 2008 |
Effect of acyclovir and phosphonoformate on cytomegalovirus infection in guinea pigs.
Topics: Acyclovir; Animals; Antiviral Agents; Cytomegalovirus Infections; Disease Models, Animal; Foscarnet; | 1984 |
Drugs for AIDS and associated infections.
Topics: Acquired Immunodeficiency Syndrome; AIDS-Related Opportunistic Infections; Amphotericin B; Antifunga | 1995 |
Reversible acute renal failure caused by the combined use of foscarnet and cyclosporin in organ transplanted patients.
Topics: Acute Kidney Injury; Adult; Antiviral Agents; Cyclosporine; Cytomegalovirus Infections; Drug Interac | 1995 |
Cytomegalovirus encephalitis resistant to anti-cytomegalovirus therapy.
Topics: Bone Marrow Transplantation; Child, Preschool; Cytomegalovirus Infections; Cytomegalovirus Retinitis | 1995 |
Cytomegalovirus ventriculoencephalitis in AIDS patients.
Topics: Adult; AIDS-Related Opportunistic Infections; Autopsy; Brain; Cerebral Ventricles; Cerebrospinal Flu | 1995 |
[Clinical value of a polymerase chain reaction on cytomegalovirus DNA in cerebrospinal fluid in HIV patients with neurological symptoms].
Topics: Adult; AIDS Dementia Complex; Cytomegalovirus; Cytomegalovirus Infections; DNA, Viral; Encephalitis, | 1995 |
Rapid screening for resistance to ganciclovir and foscarnet of primary isolates of human cytomegalovirus from culture-positive blood samples.
Topics: Antigens, Viral; Blood; Cytomegalovirus; Cytomegalovirus Infections; Drug Resistance, Microbial; Fos | 1995 |
[Lesions of the conus medullaris and the cauda equina caused by cytomegalovirus in HIV infection. 7 cases].
Topics: Acquired Immunodeficiency Syndrome; Adult; AIDS-Related Opportunistic Infections; Cauda Equina; Cyto | 1995 |
[Quantitative cytomegaloviral leukocytic antigenemia. Clinical aspects].
Topics: Antigens, Viral; Cytomegalovirus; Cytomegalovirus Infections; Foscarnet; Ganciclovir; Humans; Kidney | 1995 |
Prolonged concurrent use of ganciclovir and foscarnet in the treatment of polyradiculopathy due to cytomegalovirus in a patient with AIDS.
Topics: Acquired Immunodeficiency Syndrome; Adult; Cytomegalovirus Infections; Drug Administration Schedule; | 1994 |
Cytomegalovirus esophagitis in AIDS: a prospective evaluation of clinical response to ganciclovir therapy, relapse rate, and long-term outcome.
Topics: Adult; AIDS-Related Opportunistic Infections; Cytomegalovirus Infections; Drug Administration Schedu | 1995 |
Unusual infections following allogeneic bone marrow transplantation for chronic lymphocytic leukemia.
Topics: Adult; Anti-Bacterial Agents; Bone Marrow Transplantation; Cytomegalovirus Infections; Drug Therapy, | 1994 |
[Cytomegaloviruses--clinical aspects and therapy].
Topics: AIDS-Related Opportunistic Infections; Cytomegalovirus Infections; Foscarnet; Ganciclovir; Humans | 1994 |
Cytomegalovirus multifocal neuropathy in AIDS: analysis of 15 consecutive cases.
Topics: Acquired Immunodeficiency Syndrome; Adult; Cytomegalovirus; Cytomegalovirus Infections; DNA, Viral; | 1994 |
Pharmacist-directed program for monitoring foscarnet therapy.
Topics: Adult; Cytomegalovirus Infections; Drug Utilization Review; Foscarnet; Humans; Pharmacists; Pharmacy | 1994 |
Two AIDS patients with life-threatening pancreatitis successfully treated, one with ganciclovir the other with foscarnet.
Topics: Adult; AIDS-Related Opportunistic Infections; Cytomegalovirus Infections; Female; Foscarnet; Gancicl | 1994 |
Ganciclovir three times per week is not adequate to prevent cytomegalovirus reactivation after T cell-depleted marrow transplantation.
Topics: Adolescent; Adult; Bone Marrow Transplantation; Cytomegalovirus; Cytomegalovirus Infections; Drug Ad | 1994 |
Combined therapy with ganciclovir and foscarnet for cytomegalovirus polyradiculomyelitis in patients with AIDS.
Topics: Adult; AIDS-Related Opportunistic Infections; Cytomegalovirus Infections; Drug Therapy, Combination; | 1994 |
Actinomyces infection of a cytomegalovirus esophageal ulcer in two patients with acquired immunodeficiency syndrome.
Topics: Actinomycosis; Adult; AIDS-Related Opportunistic Infections; Cytomegalovirus Infections; Esophageal | 1994 |
Prevention of cytomegalovirus disease by a short course of preemptive ganciclovir or foscarnet.
Topics: Cytomegalovirus Infections; Foscarnet; Ganciclovir; Humans | 1994 |
Polyradiculopathy due to cytomegalovirus infection: report of a case in which an AIDS patient responded to foscarnet therapy.
Topics: Acquired Immunodeficiency Syndrome; Adult; AIDS-Related Opportunistic Infections; Cytomegalovirus; C | 1994 |
Central venous catheter infections in AIDS patients receiving treatment for cytomegalovirus disease.
Topics: AIDS-Related Opportunistic Infections; Bacterial Infections; Catheterization, Central Venous; Cathet | 1994 |
Rapid detection of cytomegalovirus strains resistant to ganciclovir through mutations within the gene UL97.
Topics: Base Sequence; Bronchoalveolar Lavage Fluid; Cerebrospinal Fluid; Cytomegalovirus; Cytomegalovirus I | 1993 |
Predisposition to cytomegalovirus infection of the gastrointestinal tract.
Topics: Cytomegalovirus Infections; Drug Therapy, Combination; Foscarnet; Ganciclovir; Gastrointestinal Dise | 1994 |
Treatment of gancyclovir resistant cytomegalovirus with foscarnet: a report of two cases occurring after bone marrow transplantation.
Topics: Adult; Bone Marrow Transplantation; Cytomegalovirus Infections; Drug Resistance; Foscarnet; Ganciclo | 1994 |
The development of cytomegalovirus encephalitis in AIDS patients receiving ganciclovir.
Topics: Adult; Aged; AIDS-Related Opportunistic Infections; Cerebral Ventricles; Confusion; Cytomegalovirus | 1994 |
Cytomegalovirus interstitial pneumonia in autologous bone marrow transplant recipients. Infectious Disease Working Party of the European Group for Bone Marrow Transplantation.
Topics: Adolescent; Adult; Bone Marrow Transplantation; Child; Child, Preschool; Cytomegalovirus Infections; | 1994 |
Evaluation of AIDS-related diarrhea.
Topics: Adult; Ampulla of Vater; Biopsy; Cholangiopancreatography, Endoscopic Retrograde; Cholangitis, Scler | 1993 |
Acute retinal necrosis in a renal allograft recipient--an unusual manifestation of cytomegalovirus infection.
Topics: Adult; Cytomegalovirus Infections; Foscarnet; Ganciclovir; Humans; Kidney Transplantation; Male; Ret | 1993 |
Penile ulceration with foscarnet therapy.
Topics: AIDS-Related Opportunistic Infections; Cytomegalovirus Infections; Foscarnet; Humans; Male; Penile D | 1993 |
Foscarnet-induced severe hypomagnesemia and other electrolyte disorders.
Topics: Adult; Cytomegalovirus Infections; Foscarnet; HIV Infections; Hospitals, Community; Hospitals, Teach | 1993 |
Reversible cardiac dysfunction associated with foscarnet therapy for cytomegalovirus esophagitis in an AIDS patient.
Topics: Acquired Immunodeficiency Syndrome; Acute Disease; Adult; AIDS-Related Opportunistic Infections; Cyt | 1993 |
Concurrent use of ganciclovir and foscarnet to treat cytomegalovirus infection in AIDS patients.
Topics: Adult; AIDS-Related Opportunistic Infections; Cytomegalovirus Infections; Demography; Drug Therapy, | 1993 |
Foscarnet--improving survival.
Topics: Cytomegalovirus Infections; Foscarnet; Humans; Retinitis | 1993 |
Intravitreal foscarnet for cytomegalovirus retinitis in a patient with acquired immunodeficiency syndrome.
Topics: AIDS-Related Opportunistic Infections; Cytomegalovirus Infections; Eye Infections, Viral; Foscarnet; | 1993 |
[Foscarnet and genital lesions].
Topics: Adult; AIDS-Related Opportunistic Infections; Cytomegalovirus Infections; Foscarnet; Humans; Male; P | 1993 |
Foscarnet treatment in various cytomegalovirus infections.
Topics: Acquired Immunodeficiency Syndrome; Colitis; Cytomegalovirus Infections; Eye Infections, Viral; Fiss | 1993 |
Transscleral iontophoresis of foscarnet.
Topics: Animals; Chromatography, High Pressure Liquid; Conjunctiva; Cytomegalovirus Infections; Foscarnet; H | 1993 |
Foscarnet penetrates the blood-brain barrier: rationale for therapy of cytomegalovirus encephalitis.
Topics: Adult; AIDS-Related Opportunistic Infections; Blood-Brain Barrier; Cytomegalovirus Infections; Encep | 1993 |
Pathophysiology and treatment of clinically resistant cytomegalovirus retinitis.
Topics: Adult; AIDS-Related Opportunistic Infections; Cytomegalovirus; Cytomegalovirus Infections; Drug Resi | 1993 |
Acalculous cholecystitis associated with cytomegalovirus and sclerosing cholangitis in a patient with acquired immunodeficiency syndrome.
Topics: Abdominal Pain; Acute Disease; Adult; AIDS-Related Opportunistic Infections; Ampulla of Vater; Biops | 1993 |
Foscarnet as inpatient prophylaxis only is insufficient to prevent cytomegalovirus infection after marrow transplantation.
Topics: Bone Marrow Transplantation; Cytomegalovirus Infections; Foscarnet; Humans; Inpatients; Time Factors | 1993 |
Double resistance to ganciclovir and foscarnet of four human cytomegalovirus strains recovered from AIDS patients.
Topics: Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; Cell Line; Cytomegalovirus; Cytomega | 1995 |
[Clinical manifestations and course of cytomegalovirus colitis in AIDS patients].
Topics: Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; Cohort Studies; Colitis; Colonoscopy | 1995 |
[Ulcer in the urethral meatus and HIV infection].
Topics: Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; Cytomegalovirus Infections; Drug Eru | 1995 |
Cytomegalovirus infection in severe combined immunodeficiency: eradication with foscarnet.
Topics: Antiviral Agents; Bone Marrow Transplantation; Cytomegalovirus Infections; Foscarnet; Humans; Infant | 1995 |
Ganciclovir in cytomegalovirus retinitis.
Topics: Adult; Antiviral Agents; Cytomegalovirus Infections; Cytomegalovirus Retinitis; Drug Therapy, Combin | 1995 |
Prognosis and response to therapy of cytomegalovirus encephalitis and meningomyelitis in AIDS.
Topics: Acyclovir; Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; Base Sequence; Cerebrospi | 1996 |
Single amino acid changes in the DNA polymerase confer foscarnet resistance and slow-growth phenotype, while mutations in the UL97-encoded phosphotransferase confer ganciclovir resistance in three double-resistant human cytomegalovirus strains recovered f
Topics: AIDS-Related Opportunistic Infections; Amino Acid Sequence; Base Sequence; Cytomegalovirus; Cytomega | 1996 |
Four dually resistant human cytomegalovirus strains from AIDS patients: single mutations in UL97 and UL54 open reading frames are responsible for ganciclovir- and foscarnet-specific resistance, respectively.
Topics: AIDS-Related Opportunistic Infections; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections | 1995 |
Treatment of cytomegalovirus retinitis in patients with AIDS.
Topics: AIDS-Related Opportunistic Infections; Antiviral Agents; Cidofovir; Cytomegalovirus Infections; Cyto | 1996 |
Current and experimental therapeutic options for cytomegalovirus disease.
Topics: Administration, Oral; Antiviral Agents; Cidofovir; Cytomegalovirus; Cytomegalovirus Infections; Cyto | 1996 |
Cytomegalovirus resistance to antiviral therapies.
Topics: Administration, Oral; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; Drug Resistance | 1996 |
Combined foscarnet-ganciclovir treatment for cytomegalovirus infections after allogeneic hemopoietic stem cell transplantation.
Topics: Adolescent; Adult; Antibodies, Viral; Cell Transplantation; Cyclosporine; Cytomegalovirus; Cytomegal | 1996 |
Cytomegalovirus papillitis in patients with acquired immune deficiency syndrome. Visual prognosis of patients treated with ganciclovir and/or foscarnet.
Topics: Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; Cytomegalovirus Infections; Cytomega | 1996 |
Foscarnet therapy for cytomegalovirus infection after allogeneic bone marrow transplantation.
Topics: Bone Marrow Transplantation; Cytomegalovirus Infections; Foscarnet; Humans; Prospective Studies; Tra | 1996 |
Patterns of resistance and sensitivity to antiviral compounds of drug-resistant strains of human cytomegalovirus selected in vitro.
Topics: Acyclovir; Adenine; Antiviral Agents; Cells, Cultured; Cidofovir; Cytarabine; Cytomegalovirus; Cytom | 1996 |
Disposition of foscarnet during peritoneal dialysis.
Topics: Acute Kidney Injury; Adult; Cytomegalovirus Infections; Foscarnet; Half-Life; Humans; Male; Peritone | 1996 |
Cytomegalovirus induced up-regulation of LFA-3 (CD58) and ICAM-1 (CD54) is a direct viral effect that is not prevented by ganciclovir or foscarnet treatment.
Topics: Antiviral Agents; Bone Marrow Transplantation; CD58 Antigens; Cytomegalovirus; Cytomegalovirus Infec | 1996 |
Cytomegalovirus pneumonia manifesting as a focal mass in acquired immunodeficiency syndrome.
Topics: Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; Biopsy, Needle; Cytomegalovirus Infe | 1996 |
Combined foscarnet -ganciclovir treatment for cytomegalovirus infections after allogeneic hemopoietic stem cell transplantation (Hsct).
Topics: Adolescent; Adult; Antiviral Agents; Cytomegalovirus Infections; Drug Therapy, Combination; Female; | 1996 |
Early ganciclovir therapy effectively controls viremia and avoids the need for cytomegalovirus (CMV) prophylaxis in renal transplant patients with cytomegalovirus antigenemia.
Topics: Adolescent; Adult; Antigens, Viral; Antiviral Agents; Chemoprevention; Child; Cytomegalovirus; Cytom | 1996 |
[Early diagnosis and treatment of cytomegalovirus polyradiculoneuritis in a child infected by HIV].
Topics: AIDS-Related Opportunistic Infections; Child; Cytomegalovirus Infections; Drug Therapy, Combination; | 1996 |
Development of ganciclovir resistance during treatment of primary cytomegalovirus infection after liver transplantation.
Topics: Adolescent; Cytomegalovirus; Cytomegalovirus Infections; DNA Mutational Analysis; Drug Resistance, M | 1997 |
[Foscarnet therapy for ganciclovir-refractory cytomegalovirus hepatitis in a patient who underwent bone marrow transplantation from an unrelated donor].
Topics: Adult; Antiviral Agents; Bone Marrow Transplantation; Combined Modality Therapy; Cytomegalovirus Inf | 1997 |
Quantitative systemic and local evaluation of the antiviral effect of ganciclovir and foscarnet induction treatment on human cytomegalovirus gastrointestinal disease of patients with AIDS. Italian Foscarnet GID Study Group.
Topics: AIDS-Related Opportunistic Infections; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections | 1997 |
New therapies for cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome.
Topics: AIDS-Related Opportunistic Infections; Antiviral Agents; Cidofovir; Cytomegalovirus Infections; Cyto | 1997 |
The treatment of AIDS-related cytomegalovirus disease with ganciclovir and foscarnet association. Three case reports.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Cytomegalovirus Infections; Drug Therap | 1996 |
Antiviral susceptibilities and analysis of UL97 and DNA polymerase sequences of clinical cytomegalovirus isolates from immunocompromised patients.
Topics: AIDS-Related Opportunistic Infections; Antiviral Agents; Base Sequence; Cytomegalovirus; Cytomegalov | 1997 |
Comparison of a new quantitative cytomegalovirus DNA assay with other detection methods.
Topics: Antibodies, Viral; Antiviral Agents; Biopsy; Cells, Cultured; Cytomegalovirus; Cytomegalovirus Infec | 1997 |
Foscarnet-induced hypercalcaemia in AIDS.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Cytomegalovirus Infections; Foscarnet; | 1997 |
Diagnosis of cytomegalovirus (CMV) polyradiculopathy and documentation of in vivo anti-CMV activity in cerebrospinal fluid by using branched DNA signal amplification and antigen assays.
Topics: Antigens, Viral; Antiviral Agents; Cells, Cultured; Cytomegalovirus; Cytomegalovirus Infections; Cyt | 1997 |
Concurrent ganciclovir and foscarnet treatment for cytomegalovirus encephalitis and retinitis in an infant with acquired immunodeficiency syndrome: case report and review.
Topics: AIDS-Related Opportunistic Infections; Antiviral Agents; Cytomegalovirus Infections; Drug Therapy, C | 1997 |
Evolution of mutations conferring multidrug resistance during prophylaxis and therapy for cytomegalovirus disease.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antiviral Agents; Cidofovir; Cytomega | 1997 |
Quantitative cytomegalovirus (CMV) antigenaemia during antiviral treatment of AIDS-related CMV disease.
Topics: Adult; AIDS-Related Opportunistic Infections; Antigens, Viral; Antiviral Agents; Biomarkers; Cytomeg | 1997 |
Successful allogeneic bone marrow transplantation in a 2.5-year-old boy with ongoing cytomegalovirus viremia and severe aplastic anemia after orthotopic liver transplantation for non-A, non-B, non-C hepatitis.
Topics: Anemia, Aplastic; Antiviral Agents; Biopsy; Bone Marrow; Bone Marrow Transplantation; Child, Prescho | 1997 |
[Cytomegalovirus pneumonia in patients with AIDS treated foscarnet. Our experience].
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Cytomegalovirus Infections; Female; Fos | 1997 |
Bone marrow transplantation for chronic myeloid leukemia (CML) from unrelated and sibling donors: single center experience.
Topics: Acyclovir; Adolescent; Adult; Antigens, Viral; Antiviral Agents; Bone Marrow Transplantation; Cause | 1997 |
How to treat the cytomegalovirus troll.
Topics: AIDS-Related Opportunistic Infections; Antiviral Agents; Cytomegalovirus Infections; DNA, Viral; Fos | 1998 |
Survival after cytomegalovirus pneumonia in two children receiving autologous peripheral blood progenitor cell transplantation (PBPCT).
Topics: Bronchoalveolar Lavage Fluid; Child, Preschool; Cytomegalovirus Infections; Disease-Free Survival; F | 1998 |
Measurement of viral sequences in cerebrospinal fluid of AIDS patients with cerebral white-matter lesions using polymerase chain reaction.
Topics: Adolescent; Adult; AIDS Dementia Complex; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Br | 1998 |
Guidelines for the treatment of cytomegalovirus diseases in patients with AIDS in the era of potent antiretroviral therapy: recommendations of an international panel. International AIDS Society-USA.
Topics: AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antiviral Agents; Cidofovir; Cytomegalovirus | 1998 |
Foscarnet decreases HIV-1 plasma load.
Topics: Acquired Immunodeficiency Syndrome; Adult; Aged; Antiviral Agents; Cytomegalovirus Infections; Femal | 1998 |
Diagnostic significance and clinical impact of quantitative assays for diagnosis of human cytomegalovirus infection/disease in immunocompromised patients.
Topics: AIDS-Related Opportunistic Infections; Antibodies, Monoclonal; Antigens, Viral; Antiviral Agents; Ce | 1998 |
A simplified assay for screening of drug resistance of cell-associated cytomegalovirus strains.
Topics: Antiviral Agents; Coculture Techniques; Cytomegalovirus; Cytomegalovirus Infections; Drug Resistance | 1998 |
Results of different strategies for reducing cytomegalovirus-associated mortality in allogeneic stem cell transplant recipients.
Topics: Acyclovir; Adolescent; Adult; Antiviral Agents; Bone Marrow; Bone Marrow Transplantation; Child; Chi | 1998 |
Risk of developing CMV retinitis following non-ocular CMV end organ disease in AIDS patients.
Topics: Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; Biopsy; Cytomegalovirus Infections; | 1998 |
Human herpesvirus 8 DNA load in leukocytes of human immunodeficiency virus-infected subjects: correlation with the presence of Kaposi's sarcoma and response to anticytomegalovirus therapy.
Topics: AIDS-Related Opportunistic Infections; Antiviral Agents; Cytomegalovirus Infections; Foscarnet; Ganc | 1999 |
Effect of antiviral drugs used to treat cytomegalovirus end-organ disease on subsequent course of previously diagnosed Kaposi's sarcoma in patients with AIDS.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Cytomegalovirus Infections; Foscarnet; | 1999 |
Photo quiz. Foscarnet-induced genital ulcers.
Topics: Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; Female; Foscarnet; Genital Diseases, | 1999 |
Expression of the late cytomegalovirus (CMV) pp150 transcript in leukocytes of AIDS patients is associated with a high viral DNA load in leukocytes and presence of CMV DNA in plasma.
Topics: AIDS-Related Opportunistic Infections; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections | 1999 |
Late cytomegalovirus pneumonia in adult allogeneic blood and marrow transplant recipients.
Topics: Adolescent; Adult; Antiviral Agents; Bone Marrow Transplantation; Cytomegalovirus Infections; Female | 1999 |
Irreversible glomerular lesions induced by crystal precipitation in a renal transplant after foscarnet therapy for cytomegalovirus infection.
Topics: Biopsy; Birefringence; Crystallization; Cytomegalovirus Infections; Foscarnet; Humans; Kidney Diseas | 1999 |
Foscarnet-induced crystalline glomerulonephritis with nephrotic syndrome and acute renal failure after kidney transplantation.
Topics: Acute Kidney Injury; AIDS-Associated Nephropathy; Antiviral Agents; Cytomegalovirus Infections; Fosc | 1999 |
[Cytomegalovirus myeloradiculitis in pregnancy].
Topics: Abortion, Induced; Adult; Antiviral Agents; Cytomegalovirus Infections; Female; Fetal Death; Follow- | 1999 |
Intravitreal toxicology and therapeutic efficacy of the carboxymethyl ester of the 1-O-octadecyl-sn-glycerol-3-phosphonoformate (ODG-PFA-O-Me), a novel lipid antiviral prodrug for intraocular drug delivery.
Topics: Animals; Antiviral Agents; Cytomegalovirus Infections; Electroretinography; Fluorescein Angiography; | 1999 |
[Lumbosacral and meningeal polyradicular disease in a patient with HIV infection].
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; Antiviral Agents; Brain; Cytome | 1999 |
Novel mechanism of inhibition of cytomegalovirus by the experimental immunosuppressive agent leflunomide.
Topics: Antiviral Agents; Blotting, Northern; Cytomegalovirus; Cytomegalovirus Infections; DNA-Directed DNA | 1999 |
Ganciclovir resistance in a heart transplant recipient infected by cytomegalovirus.
Topics: Adult; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; Drug Resistance, Microbial; Fo | 1999 |
Analysis of transcripts expressed from the UL47 gene of human cytomegalovirus.
Topics: Base Sequence; Blotting, Northern; Cytomegalovirus; Cytomegalovirus Infections; Fibroblasts; Foscarn | 1999 |
Fatal herpesvirus-6 encephalitis in a recipient of a T-cell-depleted peripheral blood stem cell transplant from a 3-loci mismatched related donor.
Topics: Cytomegalovirus Infections; DNA, Viral; Encephalitis, Viral; Fatal Outcome; Foscarnet; Ganciclovir; | 2000 |
The antisense oligonucleotide ISIS 2922 prevents cytomegalovirus-induced upregulation of IL-8 and ICAM-1 in cultured human fibroblasts.
Topics: Antiviral Agents; Cells, Cultured; Chemotaxis, Leukocyte; Cidofovir; Cytomegalovirus Infections; Cyt | 2000 |
A standardized plaque reduction assay for determination of drug susceptibilities of cytomegalovirus clinical isolates.
Topics: Antiviral Agents; Cells, Cultured; Cytomegalovirus; Cytomegalovirus Infections; Fibroblasts; Foscarn | 2000 |
[Severe cytomegalovirus enteritis in AIDS. Favorable outcome of medical treatment].
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Celiac Disease; Cytomegalovirus Infec | 2000 |
Removal of Foscarnet by hemodialysis using dialysate-side values.
Topics: Acute Kidney Injury; Aged; Anti-Bacterial Agents; Antiviral Agents; Cytomegalovirus Infections; Drug | 2000 |
Design of novel derivatives of phosphonoformate (Foscarnet) as prodrugs and antiviral agents.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Cytomegalovirus Infections; Drug Design; Foscar | 2000 |
Outcome of AIDS-associated cytomegalovirus colitis in the era of potent antiretroviral therapy.
Topics: Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; Cohort Studies; Colitis; Cytomegalov | 2000 |
NeuroImages. "Owl's eyes" of CMV ventriculitis.
Topics: Adult; Antiviral Agents; Cerebral Ventricles; Cytomegalovirus; Cytomegalovirus Infections; Encephali | 2000 |
Ganciclovir resistance: a matter of time and titre.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; C | 2000 |
Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants.
Topics: Adult; Aged; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; Drug Resistance, Microbi | 2000 |
Foscarnet--an alternative for cytomegalovirus prophylaxis after allogeneic stem cell transplantation?
Topics: Adult; Antiviral Agents; Cytomegalovirus Infections; Female; Foscarnet; Hematopoietic Stem Cell Tran | 2000 |
CMV complications in common variable immunodeficiency.
Topics: Adult; Antiviral Agents; Azathioprine; B-Lymphocytes; CD4-Positive T-Lymphocytes; CD8-Positive T-Lym | 2000 |
Growth phenotypes of cytomegalovirus isolates do not correlate with glycoprotein B, major immediate early genotypes or antiviral sensitivity.
Topics: Antiviral Agents; Cells, Cultured; Cytomegalovirus; Cytomegalovirus Infections; Cytopathogenic Effec | 2000 |
Drug-resistant human cytomegalovirus infection in children after allogeneic stem cell transplantation may have different clinical outcomes.
Topics: Antiviral Agents; Child; Cytomegalovirus; Cytomegalovirus Infections; DNA-Directed DNA Polymerase; D | 2000 |
Fatal cytomegalovirus pneumonia after preemptive antiviral therapy in a renal transplant recipient.
Topics: Antigens, Viral; Antiviral Agents; Cidofovir; Cytomegalovirus; Cytomegalovirus Infections; Cytosine; | 2000 |
Extended routine polymerase chain reaction surveillance and pre-emptive antiviral therapy for cytomegalovirus after allogeneic transplantation.
Topics: Acyclovir; Adolescent; Adult; Antifungal Agents; Antiviral Agents; Bone Marrow Transplantation; Cycl | 2000 |
Rising pp65 antigenemia during preemptive anticytomegalovirus therapy after allogeneic hematopoietic stem cell transplantation: risk factors, correlation with DNA load, and outcomes.
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Aged; Antigens, Viral; Antiviral Agents; Cause of Death; | 2001 |
Cytomegalovirus infection and non-neutropenic fever after autologous stem cell transplantation: high rates of reactivation in patients with multiple myeloma and lymphoma.
Topics: Adult; Aged; Antigens, Viral; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; Female; | 2001 |
Failure of cidofovir to reduce CMV-antigenemia in a child transplanted from a matched unrelated donor.
Topics: Adenoviridae; Antiviral Agents; Bone Marrow Transplantation; Child; Cidofovir; Cytomegalovirus Infec | 2001 |
Risk for cytomegalovirus disease in patients receiving polymerase chain reaction-based preemptive antiviral therapy after allogeneic stem cell transplantation depends on transplantation modality.
Topics: Adult; Antiviral Agents; Bone Marrow Transplantation; Cytomegalovirus; Cytomegalovirus Infections; F | 2001 |
Guide to CMV management.
Topics: Administration, Oral; AIDS-Related Opportunistic Infections; Antiviral Agents; Cytomegalovirus Infec | 1996 |
CMV resistance: "more complicated than we thought".
Topics: Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; DNA, Viral; Drug Resistance, Microbia | 1996 |
Spectrum and treatment of cytomegalovirus disease in persons with AIDS.
Topics: Acquired Immunodeficiency Syndrome; Acyclovir; Antiviral Agents; Central Nervous System Diseases; Cy | 1996 |
Responding to CMV neurologic infections.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Central Nervous System Diseases; Cytomegalovir | 1996 |
Expression dynamics of human cytomegalovirus immune evasion genes US3, US6, and US11 in the blood of lung transplant recipients.
Topics: Antigens, Viral; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; DNA Primers; DNA Pro | 2001 |
Strategies for management of cytomegalovirus (CMV) infection after allogeneic bone marrow transplantation: the "doubling of baseline CMV pp65 antigenemia" and the "cidofovir as rescue treatment approaches.
Topics: Antigens, Viral; Antiviral Agents; Bone Marrow Transplantation; Child; Cidofovir; Cytomegalovirus; C | 2001 |
Variations in the cytomegalovirus DNA polymerase and phosphotransferase genes in relation to foscarnet and ganciclovir sensitivity.
Topics: Antiviral Agents; Codon; Cytomegalovirus; Cytomegalovirus Infections; DNA-Directed DNA Polymerase; D | 2001 |
Multiple herpes simplex virus infections with various resistance patterns in a matched unrelated donor transplant recipient.
Topics: Acyclovir; Antineoplastic Agents, Alkylating; Antiviral Agents; Bone Marrow Transplantation; Cidofov | 2001 |
Cidofovir as primary pre-emptive therapy for post-transplant cytomegalovirus infections.
Topics: Adult; Antiviral Agents; Cidofovir; Cyclosporine; Cytomegalovirus; Cytomegalovirus Infections; Cytos | 2001 |
Sequence analysis of UL54 and UL97 genes and evaluation of antiviral susceptibility of human cytomegalovirus isolates obtained from kidney allograft recipients before and after treatment.
Topics: Adult; Aged; Amino Acid Sequence; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; DNA | 2001 |
[Cytomegalovirus sensitivity to anti-retroviral agents in patients infected with the human immunodeficiency virus with chorioretinitis in Spain].
Topics: Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; Chorioretinitis; Cytomegalovirus; Cy | 2001 |
Combination antiviral therapy for ganciclovir-resistant cytomegalovirus infection in solid-organ transplant recipients.
Topics: Adult; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; Drug Resistance, Microbial; Dr | 2002 |
From the National Institutes of Health.
Topics: Acquired Immunodeficiency Syndrome; Anti-Inflammatory Agents, Non-Steroidal; Antiviral Agents; Arthr | 1992 |
Foscarnet.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus Infections; Eye Infections, Vi | 1992 |
Didanosine and foscarnet marketed for use by patients with AIDS.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus Infections; Didanosine; Foscar | 1992 |
Clinical implications of herpesvirus infections in patients with AIDS. Introduction.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus Infections; Eye Infections, Vi | 1992 |
Treatment of cytomegalovirus retinitis--1992.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus Infections; Eye Infections, Vi | 1992 |
Treatment of aggressive cytomegalovirus retinitis with ganciclovir in combination with foscarnet in a child infected with human immunodeficiency virus.
Topics: Antiviral Agents; Child, Preschool; Cytomegalovirus Infections; Drug Therapy, Combination; Female; F | 1992 |
Why was treatment of cytomegalovirus retinitis randomized?
Topics: Antiviral Agents; Cytomegalovirus Infections; Eye Infections, Viral; Foscarnet; Ganciclovir; Humans; | 1992 |
Cytomegalovirus and AIDS.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Cytomegalovirus Infections; Foscarnet; | 1992 |
[Regressive diffuse leukoencephalitis under foscarnet in an AIDS infected patient].
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus Infections; Encephalitis; Fosc | 1992 |
Treatment of CMV retinitis.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus Infections; Drug Therapy, Comb | 1992 |
Treatment of CMV retinitis.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus Infections; Foscarnet; Gancicl | 1992 |
Treatment of CMV retinitis.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus Infections; Foscarnet; Gancicl | 1992 |
Foscarnet induction therapy for cytomegalovirus retinitis in AIDS: comparison of twice-daily and three-times-daily regimens.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Cytomegalovirus Infections; Drug Admini | 1992 |
Therapeutic algorithm for treatment of cytomegalovirus retinitis in persons with AIDS. A roundtable summary.
Topics: Acquired Immunodeficiency Syndrome; Adult; Algorithms; Cytomegalovirus Infections; Foscarnet; Gancic | 1992 |
CMV polyradiculopathy in AIDS--suggestions for new strategies in treatment.
Topics: Acquired Immunodeficiency Syndrome; Adult; Cytomegalovirus Infections; Foscarnet; Humans; Male; Nerv | 1992 |
Herpes simplex virus infection during foscarnet therapy.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Cytomegalovirus Infections; Foscarnet; | 1992 |
Foscarnet for treatment of cytomegalovirus infections in bone marrow transplant recipients.
Topics: Adolescent; Adult; Antiviral Agents; Bone Marrow Transplantation; Calcium; Child; Child, Preschool; | 1992 |
[Myelo-meningoradiculitis secondary to cytomegalovirus infection in a non immunocompromised patient. Treatment with foscarnet].
Topics: Adolescent; Antiviral Agents; Bone Marrow Diseases; Cytomegalovirus Infections; Foscarnet; Humans; M | 1992 |
Transplantation of the heart and lung.
Topics: Australia; Coronary Artery Disease; Costs and Cost Analysis; Cytomegalovirus Infections; Foscarnet; | 1992 |
Atypical healing of cytomegalovirus retinitis. Significance of persistent border opacification.
Topics: AIDS-Related Opportunistic Infections; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections | 1992 |
Visual field testing in the management of cytomegalovirus retinitis.
Topics: Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; Cytomegalovirus Infections; Eye Infe | 1992 |
Pharmacokinetics of foscarnet after twice-daily administrations for treatment of cytomegalovirus disease in AIDS patients.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Chromatography, High Pressure Liquid; C | 1992 |
CMV colitis in an immunocompetent adult.
Topics: Adult; Colitis; Cytomegalovirus; Cytomegalovirus Infections; Foscarnet; Humans; Immunocompetence; Ma | 1992 |
Intravitreal foscarnet for cytomegalovirus retinitis in a patient with acquired immunodeficiency syndrome.
Topics: Acquired Immunodeficiency Syndrome; Adult; Cytomegalovirus Infections; Eye Infections, Viral; Follow | 1992 |
When you give foscarnet to patients at home.
Topics: AIDS-Related Opportunistic Infections; Community Health Nursing; Cytomegalovirus Infections; Foscarn | 1992 |
Foscarnet-induced hypokalaemia.
Topics: Cytomegalovirus Infections; Female; Foscarnet; HIV Seropositivity; HIV-1; Humans; Hypokalemia; Male; | 1992 |
2.5 years survival with sequential ganciclovir/foscarnet treatment in a patient with acquired immune deficiency syndrome and cytomegalovirus retinitis.
Topics: AIDS-Related Opportunistic Infections; Cataract Extraction; Cytomegalovirus Infections; Drug Adminis | 1992 |
Opportunistic intraocular infections in AIDS.
Topics: Adolescent; Adult; AIDS-Related Opportunistic Infections; Child; Child, Preschool; Choroiditis; Cyto | 1992 |
[Cytomegalovirus retinitis in AIDS. Effectiveness and complications of long-term therapy].
Topics: AIDS-Related Opportunistic Infections; Cytomegalovirus Infections; Foscarnet; Ganciclovir; Humans; L | 1992 |
Treatment of CMV retinitis.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus Infections; Eye Infections, Vi | 1992 |
Foscarnet for CMV retinitis.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus Infections; Foscarnet; Gancicl | 1992 |
Ganciclovir/foscarnet for cytomegalovirus meningoencephalitis in AIDS.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Cytomegalovirus Infections; Drug Therap | 1992 |
Uvula and oesophageal ulcerations with foscarnet.
Topics: Adult; AIDS-Related Opportunistic Infections; Cytomegalovirus Infections; Esophagus; Foscarnet; Huma | 1992 |
Combined and alternating ganciclovir/foscarnet in HIV-related cytomegalovirus encephalitis.
Topics: Adult; AIDS-Related Opportunistic Infections; Cytomegalovirus Infections; Foscarnet; Ganciclovir; Ho | 1992 |
Foscarnet therapy for ganciclovir-resistant cytomegalovirus retinitis in patients with AIDS.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infect | 1991 |
Foscarnet in the treatment of cytomegalovirus infection of the esophagus and colon in patients with the acquired immune deficiency syndrome.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Colitis; Cytomegalovirus Infections; Es | 1991 |
Foscarnet therapy of ganciclovir-resistant cytomegalovirus in marrow transplantation.
Topics: Adult; Antiviral Agents; Bone Marrow Transplantation; Cytomegalovirus; Cytomegalovirus Infections; D | 1991 |
Successful foscarnet therapy for cytomegalovirus retinitis in an AIDS patient undergoing hemodialysis: rationale for empiric dosing and plasma level monitoring.
Topics: Acquired Immunodeficiency Syndrome; Acute Kidney Injury; Adult; Antiviral Agents; Cytomegalovirus In | 1991 |
National Eye Institute issues clinical alert about CMV retinitis in AIDS.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus Infections; Eye Infections, Vi | 1991 |
Foscarnet approved for cytomegalovirus retinitis.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus Infections; Foscarnet; Humans; | 1991 |
Cytomegalovirus infection in heart-lung transplant recipients: risk factors, clinical associations, and response to treatment.
Topics: Adolescent; Adult; Antibodies, Viral; Bacterial Infections; Child; Cytomegalovirus; Cytomegalovirus | 1991 |
From the Food and Drug Administration.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus Infections; Eye Infections, Vi | 1991 |
Cytomegalovirus infection in AIDS. Patterns of disease, response to therapy and trends in survival.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Colitis; Cytomegalovirus Infections; Female; F | 1991 |
[Prevention of genital erosions during treatments with foscarnet of cytomegalovirus infections in AIDS].
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Cytomegalovirus Infections; Foscarnet; | 1991 |
Survival of patients with AIDS and cytomegalovirus disease treated with ganciclovir or foscarnet.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Cytomegalovirus Infections; Female; Fos | 1991 |
Early virus isolation, early structural antigen detection and DNA amplification by the polymerase chain reaction in polymorphonuclear leukocytes from AIDS patients with human cytomegalovirus viraemia.
Topics: Acquired Immunodeficiency Syndrome; Antigens, Viral; Antiviral Agents; Cytomegalovirus; Cytomegalovi | 1991 |
[Therapeutic alternative or 2d choice drug. Trisodium phosphonoformate in cytomegalovirus retinitis].
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Chorioretinitis; Cytomegalovirus Infections; D | 1991 |
Sensitive, reproducible and convenient fluorometric assay for the in vitro evaluation of anti-cytomegalovirus agents.
Topics: Acyclovir; Antiviral Agents; Cidofovir; Cytomegalovirus; Cytomegalovirus Infections; Cytosine; Ester | 1991 |
Thromboembolic disease in AIDS is associated with cytomegalovirus disease.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Cytomegalovirus Infections; Foscarnet; | 1991 |
Cytomegalovirus isolate resistant to ganciclovir and foscarnet from a marrow transplant patient.
Topics: Adult; Antiviral Agents; Bone Transplantation; Cytomegalovirus; Cytomegalovirus Infections; Drug Res | 1991 |
Simultaneous treatment of cytomegalovirus retinitis with ganciclovir and foscarnet.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Cytomegalovirus Infections; Eye Infecti | 1991 |
Treatment of cytomegalovirus retinitis with ganciclovir and foscarnet.
Topics: Adult; Cytomegalovirus Infections; Drug Combinations; Foscarnet; Ganciclovir; HIV Seropositivity; Hu | 1991 |
Seeing the way forward for treatment of CMV retinitis.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Clinical Trials as Topic; Cytomegalovirus Infe | 1991 |
CMV retinitis and the use of FK 506.
Topics: Acyclovir; Antiviral Agents; Cytomegalovirus Infections; Foscarnet; Humans; Immunosuppression Therap | 1991 |
[Cytomegalovirus ileocolitis in patients with HIV infection is a treatable cause of severe abdominal problems].
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Cecum; Crohn Disease; Cytomegalovirus I | 1991 |
Foscarnet and penile ulceration.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus Infections; Foscarnet; Herpes | 1990 |
Penile ulcerations with foscarnet.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Cytomegalovirus Infections; Foscarnet; | 1990 |
[Treatment of Cytomegalovirus infection].
Topics: Antiviral Agents; Cytomegalovirus Infections; Foscarnet; Ganciclovir; Humans; Immune Tolerance; Phos | 1990 |
Foscarnet therapy of cytomegalovirus retinitis in AIDS.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus Infections; Foscarnet; Humans; | 1990 |
Nephrogenic diabetes insipidus associated with foscarnet treatment of cytomegalovirus retinitis.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Cytomegalovirus Infections; Diabetes In | 1990 |
Fixed drug eruption due to foscarnet.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Cytomegalovirus Infections; Drug Erupti | 1990 |
Prevention of foscarnet nephrotoxicity.
Topics: Adult; Antiviral Agents; Cytomegalovirus Infections; Eye Infections, Viral; Female; Fluid Therapy; F | 1990 |
Wider access provided to AIDS drugs with actions against HIV, CMV infections.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus Infections; Foscarnet; HIV Inf | 1990 |
[Chemotherapy of cytomegalovirus infections].
Topics: Acyclovir; Adenine; Cytomegalovirus Infections; Foscarnet; Ganciclovir; Humans; Organophosphonates; | 1989 |
[Diagnosis and treatment of cytomegalovirus infections].
Topics: Acyclovir; Antigens, Viral; Cytomegalovirus; Cytomegalovirus Infections; DNA, Viral; Female; Foscarn | 1989 |
Foscarnet in the treatment of cytomegalovirus retinitis in acquired immune deficiency syndrome.
Topics: Acquired Immunodeficiency Syndrome; Adult; Creatine; Cytomegalovirus Infections; Drug Therapy, Combi | 1989 |
Foscarnet treatment of cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Calcium; Cytomegalovirus Infections; Fo | 1989 |
Pharmacokinetics of intermittently administered intravenous foscarnet in the treatment of acquired immunodeficiency syndrome patients with serious cytomegalovirus retinitis.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Cytomegalovirus Infections; Foscarnet; | 1989 |
Foscarnet nephrotoxicity: mechanism, incidence and prevention.
Topics: Acute Kidney Injury; Adult; Aged; Cohort Studies; Creatinine; Cytomegalovirus Infections; Fluid Ther | 1989 |
Foscarnet prophylaxis in marrow transplant recipients.
Topics: Bone Marrow Transplantation; Cytomegalovirus; Cytomegalovirus Infections; Foscarnet; Humans; Nucleic | 1989 |
Evaluation by immune scanning electron microscopy of foscarnet treatment of cytomegalovirus infection in patients with renal transplants.
Topics: Adolescent; Adult; Aged; Child; Child, Preschool; Cytomegalovirus; Cytomegalovirus Infections; Drug | 1989 |
Tubulointerstitial nephritis caused by the antiviral agent foscarnet.
Topics: Adult; Antiviral Agents; Cytomegalovirus Infections; Female; Foscarnet; Humans; Kidney Transplantati | 1989 |
Foscarnet infusion at home.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Cytomegalovirus Infections; Drug Admini | 1989 |
Treatment of CMV retinitis in an AIDS patient.
Topics: Acquired Immunodeficiency Syndrome; Acyclovir; Antiviral Agents; Cytomegalovirus Infections; Foscarn | 1987 |
Aerosol administration of antiviral agents to treat lung infection due to murine cytomegalovirus.
Topics: Acyclovir; Administration, Oral; Aerosols; Animals; Antiviral Agents; Cytomegalovirus Infections; Di | 1988 |
Treatment of cytomegalovirus retinitis with trisodium phosphonoformate hexahydrate (Foscarnet).
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Cytomegalovirus Infections; Foscarnet; | 1988 |
[Cytomegaloviruses and antiviral agents--a review].
Topics: Antiviral Agents; Cytomegalovirus Infections; Foscarnet; Humans; Phosphonoacetic Acid | 1988 |
Acute renal failure induced by foscarnet: 4 cases.
Topics: Acquired Immunodeficiency Syndrome; Acute Kidney Injury; Adult; Antiviral Agents; Chorioretinitis; C | 1988 |
Effect of Foscarnet therapy on infection with human immunodeficiency virus in patients with AIDS.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus Infections; Foscarnet; HIV; HI | 1988 |
Failure of antiviral therapy for acquired immunodeficiency syndrome-related cytomegalovirus myelitis.
Topics: Acquired Immunodeficiency Syndrome; Acyclovir; Adult; Antiviral Agents; Cytomegalovirus Infections; | 1988 |
Foscarnet as treatment for cytomegalovirus retinitis following bone marrow transplantation.
Topics: Adult; Antiviral Agents; Bone Marrow Transplantation; Busulfan; Cataract; Cytomegalovirus Infections | 1988 |
Foscarnet for cytomegalovirus pneumonitis.
Topics: Adult; Cytomegalovirus Infections; Foscarnet; Humans; Male; Organophosphorus Compounds; Phosphonoace | 1985 |
Foscarnet for cytomegalovirus infections.
Topics: Antiviral Agents; Cytomegalovirus Infections; Foscarnet; Humans; Organophosphorus Compounds; Phospho | 1985 |
Foscarnet infusion at home.
Topics: Acquired Immunodeficiency Syndrome; Adult; Cytomegalovirus Infections; Foscarnet; HIV Antigens; Home | 1988 |
Intravenous foscarnet for the treatment of severe cytomegalovirus infection in allograft recipients.
Topics: Adult; Bone Marrow Transplantation; Child; Cytomegalovirus Infections; Female; Foscarnet; Humans; Im | 1985 |
Foscarnet for cytomegalovirus retinitis.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus Infections; Foscarnet; Humans; | 1985 |
Clinical experiences with phosphonoformate (foscarnet) treatment of viral diseases following renal transplantation.
Topics: Adult; Aged; Antiviral Agents; Cytomegalovirus Infections; Female; Foscarnet; Herpes Simplex; Herpes | 1985 |
Pharmacokinetics, safety and preliminary clinical experiences using foscarnet in the treatment of cytomegalovirus infections in bone marrow and renal transplant recipients.
Topics: Adult; Aged; Antiviral Agents; Bone Marrow Transplantation; Cytomegalovirus Infections; Electrolytes | 1986 |
Deoxythymidine kinase, a possible marker for monitoring activity of cytomegalovirus infection after renal transplantation.
Topics: Antiviral Agents; Cytomegalovirus Infections; Foscarnet; Humans; Kidney Transplantation; Male; Middl | 1986 |
Serum thymidine kinase in transplant patients: its relation to cytomegalovirus activity, renal transplant rejection and its use for monitoring of antiviral therapy.
Topics: Adult; Antiviral Agents; Cell Division; Cytomegalovirus Infections; Female; Foscarnet; Graft Rejecti | 1986 |
[Importance of Foscarnet in the treatment of cytomegalovirus pneumopathy in a patient with acquired immunodeficiency syndrome].
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Cytomegalovirus Infections; Foscarnet; | 1986 |
[Prevention and treatment of cytomegalovirus infections after graft of allogenic bone marrow].
Topics: Acyclovir; Antiviral Agents; Bone Marrow Transplantation; Cytomegalovirus Infections; Foscarnet; Gan | 1987 |
Treatment of cytomegalovirus pneumonitis with foscarnet (trisodium phosphonoformate) in patients with AIDS.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Cytomegalovirus Infections; Foscarnet; | 1987 |